6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 50_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 1_CD General_NNP information_NN Shire_NNP plc_NN Shire_NNP or_CC the_DT Company_NN and_CC its_PRP$ subsidiaries_NNS together_RB the_DT Group_NNP develop_VB and_CC market_NN products_NNS for_IN specialty_NN physicians_NNS ._.
The_DT Group_NNP focuses_VBZ on_IN four_CD therapeutic_JJ areas_NNS :_: central_JJ nervous_JJ system_NN ,_, gastro-intestinal_JJ ,_, human_JJ genetic_JJ therapies_NNS and_CC general_JJ products_NNS ._.
The_DT Companys_NNP ordinary_JJ shares_NNS are_VBP traded_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP LSE_NNP ._.
On_IN November_NNP 25_CD ,_, 2005_CD a_DT Scheme_NN of_IN Arrangement_NN ,_, approved_VBN by_IN the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP ,_, became_VBD effective_JJ ._.
Under_IN the_DT terms_NNS of_IN the_DT Scheme_NNP ,_, Shire_NNP replaced_VBD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN SPG_NNP as_IN the_DT holding_VBG company_NN of_IN the_DT Shire_NNP Group_NNP ._.
SPGs_NNS ordinary_JJ shareholders_NNS received_VBD one_CD Shire_NNP ordinary_JJ share_NN for_IN each_DT SPG_NNP ordinary_JJ share_NN held_VBN at_IN 5.30_CD pm_NN on_IN November_NNP 24_CD ,_, 2005_CD ._.
The_DT Shire_NNP ordinary_JJ shares_NNS were_VBD admitted_VBN to_TO the_DT official_JJ list_NN and_CC to_TO trading_VBG on_IN the_DT LSE_NNP at_IN 8.00_CD am_VBP GMT_NNP on_IN November_NNP 25_CD ,_, 2005_CD ._.
The_DT listing_NN of_IN SPGs_NNS ordinary_JJ shares_NNS was_VBD canceled_VBN at_IN the_DT same_JJ time_NN ._.
The_DT Company_NN also_RB has_VBZ American_JJ Depositary_NNP Shares_NNP ADSs_NNPS trading_NN on_IN the_DT NASDAQ_NNP National_NNP Market_NNP ._.
Each_DT ADS_NNPS represents_VBZ three_CD ordinary_JJ shares_NNS of_IN Shire_NNP ._.
An_DT ADS_NNPS is_VBZ evidenced_VBN by_IN an_DT American_JJ Depositary_NNP Receipt_NNP ADR_NNP issued_VBN by_IN Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP as_IN depositary_NN ._.
As_IN at_IN February_NNP 21_CD ,_, 2006_CD ,_, the_DT proportion_NN of_IN ordinary_JJ shares_NNS represented_VBN by_IN ADRs_NNS was_VBD 30_CD %_NN of_IN the_DT outstanding_JJ ordinary_JJ shares_NNS ._.
In_IN consequence_NN of_IN the_DT implementation_NN of_IN the_DT Scheme_NNP of_IN Arrangement_NNP ,_, ADSs_NNP representing_VBG ordinary_JJ shares_NNS of_IN SPG_NNP were_VBD replaced_VBN by_IN ADSs_NNS representing_VBG ordinary_JJ shares_NNS of_IN Shire_NNP on_IN a_DT one-for-one_JJ basis_NN ._.
Dealings_NNS in_IN ADSs_NNS representing_VBG ordinary_JJ shares_NNS of_IN Shire_NNP on_IN NASDAQ_NNP commenced_VBD at_IN 9.30_CD am_VBP EST_NN on_IN November_NNP 25_CD ,_, 2005_CD ._.
ADSs_NNS representing_VBG ordinary_JJ shares_NNS of_IN SPG_NNP were_VBD canceled_VBN at_IN the_DT same_JJ time_NN ._.
Exchangeable_JJ shares_NNS are_VBP included_VBN as_IN part_NN of_IN share_NN capital_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT consolidated_JJ Groups_NNS capital_NN structure_NN ._.
Further_JJ details_NNS are_VBP shown_VBN in_IN Note_NN 30_CD ._.
The_DT Company_NN is_VBZ a_DT public_JJ limited_JJ company_NN incorporated_VBN under_IN the_DT Companies_NNS Act_NNP ,_, 1985_CD and_CC domiciled_VBD in_IN the_DT United_NNP Kingdom_NNP ._.
The_DT address_NN of_IN its_PRP$ registered_JJ office_NN is_VBZ Hampshire_NNP International_NNP Business_NNP Park_NNP ,_, Chineham_NNP ,_, Basingstoke_NNP ,_, Hampshire_NNP ,_, United_NNP Kingdom_NNP ._.
These_DT accounts_NNS are_VBP presented_VBN in_IN US_NNP Dollars_NNPS as_IN this_DT is_VBZ the_DT currency_NN of_IN the_DT primary_JJ economic_JJ environment_NN in_IN which_WDT the_DT Group_NNP operates_VBZ ._.
2_CD Significant_JJ accounting_NN policies_NNS The_DT principal_JJ accounting_NN policies_NNS adopted_VBN in_IN the_DT preparation_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS are_VBP set_VBN out_RP below_IN ._.
a_DT Basis_NN of_IN accounting_NN The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP for_IN the_DT first_JJ time_NN ._.
The_DT disclosures_NNS required_VBN by_IN IFRS_NNP 1_CD concerning_VBG the_DT transition_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP are_VBP given_VBN in_IN Note_NN 40_CD ._.
The_DT financial_JJ statements_NNS have_VBP also_RB been_VBN prepared_VBN in_IN accordance_NN with_IN IFRS_NNP adopted_VBD for_IN use_NN in_IN the_DT European_NNP Union_NNP and_CC therefore_RB comply_VB with_IN Article_NNP 4_CD of_IN the_DT EU_NNP IAS_NNP Regulation_NN ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN on_IN the_DT historical_JJ cost_NN basis_NN ,_, except_IN for_IN the_DT revaluation_NN of_IN financial_JJ assets_NNS ,_, borrowings_NNS and_CC derivatives_NNS ._.
The_DT principal_JJ accounting_NN policies_NNS adopted_VBN are_VBP set_VBN out_RP below_IN ._.
b_NN Consolidation_NN Subsidiaries_NNPS Subsidiaries_NNPS are_VBP all_DT entities_NNS over_IN which_WDT the_DT Group_NNP has_VBZ the_DT power_NN to_TO govern_VB the_DT financial_JJ and_CC operating_VBG policies_NNS of_IN the_DT entity_NN concerned_VBN ,_, generally_RB accompanying_VBG a_DT shareholding_NN of_IN more_JJR than_IN one_CD half_NN of_IN the_DT voting_NN rights_NNS ._.
Subsidiaries_NNS are_VBP fully_RB consolidated_VBN from_IN the_DT date_NN on_IN which_WDT control_NN is_VBZ transferred_VBN to_TO the_DT Group_NNP ._.
They_PRP are_VBP fide-consolidated_VBN from_IN the_DT date_NN on_IN which_WDT control_NN ceases_VBZ ._.
The_DT purchase_NN method_NN of_IN accounting_NN is_VBZ used_VBN to_TO account_VB for_IN the_DT acquisition_NN of_IN subsidiaries_NNS by_IN the_DT Group_NNP ._.
The_DT cost_NN of_IN an_DT acquisition_NN is_VBZ measured_VBN as_IN the_DT fair_JJ value_NN of_IN the_DT assets_NNS exchanged_VBD ,_, equity_NN instruments_NNS issued_VBN and_CC liabilities_NNS incurred_VBN or_CC assumed_VBN at_IN the_DT date_NN of_IN exchange_NN ,_, plus_CC costs_NNS directly_RB attributable_JJ to_TO the_DT acquisition_NN ._.
Identifiable_JJ assets_NNS acquired_VBN together_RB with_IN liabilities_NNS and_CC contingent_JJ liabilities_NNS assumed_VBD in_IN a_DT business_NN combination_NN are_VBP measured_VBN initially_RB at_IN their_PRP$ fair_JJ values_NNS at_IN the_DT acquisition_NN date_NN ,_, irrespective_RB of_IN the_DT extent_NN of_IN any_DT minority_NN interest_NN ._.
The_DT excess_NN of_IN the_DT cost_NN of_IN acquisition_NN over_IN the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ net_JJ assets_NNS acquired_VBN is_VBZ recorded_VBN as_IN goodwill_NN ._.
Where_WRB necessary_JJ ,_, adjustments_NNS are_VBP made_VBN to_TO the_DT financial_JJ statements_NNS of_IN subsidiaries_NNS to_TO bring_VB the_DT accounting_NN policies_NNS used_VBN in_IN line_NN with_IN those_DT used_VBN by_IN the_DT Group_NNP ._.
Inter-company_JJ transactions_NNS ,_, balances_NNS and_CC unrealized_JJ gains_NNS on_IN transactions_NNS between_IN companies_NNS in_IN the_DT Group_NNP are_VBP eliminated_VBN on_IN consolidation_NN ._.
Unrealized_JJ losses_NNS on_IN transactions_NNS between_IN companies_NNS in_IN the_DT Group_NNP are_VBP also_RB eliminated_VBN unless_IN the_DT transaction_NN provides_VBZ evidence_NN of_IN an_DT impairment_NN of_IN the_DT asset_NN transferred_VBN ._.
Associates_NNP Associates_NNPS are_VBP all_DT entities_NNS over_IN which_WDT the_DT Group_NNP is_VBZ in_IN a_DT position_NN to_TO exercise_VB significant_JJ influence_NN but_CC not_RB control_VB or_CC joint_JJ control_NN ,_, through_IN participation_NN in_IN the_DT financial_JJ and_CC operating_NN policy_NN decisions_NNS of_IN the_DT investee_NN ._.
Significant_JJ influence_NN is_VBZ the_DT power_NN to_TO participate_VB in_IN the_DT financial_JJ and_CC operating_NN policy_NN decisions_NNS of_IN the_DT investee_NN but_CC not_RB the_DT control_NN or_CC joint_JJ control_NN over_IN those_DT policies_NNS ._.
In_IN general_JJ this_DT would_MD be_VB a_DT shareholding_NN in_IN an_DT entity_NN entitling_VBG the_DT Group_NNP to_TO between_IN 20_CD %_NN and_CC 50_CD %_NN of_IN the_DT voting_NN rights_NNS of_IN that_DT entity_NN ._.
50_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 51_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS Investments_NNP in_IN associates_NNS are_VBP accounted_VBN for_IN by_IN the_DT equity_NN method_NN of_IN accounting_NN and_CC are_VBP initially_RB recognized_VBN at_IN cost_NN ._.
The_DT Groups_NNS share_NN of_IN its_PRP$ associates_NNS post-acquisition_JJ profits_NNS or_CC losses_NNS is_VBZ recognized_VBN in_IN the_DT income_NN statement_NN and_CC its_PRP$ share_NN of_IN post-acquisition_JJ movements_NNS in_IN reserves_NNS is_VBZ recognized_VBN in_IN reserves_NNS ._.
The_DT cumulative_JJ post-acquisition_NN movements_NNS are_VBP adjusted_VBN against_IN the_DT carrying_VBG amount_NN of_IN the_DT investment_NN ._.
When_WRB the_DT Groups_NNS share_NN of_IN losses_NNS in_IN an_DT associate_JJ equals_VBZ or_CC exceeds_VBZ its_PRP$ interest_NN in_IN the_DT associate_NN ,_, including_VBG any_DT unsecured_JJ receivables_NN due_JJ from_IN that_DT associate_NN ,_, the_DT Group_NNP does_VBZ not_RB recognize_VB such_JJ excess_JJ losses_NNS ,_, unless_IN ,_, and_CC to_TO the_DT extent_NN it_PRP has_VBZ incurred_VBN obligations_NNS or_CC made_VBN payments_NNS on_IN behalf_NN of_IN the_DT associate_NN ._.
Any_DT excess_NN of_IN the_DT cost_NN of_IN acquisition_NN over_IN the_DT Groups_NNS share_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT identifiable_JJ net_JJ assets_NNS of_IN the_DT associate_NN at_IN the_DT date_NN of_IN acquisition_NN is_VBZ recognized_VBN as_IN goodwill_NN ._.
Any_DT deficiency_NN of_IN the_DT cost_NN of_IN acquisition_NN below_IN the_DT Groups_NNS share_NN of_IN fair_JJ values_NNS of_IN the_DT identifiable_JJ net_JJ assets_NNS of_IN the_DT associate_NN at_IN the_DT date_NN of_IN acquisition_NN i._FW e._FW discount_NN on_IN acquisition_NN is_VBZ credited_VBN to_TO the_DT income_NN statement_NN in_IN the_DT period_NN of_IN acquisition_NN ._.
Unrealized_JJ gains_NNS on_IN transactions_NNS between_IN the_DT Group_NNP and_CC its_PRP$ associates_NNS are_VBP eliminated_VBN to_TO the_DT extent_NN of_IN the_DT Groups_NNS interest_NN in_IN the_DT associate_NN ._.
Unrealized_JJ losses_NNS between_IN the_DT Group_NNP and_CC its_PRP$ associates_NNS are_VBP also_RB eliminated_VBN unless_IN the_DT transaction_NN provides_VBZ evidence_NN of_IN an_DT impairment_NN of_IN the_DT asset_NN transferred_VBN ._.
Joint_NNP ventures_NNS The_DT Groups_NNS interests_NNS in_IN jointly_RB controlled_VBN entities_NNS are_VBP accounted_VBN for_IN by_IN the_DT equity_NN method_NN ._.
c_NN Foreign_JJ currency_NN translation_NN Functional_NNP and_CC presentational_JJ currency_NN Items_NNS included_VBD in_IN the_DT individual_JJ financial_JJ statements_NNS of_IN each_DT of_IN the_DT Groups_NNS entities_NNS are_VBP measured_VBN using_VBG the_DT currency_NN of_IN the_DT primary_JJ economic_JJ environment_NN in_IN which_WDT the_DT entity_NN operates_VBZ the_DT functional_JJ currency_NN ._.
The_DT consolidated_JJ financial_JJ statements_NNS are_VBP presented_VBN in_IN US_NNP Dollars_NNPS ,_, which_WDT is_VBZ the_DT Groups_NNS presentational_JJ currency_NN ._.
Transactions_NNS and_CC balances_NNS Foreign_JJ currency_NN transactions_NNS are_VBP translated_VBN into_IN the_DT functional_JJ currency_NN using_VBG the_DT exchange_NN rates_NNS prevailing_VBG at_IN the_DT dates_NNS of_IN the_DT transactions_NNS in_IN question_NN ._.
Foreign_JJ exchange_NN gains_NNS and_CC losses_NNS resulting_VBG from_IN the_DT settlement_NN of_IN such_JJ transactions_NNS and_CC from_IN the_DT translation_NN at_IN the_DT year-end_JJ exchange_NN rates_NNS of_IN monetary_JJ assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS are_VBP recognized_VBN in_IN the_DT income_NN statement_NN ._.
Group_NNP companies_NNS The_DT results_NNS and_CC balance_NN sheets_NNS of_IN all_DT Group_NNP entities_NNS that_WDT have_VBP a_DT functional_JJ currency_NN different_JJ from_IN the_DT presentational_JJ currency_NN are_VBP translated_VBN into_IN the_DT presentational_JJ currency_NN as_IN follows_VBZ :_: assets_NNS and_CC liabilities_NNS are_VBP translated_VBN at_IN the_DT closing_NN rate_NN on_IN the_DT balance_NN sheet_NN date_NN :_: income_NN and_CC expense_NN are_VBP translated_VBN at_IN average_JJ exchange_NN rates_NNS for_IN the_DT periods_NNS of_IN the_DT income_NN statement_NN unless_IN this_DT average_NN is_VBZ not_RB a_DT reasonable_JJ approximation_NN of_IN the_DT cumulative_JJ effect_NN of_IN the_DT rates_NNS prevailing_VBG on_IN the_DT transaction_NN dates_NNS ,_, in_IN which_WDT case_NN income_NN and_CC expenses_NNS are_VBP translated_VBN at_IN the_DT dates_NNS of_IN the_DT transactions_NNS :_: and_CC all_DT resulting_VBG exchange_NN differences_NNS are_VBP recognized_VBN as_IN a_DT separate_JJ component_NN of_IN equity_NN ._.
On_IN consolidation_NN ,_, exchange_NN differences_NNS arising_VBG from_IN the_DT translation_NN of_IN the_DT net_JJ investment_NN in_IN entities_NNS in_IN the_DT Group_NNP are_VBP taken_VBN to_TO shareholders_NNS equity_NN ._.
When_WRB an_DT entity_NN of_IN the_DT Group_NNP is_VBZ sold_VBN ,_, any_DT such_JJ exchange_NN differences_NNS are_VBP recognized_VBN in_IN the_DT income_NN statement_NN as_IN part_NN of_IN the_DT gain_NN or_CC loss_NN on_IN sale_NN ._.
Goodwill_NN and_CC fair_JJ value_NN adjustments_NNS arising_VBG on_IN the_DT acquisition_NN of_IN an_DT operation_NN are_VBP treated_VBN as_IN assets_NNS and_CC liabilities_NNS of_IN a_DT company_NN in_IN the_DT Group_NNP and_CC translated_VBN at_IN the_DT closing_NN rate_NN on_IN the_DT balance_NN sheet_NN date_NN ._.
d_LS Segment_NNP reporting_VBG A_DT business_NN segment_NN is_VBZ a_DT group_NN of_IN assets_NNS and_CC operations_NNS engaged_VBD in_IN providing_VBG products_NNS or_CC services_NNS that_WDT are_VBP subject_JJ to_TO risks_NNS and_CC returns_NNS that_WDT are_VBP different_JJ from_IN those_DT of_IN other_JJ business_NN segments_NNS ._.
A_DT geographical_JJ segment_NN is_VBZ engaged_VBN in_IN providing_VBG products_NNS or_CC services_NNS within_IN a_DT particular_JJ economic_JJ environment_NN that_WDT is_VBZ subject_JJ to_TO risks_NNS and_CC returns_NNS that_WDT are_VBP different_JJ from_IN those_DT of_IN components_NNS operating_VBG in_IN other_JJ economic_JJ environments_NNS ._.
e_LS Revenue_NN recognition_NN Revenues_NNS are_VBP stated_VBN net_NN of_IN VAT_NNP and_CC similar_JJ taxes_NNS ,_, trade_NN discounts_NNS and_CC intra-Group_JJ transactions_NNS ._.
The_DT principal_JJ components_NNS of_IN the_DT Groups_NNS turnover_NN and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP set_VBN out_RP below_IN :_: Product_NN sales_NNS revenue_NN from_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS or_CC at_IN the_DT time_NN of_IN delivery_NN depending_VBG on_IN the_DT terms_NNS of_IN sale_NN ._.
Provisions_NNS for_IN certain_JJ rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN :_: Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 51_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 52_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS Licensing_VBG and_CC development_NN fees_NNS licensing_NN and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN license_NN agreements_NNS and_CC from_IN collaborative_JJ research_NN and_CC development_NN arrangements_NNS :_: initial_JJ license_NN fees_NNS are_VBP not_RB considered_VBN to_TO be_VB separable_JJ from_IN the_DT associated_VBN research_NN and_CC development_NN activities_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP nonrefundable_JJ and_CC not_RB creditable_JJ against_IN research_NN and_CC development_NN services_NNS to_TO be_VB rendered_VBN ._.
Initial_JJ license_NN fees_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT license_NN term_NN or_CC the_DT period_NN of_IN the_DT associated_VBN research_NN and_CC development_NN agreement_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ license_NN fees_NNS are_VBP not_RB for_IN a_DT defined_VBN period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT license_NN relates_VBZ :_: Milestones_NNS during_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS ,_, the_DT Group_NNP receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenue_NN is_VBZ recognized_VBN on_IN achievement_NN of_IN milestones_NNS :_: and_CC the_DT Group_NNP also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB receivable_NN ._.
If_IN milestone_NN payments_NNS are_VBP creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, the_DT milestones_NNS are_VBP deferred_VBN and_CC released_VBN over_IN the_DT period_NN in_IN which_WDT the_DT royalties_NNS are_VBP anticipated_VBN to_TO be_VB paid_VBN ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
Royalty_NN income_NN royalty_NN income_NN is_VBZ recognized_VBN on_IN an_DT accruals_NNS basis_NN in_IN accordance_NN with_IN the_DT substance_NN of_IN the_DT relevant_JJ agreements_NNS ._.
Interest_NN income_NN interest_NN income_NN is_VBZ recognized_VBN on_IN a_DT time-proportion_JJ basis_NN using_VBG the_DT effective_JJ interest_NN method_NN ._.
Dividend_NN income_NN dividend_NN income_NN is_VBZ recognized_VBN when_WRB the_DT right_NN to_TO receive_VB payment_NN is_VBZ established_VBN ._.
f_LS Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN is_VBZ shown_VBN at_IN cost_NN ,_, less_JJR subsequent_JJ depreciation_NN and_CC impairment_NN ,_, except_IN for_IN land_NN ,_, which_WDT is_VBZ shown_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realizable_JJ value_NN ._.
Cost_NN includes_VBZ expenditure_NN that_WDT is_VBZ directly_RB attributable_JJ to_TO the_DT acquisition_NN of_IN the_DT assets_NNS ._.
Subsequent_JJ costs_NNS are_VBP included_VBN in_IN the_DT assets_NNS carrying_VBG amount_NN or_CC recognized_VBN as_IN a_DT separate_JJ asset_NN ,_, as_IN appropriate_JJ ,_, only_RB when_WRB it_PRP is_VBZ probable_JJ that_IN future_JJ economic_JJ benefits_NNS associated_VBN with_IN the_DT item_NN will_MD flow_VB to_TO the_DT Group_NNP and_CC the_DT cost_NN of_IN the_DT item_NN can_MD be_VB measured_VBN reliably_RB ._.
Where_WRB the_DT expenditure_NN constitutes_VBZ repairs_NNS and_CC maintenance_NN ,_, it_PRP is_VBZ charged_VBN to_TO the_DT income_NN statement_NN during_IN the_DT financial_JJ period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Depreciation_NN is_VBZ calculated_VBN using_VBG the_DT straight-line_JJ method_NN to_TO allocate_VB the_DT difference_NN between_IN the_DT cost_NN of_IN each_DT asset_NN and_CC its_PRP$ residual_JJ value_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN as_IN follows_VBZ :_: Land_NNP Buildings_NNS 20_CD to_TO 50_CD years_NNS Furniture_NNP and_CC fittings_NNS 3_CD to10_CD years_NNS Equipment_NNP and_CC other_JJ 3_CD to10_CD years_NNS Motor_NNP vehicles_NNS 4_CD to_TO 5_CD years_NNS Residual_JJ values_NNS and_CC the_DT useful_JJ lives_NNS of_IN assets_NNS are_VBP reviewed_VBN ,_, and_CC adjusted_VBN if_IN appropriate_JJ ,_, at_IN each_DT balance_NN sheet_NN date_NN ._.
An_DT assets_NNS carrying_VBG amount_NN is_VBZ written_VBN down_RP immediately_RB to_TO its_PRP$ recoverable_JJ amount_NN if_IN the_DT assets_NNS carrying_VBG amount_NN is_VBZ greater_JJR than_IN its_PRP$ estimated_VBN recoverable_JJ amount_NN ._.
Gains_NNS and_CC losses_NNS on_IN disposals_NNS are_VBP determined_VBN by_IN comparing_VBG the_DT disposal_NN proceeds_NNS with_IN the_DT carrying_VBG amount_NN and_CC are_VBP included_VBN in_IN the_DT income_NN statement_NN ._.
Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP depreciated_VBN over_IN their_PRP$ expected_VBN useful_JJ lives_NNS on_IN the_DT same_JJ basis_NN as_IN owned_VBN assets_NNS ,_, or_CC where_WRB shorter_JJR ,_, over_IN the_DT term_NN of_IN the_DT relevant_JJ lease_NN ._.
Properties_NNP in_IN the_DT course_NN of_IN construction_NN are_VBP carried_VBN at_IN cost_NN less_JJR any_DT recognized_VBN impairment_NN loss_NN ._.
Cost_NN includes_VBZ professional_JJ fees_NNS and_CC ,_, for_IN qualifying_VBG assets_NNS ,_, borrowing_VBG costs_NNS capitalized_VBN in_IN accordance_NN with_IN the_DT Groups_NNS accounting_VBG policy_NN ._.
Depreciation_NN of_IN these_DT assets_NNS commences_NNS when_WRB the_DT assets_NNS are_VBP ready_JJ for_IN their_PRP$ intended_VBN use_NN ._.
52_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 53_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS g_VBP Borrowing_NN costs_NNS Borrowing_VBG costs_NNS directly_RB attributable_JJ to_TO the_DT acquisition_NN ,_, construction_NN or_CC production_NN of_IN qualifying_VBG assets_NNS ,_, which_WDT are_VBP assets_NNS that_WDT necessarily_RB take_VB a_DT substantial_JJ period_NN of_IN time_NN to_TO get_VB ready_JJ for_IN their_PRP$ intended_VBN use_NN or_CC sale_NN ,_, are_VBP added_VBN to_TO the_DT cost_NN of_IN those_DT assets_NNS ,_, until_IN such_JJ time_NN as_IN the_DT assets_NNS are_VBP substantially_RB ready_JJ for_IN their_PRP$ intended_VBN use_NN or_CC sale_NN ._.
Investment_NN income_NN earned_VBN on_IN the_DT temporary_JJ investment_NN of_IN specific_JJ borrowings_NNS pending_VBG their_PRP$ expenditure_NN on_IN qualifying_VBG assets_NNS is_VBZ deducted_VBN from_IN the_DT borrowing_NN costs_VBZ eligible_JJ for_IN capitalization_NN ._.
All_DT other_JJ borrowing_NN costs_NNS are_VBP recognized_VBN in_IN profit_NN or_CC loss_NN in_IN the_DT period_NN in_IN which_WDT they_PRP are_VBP incurred_VBN ._.
h_NN Intangible_JJ assets_NNS Goodwill_NNP Goodwill_NNP represents_VBZ the_DT excess_NN of_IN the_DT cost_NN of_IN an_DT acquisition_NN over_IN the_DT fair_JJ value_NN of_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ identifiable_JJ assets_NNS of_IN the_DT acquired_VBN subsidiary_NN associate_NN or_CC jointly_RB controlled_VBN entity_NN at_IN the_DT date_NN of_IN acquisition_NN ._.
Goodwill_NN is_VBZ tested_VBN annually_RB for_IN impairment_NN and_CC carried_VBD at_IN cost_NN less_JJR accumulated_VBN impairment_NN losses_NNS ._.
Any_DT impairment_NN is_VBZ recognized_VBN immediately_RB in_IN profit_NN or_CC loss_NN and_CC is_VBZ not_RB subsequently_RB reversed_JJ ._.
For_IN the_DT purpose_NN of_IN impairment_NN testing_NN ,_, goodwill_NN is_VBZ allocated_VBN to_TO each_DT of_IN the_DT Groups_NNS cash-generating_JJ units_NNS expected_VBN to_TO benefit_VB from_IN the_DT synergies_NNS of_IN the_DT combination_NN ._.
Each_DT of_IN those_DT cash_NN generating_VBG units_NNS represents_VBZ the_DT Groups_NNS investment_NN in_IN operations_NNS by_IN each_DT primary_JJ reporting_NN segment_NN ._.
Cash-generating_VBG units_NNS to_TO which_WDT goodwill_NN had_VBD been_VBN allocated_VBN are_VBP tested_VBN for_IN impairment_NN annually_RB ,_, or_CC more_RBR frequently_RB when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT unit_NN may_MD be_VB impaired_VBN ._.
If_IN the_DT recoverable_JJ amount_NN of_IN the_DT cash-generating_JJ unit_NN is_VBZ less_JJR than_IN the_DT carrying_VBG amount_NN of_IN the_DT unit_NN ,_, the_DT impairment_NN loss_NN is_VBZ allocated_VBN first_RB to_TO reduce_VB the_DT carrying_VBG amount_NN of_IN any_DT goodwill_NN allocated_VBN to_TO the_DT unit_NN and_CC then_RB to_TO the_DT other_JJ assets_NNS of_IN the_DT unit_NN pro-rata_JJ on_IN the_DT basis_NN of_IN the_DT carrying_VBG amount_NN of_IN each_DT asset_NN in_IN the_DT unit_NN ._.
On_IN disposal_NN of_IN a_DT subsidiary_NN ,_, associate_NN or_CC jointly_RB controlled_VBN entity_NN ,_, the_DT attributable_JJ amount_NN of_IN goodwill_NN is_VBZ included_VBN in_IN the_DT determination_NN of_IN the_DT profit_NN or_CC loss_NN on_IN disposal_NN ._.
Goodwill_NN arising_VBG on_IN acquisitions_NNS before_IN the_DT date_NN of_IN transition_NN to_TO IFRS_NNP has_VBZ been_VBN retained_VBN at_IN the_DT previous_JJ UK_NNP GAAP_NNP amounts_VBZ subject_JJ to_TO being_VBG tested_VBN for_IN impairment_NN at_IN that_DT date_NN ._.
Goodwill_NN written_VBN off_RP to_TO reserves_NNS under_IN UK_NNP GAAP_NNP prior_RB to_TO 1998_CD has_VBZ not_RB been_VBN reinstated_VBN and_CC is_VBZ not_RB included_VBN in_IN determining_VBG any_DT subsequent_JJ profit_NN or_CC loss_NN disposal_NN ._.
Research_NNP and_CC development_NN Research_NN expenditure_NN is_VBZ recognized_VBN as_IN an_DT expense_NN as_IN incurred_VBN ._.
Internal_NNP development_NN costs_NNS are_VBP recognized_VBN as_IN intangible_JJ assets_NNS when_WRB an_DT asset_NN is_VBZ created_VBN that_IN can_MD be_VB identified_VBN ,_, it_PRP is_VBZ probable_JJ that_IN future_JJ economic_JJ benefits_NNS will_MD flow_VB to_TO the_DT Group_NNP and_CC costs_NNS can_MD be_VB measured_VBN reliably_RB ._.
The_DT Group_NNP considers_VBZ that_IN regulatory_JJ and_CC other_JJ uncertainties_NNS inherent_JJ in_IN the_DT development_NN of_IN new_JJ products_NNS mean_VBP that_IN such_JJ criteria_NNS are_VBP not_RB met_VBN until_IN the_DT commercial_JJ launch_NN of_IN the_DT product_NN and_CC therefore_RB ,_, pre-launch_JJ internal_JJ development_NN costs_NNS are_VBP expensed_VBN as_IN incurred_VBN ._.
No_DT significant_JJ direct_JJ development_NN costs_NNS are_VBP incurred_VBN post_NN commercial_JJ launch_NN ._.
Where_WRB the_DT recognition_NN criteria_NNS are_VBP met_VBN ,_, internal_JJ development_NN costs_NNS are_VBP capitalized_VBN and_CC amortised_VBN on_IN a_DT straight-line_JJ basis_NN over_IN their_PRP$ useful_JJ economic_JJ lives_NNS from_IN product_NN launch_NN ._.
Payments_NNS to_TO in-license_JJ products_NNS and_CC compounds_NNS from_IN third_JJ parties_NNS ,_, generally_RB taking_VBG the_DT form_NN of_IN up-front_JJ payments_NNS and_CC milestones_NNS ,_, are_VBP capitalized_VBN ._.
Development_NNP costs_VBZ previously_RB recognized_VBN as_IN an_DT expense_NN are_VBP not_RB recognized_VBN as_IN an_DT asset_NN in_IN subsequent_JJ periods_NNS ._.
Intellectual_NNP property_NN Intellectual_NNP property_NN ,_, including_VBG trademarks_NNS ,_, is_VBZ recognized_VBN at_IN purchase_NN cost_NN and_CC amortised_VBN in_IN equal_JJ annual_JJ instalments_NNS over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT product_NN post_NN its_PRP$ launch_NN generally_RB not_RB exceeding_VBG 20_CD years_NNS ._.
Intellectual_NNP property_NN related_VBN to_TO a_DT marketed_VBN product_NN can_MD have_VB a_DT useful_JJ life_NN exceeding_VBG 20_CD years_NNS when_WRB the_DT Group_NNP believes_VBZ that_IN the_DT product_NN is_VBZ well_RB established_VBN in_IN its_PRP$ market_NN ._.
Computer_NNP software_NN The_DT costs_NNS of_IN acquiring_VBG computer_NN software_NN licenses_NNS and_CC implementing_VBG the_DT specific_JJ software_NN are_VBP capitalized_VBN ._.
These_DT costs_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS three_CD to_TO five_CD years_NNS ._.
Costs_NNS associated_VBN with_IN maintaining_VBG computer_NN software_NN programs_NNS are_VBP recognized_VBN as_IN an_DT expense_NN as_IN incurred_VBN ._.
i_FW Impairment_NN of_IN tangible_JJ and_CC intangible_JJ assets_NNS excluding_VBG goodwill_NN At_IN each_DT balance_NN sheet_NN date_NN ,_, the_DT Group_NNP reviews_VBZ the_DT carrying_VBG amounts_NNS of_IN its_PRP$ tangible_JJ and_CC intangible_JJ assets_NNS to_TO determine_VB whether_IN there_EX is_VBZ any_DT indication_NN that_IN those_DT assets_NNS have_VBP suffered_VBN an_DT impairment_NN loss_NN ._.
If_IN any_DT such_JJ indication_NN exists_VBZ ,_, the_DT recoverable_JJ amount_NN of_IN the_DT asset_NN is_VBZ estimated_VBN in_IN order_NN to_TO determine_VB the_DT extent_NN of_IN the_DT impairment_NN loss_NN if_IN any_DT ._.
Where_WRB the_DT asset_NN does_VBZ not_RB generate_VB cash_NN flows_NNS that_WDT are_VBP independent_JJ from_IN other_JJ assets_NNS ,_, the_DT Group_NNP estimates_VBZ the_DT recoverable_JJ amount_NN of_IN the_DT cash-generating_JJ unit_NN to_TO which_WDT the_DT asset_NN belongs_VBZ ._.
An_DT intangible_JJ asset_NN with_IN an_DT indefinite_JJ useful_JJ life_NN is_VBZ tested_VBN for_IN impairment_NN annually_RB and_CC whenever_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT asset_NN may_MD be_VB impaired_VBN ._.
The_DT recoverable_JJ amount_NN is_VBZ the_DT higher_JJR of_IN fair_JJ value_NN less_RBR costs_NNS to_TO sell_VB and_CC value_NN in_IN use_NN ._.
In_IN assessing_VBG value_NN in_IN use_NN ,_, the_DT estimated_JJ future_JJ cash_NN flows_NNS are_VBP discounted_VBN to_TO their_PRP$ present_JJ value_NN using_VBG a_DT pre-tax_JJ discount_NN rate_NN that_WDT reflects_VBZ current_JJ market_NN assessments_NNS of_IN the_DT time_NN value_NN of_IN money_NN and_CC the_DT risks_NNS specific_JJ to_TO the_DT asset_NN for_IN which_WDT the_DT estimates_NNS of_IN future_JJ cash_NN flows_NNS have_VBP not_RB been_VBN adjusted_VBN ._.
If_IN the_DT recoverable_JJ amount_NN of_IN an_DT asset_NN or_CC cash-generating_JJ unit_NN is_VBZ estimated_VBN to_TO be_VB less_JJR than_IN its_PRP$ carrying_VBG amount_NN ,_, the_DT carrying_VBG amount_NN of_IN the_DT asset_NN or_CC cash-generating_JJ unit_NN is_VBZ reduced_VBN to_TO its_PRP$ recoverable_JJ amount_NN ._.
An_DT impairment_NN loss_NN is_VBZ recognized_VBN as_IN an_DT expense_NN immediately_RB ,_, unless_IN the_DT relevant_JJ asset_NN is_VBZ carried_VBN at_IN a_DT revalued_VBN amount_NN ,_, in_IN which_WDT case_NN the_DT impairment_NN loss_NN is_VBZ treated_VBN as_IN a_DT revaluation_NN decrease_NN to_TO the_DT extent_NN that_IN a_DT revaluation_NN surplus_NN exists_VBZ ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 53_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 54_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS Where_WRB an_DT impairment_NN loss_NN subsequently_RB reverses_VBZ ,_, the_DT carrying_VBG amount_NN of_IN the_DT asset_NN or_CC cash-generating_JJ unit_NN is_VBZ increased_VBN to_TO the_DT revised_VBN estimate_NN of_IN its_PRP$ recoverable_JJ amount_NN ,_, but_CC only_RB to_TO the_DT extent_NN that_IN the_DT increased_VBN carrying_VBG amount_NN does_VBZ not_RB exceed_VB the_DT carrying_VBG amount_NN that_WDT would_MD have_VB been_VBN determined_VBN had_VBD no_DT impairment_NN loss_NN been_VBN recognized_VBN ._.
A_DT reversal_NN of_IN an_DT impairment_NN loss_NN is_VBZ recognized_VBN as_IN income_NN immediately_RB ,_, unless_IN the_DT relevant_JJ asset_NN is_VBZ carried_VBN at_IN a_DT revalued_VBN amount_NN ,_, in_IN which_WDT case_NN the_DT reversal_NN of_IN the_DT impairment_NN loss_NN is_VBZ treated_VBN as_IN a_DT revaluation_NN increase_NN ._.
j_NNP Financial_NNP assets_NNS From_IN January_NNP 1_CD ,_, 2004_CD to_TO December_NNP 31_CD ,_, 2004_CD :_: Financial_NNP assets_NNS include_VBP investments_NNS in_IN companies_NNS other_JJ than_IN subsidiaries_NNS ,_, associates_NNS and_CC joint_JJ ventures_NNS ,_, financial_JJ receivables_NN held_VBN for_IN investment_NN purposes_NNS ,_, treasury_NN stock_NN and_CC other_JJ securities_NNS ._.
Financial_JJ assets_NNS are_VBP recorded_VBN at_IN cost_NN ,_, including_VBG additional_JJ direct_JJ charges_NNS ,_, less_JJR provision_NN for_IN any_DT impairment_NN ._.
From_IN January_NNP 1,2005_CD :_: From_IN January_NNP 1_CD ,_, 2005_CD the_DT Group_NNP applied_VBD IAS_NNP 32_CD and_CC IAS_NNP 39_CD ._.
The_DT Group_NNP has_VBZ chosen_VBN to_TO apply_VB these_DT standards_NNS prospectively_RB ,_, which_WDT has_VBZ resulted_VBN in_IN the_DT accounting_NN policy_NN described_VBD below_IN :_: The_DT Group_NNP classifies_VBZ its_PRP$ investments_NNS in_IN the_DT following_VBG categories_NNS :_: financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN ,_, loans_NNS and_CC receivables_NNS ,_, held-tomaturity_JJ investments_NNS and_CC available-for-sale_JJ financial_JJ assets_NNS ._.
The_DT classification_NN depends_VBZ on_IN the_DT purpose_NN for_IN which_WDT the_DT investments_NNS were_VBD acquired_VBN ._.
Management_NNP determines_VBZ the_DT classification_NN of_IN its_PRP$ investments_NNS at_IN initial_JJ recognition_NN and_CC re-evaluates_VBZ this_DT designation_NN at_IN every_DT reporting_NN date_NN ._.
Financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN This_DT category_NN has_VBZ two_CD sub-categories_NNS :_: financial_JJ assets_NNS held_VBN for_IN trading_NN ,_, and_CC those_DT designated_VBN at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN at_IN inception_NN ._.
A_DT financial_JJ asset_NN is_VBZ classified_VBN in_IN this_DT latter_JJ category_NN if_IN acquired_VBN principally_RB for_IN the_DT purpose_NN of_IN selling_VBG in_IN the_DT short_JJ term_NN or_CC if_IN so_RB designated_VBN by_IN management_NN ._.
Derivatives_NNS are_VBP also_RB categorised_VBN as_IN held_VBN for_IN trading_NN unless_IN they_PRP are_VBP designated_VBN as_IN hedges_NNS ._.
Assets_NNS in_IN this_DT category_NN are_VBP classified_VBN as_IN current_JJ assets_NNS if_IN they_PRP are_VBP either_RB held_VBN for_IN trading_NN or_CC are_VBP expected_VBN to_TO be_VB realized_VBN within_IN 12_CD months_NNS of_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT Group_NNP allocates_VBZ derivatives_NNS to_TO this_DT category_NN ._.
Loans_NNS and_CC receivables_NN Loans_NNS and_CC receivables_NNS are_VBP non-derivative_JJ financial_JJ assets_NNS with_IN fixed_VBN or_CC determinable_JJ payments_NNS that_WDT are_VBP not_RB quoted_VBN in_IN an_DT active_JJ market_NN ._.
They_PRP arise_VBP when_WRB the_DT Group_NNP provides_VBZ money_NN ,_, goods_NNS or_CC services_NNS directly_RB to_TO a_DT debtor_NN with_IN no_DT intention_NN of_IN trading_VBG the_DT receivable_NN ._.
They_PRP are_VBP included_VBN in_IN current_JJ assets_NNS ,_, except_IN for_IN maturities_NNS greater_JJR than_IN 12_CD months_NNS after_IN the_DT balance_NN sheet_NN date_NN ,_, which_WDT are_VBP classified_VBN as_IN non-current_JJ assets_NNS ._.
Held-to-maturity_JJ investments_NNS Held-to-maturity_JJ investments_NNS are_VBP non-derivative_JJ financial_JJ assets_NNS with_IN fixed_VBN or_CC determinable_JJ payments_NNS and_CC fixed_VBN maturities_NNS that_IN the_DT Groups_NNS management_NN has_VBZ the_DT positive_JJ intention_NN and_CC ability_NN to_TO hold_VB to_TO maturity_NN ._.
There_EX are_VBP no_DT investments_NNS allocated_VBN to_TO this_DT category_NN ._.
Available-for-sale_JJ financial_JJ assets_NNS Available-for-sale_JJ financial_JJ assets_NNS are_VBP non-derivatives_NNS that_WDT are_VBP either_RB designated_VBN in_IN this_DT category_NN or_CC not_RB classified_VBN in_IN any_DT of_IN the_DT other_JJ categories_NNS ._.
They_PRP are_VBP included_VBN in_IN non-current_JJ assets_NNS unless_IN management_NN intends_VBZ to_TO dispose_VB of_IN the_DT investment_NN within_IN 12_CD months_NNS of_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT Group_NNP allocates_VBZ all_DT its_PRP$ equity_NN investments_NNS which_WDT are_VBP not_RB investments_NNS in_IN subsidiaries_NNS ,_, associates_NNS or_CC joint_JJ ventures_NNS to_TO this_DT category_NN ._.
Purchases_NNS and_CC sales_NNS of_IN investments_NNS are_VBP recognized_VBN on_IN trade-date_NN the_DT date_NN on_IN which_WDT the_DT Group_NNP commits_VBZ to_TO purchase_VB or_CC sell_VB the_DT asset_NN ._.
Investments_NNP are_VBP initially_RB recognized_VBN at_IN fair_JJ value_NN plus_CC transaction_NN costs_NNS for_IN all_DT financial_JJ assets_NNS not_RB carried_VBD at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN ._.
Investments_NNP are_VBP derecognised_VBN when_WRB the_DT rights_NNS to_TO receive_VB cash_NN flows_NNS from_IN the_DT investments_NNS have_VBP expired_VBN or_CC have_VBP been_VBN transferred_VBN and_CC the_DT Group_NNP has_VBZ transferred_VBN substantially_RB all_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN ._.
Available-for-sale_JJ financial_JJ assets_NNS and_CC financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN are_VBP subsequently_RB carried_VBN at_IN fair_JJ value_NN ._.
Loans_NNS and_CC receivables_NNS and_CC held-to-maturity_JJ investments_NNS are_VBP carried_VBN at_IN amortised_JJ cost_NN using_VBG the_DT effective_JJ interest_NN method_NN ._.
Realised_VBN and_CC unrealized_JJ gains_NNS and_CC losses_NNS arising_VBG from_IN changes_NNS in_IN the_DT fair_JJ value_NN of_IN the_DT financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN category_NN are_VBP included_VBN in_IN the_DT income_NN statement_NN in_IN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
Unrealized_JJ gains_NNS and_CC losses_NNS arising_VBG from_IN changes_NNS in_IN the_DT fair_JJ value_NN of_IN non-monetary_JJ securities_NNS classified_VBN as_IN available-for-sale_NN are_VBP recognized_VBN in_IN equity_NN ._.
When_WRB securities_NNS classified_VBN as_IN available-for-sale_NN are_VBP sold_VBN or_CC impaired_VBN ,_, the_DT accumulated_VBN fair_JJ value_NN adjustments_NNS are_VBP included_VBN in_IN the_DT income_NN statement_NN as_IN gains_NNS and_CC losses_NNS from_IN investment_NN securities_NNS ._.
The_DT fair_JJ values_NNS of_IN quoted_VBN investments_NNS are_VBP based_VBN on_IN current_JJ bid_NN prices_NNS ._.
If_IN the_DT market_NN for_IN a_DT financial_JJ asset_NN is_VBZ not_RB active_JJ and_CC for_IN unlisted_JJ securities_NNS ,_, the_DT Group_NNP establishes_VBZ fair_JJ value_NN by_IN using_VBG valuation_NN techniques_NNS unless_IN fair_JJ value_NN can_MD not_RB be_VB reliably_RB measured_VBN ._.
In_IN this_DT case_NN such_JJ unquoted_JJ equity_NN instruments_NNS are_VBP measured_VBN at_IN cost_NN ._.
The_DT Group_NNP assesses_VBZ at_IN each_DT balance_NN sheet_NN date_NN whether_IN there_EX is_VBZ objective_JJ evidence_NN that_IN a_DT financial_JJ asset_NN or_CC a_DT group_NN of_IN financial_JJ assets_NNS is_VBZ impaired_VBN ._.
In_IN the_DT case_NN of_IN equity_NN securities_NNS classified_VBN as_IN available-for-sale_JJ ,_, a_DT significant_JJ or_CC prolonged_JJ decline_NN in_IN the_DT fair_JJ value_NN of_IN the_DT security_NN below_IN its_PRP$ cost_NN is_VBZ considered_VBN in_IN determining_VBG whether_IN the_DT securities_NNS are_VBP impaired_VBN ._.
If_IN any_DT such_JJ evidence_NN exists_VBZ for_IN available-for-sale_JJ financial_JJ assets_NNS ,_, the_DT cumulative_JJ loss_NN measured_VBN as_IN the_DT difference_NN between_IN the_DT acquisition_NN cost_NN and_CC the_DT current_JJ fair_JJ value_NN ,_, less_JJR any_DT impairment_NN loss_NN on_IN that_DT financial_JJ asset_NN previously_RB recognized_VBN in_IN profit_NN or_CC loss_NN is_VBZ removed_VBN from_IN equity_NN and_CC recognized_VBN in_IN the_DT income_NN statement_NN ._.
Impairment_NN losses_NNS recognized_VBN in_IN the_DT income_NN statement_NN on_IN equity_NN instruments_NNS are_VBP not_RB reversed_VBN through_IN the_DT income_NN statement_NN ._.
54_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 55_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS k_NN Accounting_NN for_IN derivative_JJ financial_JJ instruments_NNS and_CC hedging_VBG activities_NNS From_IN January_NNP 1_CD ,_, 2004_CD to_TO December_NNP 31_CD ,_, 2004_CD :_: The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO reduce_VB exposure_NN to_TO foreign_JJ exchange_NN risk_NN and_CC interest_NN rate_NN movements_NNS ._.
The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS for_IN speculative_JJ purposes_NNS ._.
For_IN a_DT forward_RB foreign_JJ exchange_NN contract_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN ,_, the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ foreign_JJ currency_NN assets_NNS or_CC liabilities_NNS or_CC to_TO a_DT probable_JJ commitment_NN ._.
It_PRP must_MD involve_VB the_DT same_JJ currency_NN or_CC similar_JJ currencies_NNS as_IN the_DT hedged_VBN item_NN and_CC must_MD also_RB reduce_VB the_DT risk_NN of_IN foreign_JJ currency_NN exchange_NN movements_NNS on_IN the_DT Groups_NNS operations_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG on_IN these_DT contracts_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN the_DT income_NN statement_NN ,_, or_CC as_IN adjustments_NNS to_TO the_DT carrying_VBG amount_NN of_IN fixed_JJ assets_NNS ,_, only_RB when_WRB the_DT hedged_VBN transaction_NN has_VBZ itself_PRP been_VBN reflected_VBN in_IN the_DT Groups_NNS accounts_NNS ._.
For_IN an_DT interest_NN rate_NN swap_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ assets_NNS or_CC liabilities_NNS or_CC a_DT probable_JJ commitment_NN and_CC must_MD change_VB the_DT nature_NN of_IN the_DT interest_NN rate_NN by_IN converting_VBG a_DT fixed_JJ rate_NN to_TO a_DT variable_JJ rate_NN or_CC vice_NN versa_RB ._.
Interest_NN differentials_NNS under_IN these_DT swaps_NNS are_VBP recognized_VBN by_IN adjusting_VBG net_JJ interest_NN payable_JJ over_IN the_DT periods_NNS of_IN the_DT contracts_NNS ._.
If_IN an_DT instrument_NN ceases_VBZ to_TO be_VB accounted_VBN for_IN as_IN a_DT hedge_NN ,_, for_IN example_NN because_IN the_DT underlying_VBG hedged_JJ position_NN is_VBZ eliminated_VBN ,_, the_DT instrument_NN is_VBZ marked_VBN to_TO market_NN and_CC any_DT resulting_JJ profit_NN or_CC loss_NN recognized_VBN at_IN that_DT time_NN ._.
From_IN January_NNP 1_CD ,_, 2005_CD onwards_NNS From_IN January_NNP 1_CD ,_, 2005_CD the_DT Group_NNP applied_VBD IAS_NNP 32_CD and_CC IAS_NNP 39_CD ._.
The_DT Group_NNP has_VBZ chosen_VBN to_TO apply_VB these_DT standards_NNS prospectively_RB ,_, which_WDT has_VBZ resulted_VBN in_IN the_DT accounting_NN policy_NN described_VBD below_IN :_: Derivatives_NNS are_VBP initially_RB recognized_VBN at_IN fair_JJ value_NN on_IN the_DT date_NN on_IN which_WDT a_DT derivative_JJ contract_NN is_VBZ entered_VBN into_IN and_CC are_VBP subsequently_RB re-measured_JJ at_IN their_PRP$ fair_JJ value_NN ._.
The_DT method_NN of_IN recognizing_VBG the_DT resulting_VBG gain_NN or_CC loss_NN depends_VBZ on_IN whether_IN the_DT derivative_NN is_VBZ designated_VBN as_IN a_DT hedging_NN instrument_NN ,_, and_CC if_IN so_RB ,_, the_DT nature_NN of_IN the_DT item_NN being_VBG hedged_VBN ._.
Currently_RB ,_, the_DT Group_NNP does_VBZ not_RB designate_VB any_DT of_IN its_PRP$ derivatives_NNS as_IN a_DT hedging_NN instrument_NN and_CC therefore_RB none_NN qualify_VB for_IN hedge_JJ accounting_NN ._.
Changes_NNS in_IN the_DT fair_JJ value_NN of_IN any_DT derivative_JJ instruments_NNS that_WDT do_VBP not_RB qualify_VB for_IN hedge_JJ accounting_NN are_VBP recognized_VBN immediately_RB in_IN the_DT income_NN statement_NN ._.
l_NN Leases_VBZ Leases_NNS of_IN property_NN ,_, plant_NN and_CC equipment_NN where_WRB the_DT Group_NNP has_VBZ substantially_RB all_PDT the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN are_VBP classified_VBN as_IN finance_NN leases_NNS ._.
Finance_NNP leases_NNS are_VBP capitalized_VBN at_IN the_DT leases_NNS inception_NN at_IN the_DT lower_JJR of_IN the_DT fair_JJ value_NN of_IN the_DT leased_VBN asset_NN and_CC the_DT present_JJ value_NN of_IN the_DT future_JJ minimum_NN lease_NN payments_NNS ._.
Each_DT lease_NN payment_NN is_VBZ allocated_VBN between_IN the_DT underlying_VBG liability_NN to_TO the_DT lessor_NN and_CC the_DT associated_VBN finance_NN charges_NNS so_RB as_IN to_TO achieve_VB a_DT constant_JJ rate_NN on_IN the_DT finance_NN balance_NN outstanding_JJ ._.
The_DT corresponding_JJ rental_JJ obligations_NNS ,_, net_NN of_IN finance_NN charges_NNS ,_, are_VBP included_VBN in_IN Borrowings_NNS ._.
The_DT interest_NN element_NN of_IN the_DT finance_NN cost_NN is_VBZ charged_VBN to_TO the_DT income_NN statement_NN over_IN the_DT lease_NN period_NN so_RB as_IN to_TO produce_VB a_DT constant_JJ periodic_JJ rate_NN of_IN interest_NN on_IN the_DT remaining_VBG balance_NN of_IN the_DT liability_NN for_IN each_DT period_NN ._.
The_DT property_NN ,_, plant_NN and_CC equipment_NN acquired_VBN under_IN finance_NN leases_NNS are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT assets_NNS useful_JJ life_NN and_CC the_DT lease_NN term_NN ._.
Leases_NNS where_WRB the_DT lessor_JJR retains_VBZ a_DT significant_JJ portion_NN of_IN the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN are_VBP classified_VBN as_IN operating_VBG leases_NNS ._.
Payments_NNS made_VBN under_IN operating_VBG leases_NNS net_NN of_IN any_DT incentives_NNS received_VBD from_IN the_DT lessor_NN are_VBP charged_VBN to_TO the_DT income_NN statement_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT period_NN of_IN the_DT lease_NN ._.
m_FW Inventories_NNS Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realizable_JJ value_NN except_IN where_WRB arising_VBG on_IN business_NN combination_NN ._.
Cost_NN is_VBZ determined_VBN using_VBG the_DT firstin-first-out_JJ FIFO_NNP method_NN ._.
The_DT cost_NN of_IN finished_VBN goods_NNS and_CC work_NN in_IN progress_NN comprises_VBZ raw_JJ materials_NNS ,_, direct_JJ labor_NN ,_, other_JJ direct_JJ costs_NNS and_CC related_JJ production_NN overheads_NNS based_VBN on_IN normal_JJ operating_NN capacity_NN ._.
Net_JJ realizable_JJ value_NN is_VBZ the_DT estimated_VBN selling_NN price_NN in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, less_JJR all_DT estimated_VBN costs_NNS of_IN completion_NN and_CC costs_NNS to_TO be_VB incurred_VBN in_IN marketing_NN ,_, selling_VBG and_CC distribution_NN ._.
n_NNP Trade_NNP receivables_NN Trade_NNP receivables_NNS do_VBP not_RB carry_VB any_DT interest_NN and_CC are_VBP stated_VBN at_IN their_PRP$ nominal_JJ value_NN as_IN reduced_VBN by_IN appropriate_JJ allowances_NNS for_IN estimated_VBN irrecoverable_JJ amounts_NNS ._.
o_NN Cash_NN ,_, cash_NN equivalents_NNS and_CC restricted_VBN cash_NN Cash_NN and_CC cash_NN equivalents_NNS are_VBP carried_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN ._.
Cash_NN and_CC cash_NN equivalents_NNS comprise_VBP cash_NN on_IN hand_NN ,_, deposits_NNS held_VBD at_IN call_NN with_IN banks_NNS and_CC other_JJ short-term_JJ ,_, highly_RB liquid_JJ investments_NNS with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ._.
Restricted_VBN cash_NN is_VBZ carried_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN ._.
Restricted_VBN cash_NN comprises_VBZ reserve_NN funds_NNS required_VBN for_IN financial_JJ guarantee_NN contracts_NNS and_CC collateral_NN against_IN certain_JJ leased_VBN assets_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 55_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 56_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS p_VBP Share_NN capital_NN Ordinary_NNP shares_NNS are_VBP classified_VBN as_IN equity_NN ._.
Incremental_JJ costs_NNS directly_RB attributable_JJ to_TO the_DT issue_NN of_IN new_JJ shares_NNS or_CC options_NNS are_VBP shown_VBN in_IN equity_NN as_IN a_DT deduction_NN ,_, net_NN of_IN tax_NN ,_, from_IN the_DT proceeds_NNS other_JJ than_IN where_WRB the_DT issue_NN of_IN new_JJ shares_NNS or_CC options_NNS relates_VBZ to_TO the_DT acquisition_NN of_IN a_DT business_NN ,_, in_IN which_WDT case_NN such_JJ incremental_JJ costs_NNS are_VBP included_VBN in_IN the_DT cost_NN of_IN acquisition_NN as_IN part_NN of_IN the_DT purchase_NN consideration_NN ._.
Where_WRB any_DT company_NN in_IN the_DT Group_NNP purchases_NNS the_DT Companys_NNPS equity_NN share_NN capital_NN treasury_NN shares_NNS ,_, the_DT consideration_NN paid_VBN ,_, including_VBG any_DT directly_RB attributable_JJ incremental_JJ costs_NNS net_JJ of_IN income_NN taxes_NNS ,_, is_VBZ deducted_VBN from_IN equity_NN attributable_JJ to_TO the_DT Companys_NNPS equity_NN holders_NNS until_IN the_DT shares_NNS are_VBP canceled_VBN ,_, reissued_VBN or_CC disposed_VBN of_IN ._.
Where_WRB such_JJ shares_NNS are_VBP subsequently_RB sold_VBN or_CC reissued_VBN ,_, any_DT consideration_NN received_VBD ,_, net_NN of_IN any_DT directly_RB attributable_JJ incremental_JJ transaction_NN costs_NNS and_CC the_DT related_JJ income_NN tax_NN effects_NNS ,_, is_VBZ included_VBN in_IN equity_NN attributable_JJ to_TO the_DT Companys_NNPS equity_NN holders_NNS ._.
q_NN Borrowings_NNS From_IN January_NNP 1_CD ,_, 2004_CD to_TO December_NNP 31_CD ,_, 2004_CD :_: Borrowings_NNS are_VBP stated_VBN at_IN the_DT amount_NN of_IN the_DT net_JJ proceeds_NNS after_IN deduction_NN of_IN issue_NN costs_NNS ._.
The_DT carrying_VBG amount_NN is_VBZ increased_VBN by_IN the_DT finance_NN cost_NN in_IN respect_NN of_IN the_DT accounting_NN period_NN and_CC reduced_VBN by_IN payments_NNS made_VBN in_IN the_DT period_NN ._.
From_IN January_NNP 1_CD ,_, 2005_CD :_: From_IN January_NNP 1_CD ,_, 2005_CD the_DT Group_NNP applied_VBD IAS_NNP 32_CD and_CC IAS_NNP 39_CD ._.
The_DT Group_NNP has_VBZ chosen_VBN to_TO apply_VB these_DT standards_NNS prospectively_RB ,_, which_WDT has_VBZ resulted_VBN in_IN the_DT accounting_NN policy_NN described_VBD below_IN :_: Borrowings_NNS are_VBP recognized_VBN initially_RB at_IN fair_JJ value_NN ,_, net_NN of_IN transaction_NN costs_NNS incurred_VBN ._.
Borrowings_NNS are_VBP subsequently_RB stated_VBN at_IN amortised_JJ cost_NN :_: any_DT difference_NN between_IN proceeds_NNS net_NN of_IN transaction_NN costs_NNS and_CC the_DT redemption_NN value_NN is_VBZ recognized_VBN in_IN the_DT income_NN statement_NN over_IN the_DT period_NN of_IN the_DT borrowings_NNS using_VBG the_DT effective_JJ interest_NN method_NN ._.
Convertible_JJ loan_NN notes_NNS are_VBP regarded_VBN as_IN compound_NN instruments_NNS ,_, consisting_VBG of_IN a_DT liability_NN component_NN and_CC an_DT equity_NN component_NN ._.
The_DT fair_JJ value_NN of_IN the_DT liability_NN portion_NN of_IN a_DT convertible_JJ bond_NN is_VBZ determined_VBN using_VBG a_DT market_NN interest_NN rate_NN for_IN an_DT equivalent_JJ non-convertible_JJ bond_NN ._.
This_DT amount_NN is_VBZ recorded_VBN as_IN a_DT liability_NN on_IN an_DT amortised_JJ cost_NN basis_NN until_IN extinguished_VBN on_IN conversion_NN or_CC maturity_NN of_IN the_DT bonds_NNS ._.
The_DT remainder_NN of_IN the_DT proceeds_NNS is_VBZ allocated_VBN to_TO the_DT conversion_NN option_NN ._.
This_DT is_VBZ recognized_VBN and_CC included_VBN in_IN shareholders_NNS equity_NN ,_, net_NN of_IN income_NN tax_NN effects_NNS ._.
Borrowings_NNS are_VBP classified_VBN as_IN current_JJ liabilities_NNS unless_IN the_DT Group_NNP has_VBZ an_DT unconditional_JJ right_NN to_TO defer_VB settlement_NN of_IN the_DT liability_NN for_IN at_IN least_JJS 12_CD months_NNS after_IN the_DT balance_NN sheet_NN date_NN ._.
r_NN Taxation_NNP The_NNP tax_NN expense_NN represents_VBZ the_DT sum_NN of_IN the_DT current_JJ and_CC deferred_JJ tax_NN ._.
Taxable_JJ profit_NN differs_VBZ from_IN net_JJ profit_NN as_IN reported_VBN in_IN the_DT income_NN statement_NN because_IN it_PRP excludes_VBZ items_NNS of_IN income_NN or_CC expense_NN that_WDT are_VBP taxable_JJ or_CC deductible_JJ in_IN other_JJ years_NNS and_CC it_PRP further_RB excludes_VBZ items_NNS that_WDT are_VBP never_RB taxable_JJ or_CC deductible_JJ ._.
The_DT Groups_NNS liability_NN for_IN current_JJ tax_NN is_VBZ calculated_VBN using_VBG tax_NN rates_NNS that_WDT have_VBP been_VBN enacted_VBN or_CC substantively_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN is_VBZ the_DT tax_NN expected_VBN to_TO be_VB payable_JJ or_CC recoverable_JJ on_IN differences_NNS between_IN the_DT carrying_VBG amounts_NNS of_IN assets_NNS and_CC liabilities_NNS in_IN the_DT financial_JJ statements_NNS and_CC the_DT corresponding_JJ tax_NN bases_NNS used_VBN in_IN the_DT computation_NN of_IN taxable_JJ profit_NN ,_, and_CC is_VBZ accounted_VBN for_IN using_VBG the_DT balance_NN sheet_NN liability_NN method_NN ._.
Deferred_JJ tax_NN liabilities_NNS are_VBP generally_RB recognized_VBN for_IN all_DT taxable_JJ temporary_JJ differences_NNS and_CC deferred_VBN tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ probable_JJ that_IN taxable_JJ profits_NNS will_MD be_VB available_JJ against_IN which_WDT deductible_JJ temporary_JJ differences_NNS can_MD be_VB utilised_VBN ._.
Such_JJ assets_NNS and_CC liabilities_NNS are_VBP not_RB recognized_VBN if_IN the_DT temporary_JJ difference_NN arises_VBZ from_IN the_DT initial_JJ recognition_NN of_IN goodwill_NN or_CC from_IN the_DT initial_JJ recognition_NN other_JJ than_IN in_IN a_DT business_NN combination_NN of_IN other_JJ assets_NNS and_CC liabilities_NNS in_IN a_DT transaction_NN that_WDT affects_VBZ neither_CC the_DT tax_NN profit_NN not_RB the_DT accounting_NN profit_NN ._.
Deferred_JJ tax_NN liabilities_NNS are_VBP recognized_VBN for_IN taxable_JJ temporary_JJ differences_NNS arising_VBG on_IN investments_NNS in_IN subsidiaries_NNS and_CC associates_NNS ,_, and_CC interests_NNS in_IN joint_JJ ventures_NNS ,_, except_IN where_WRB the_DT Group_NNP is_VBZ able_JJ to_TO control_VB the_DT reversal_NN of_IN the_DT temporary_JJ difference_NN and_CC it_PRP is_VBZ probable_JJ that_IN the_DT temporary_JJ difference_NN will_MD not_RB reverse_VB in_IN the_DT foreseeable_JJ future_NN ._.
The_DT carrying_VBG amount_NN of_IN deferred_JJ tax_NN assets_NNS is_VBZ reviewed_VBN at_IN each_DT balance_NN sheet_NN date_NN and_CC reduced_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ no_RB longer_RB probable_JJ that_IN sufficient_JJ taxable_JJ profits_NNS will_MD be_VB available_JJ to_TO allow_VB all_DT or_CC part_NN of_IN the_DT asset_NN to_TO be_VB recovered_VBN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP offset_VBN when_WRB there_EX is_VBZ a_DT legally_RB enforceable_JJ right_NN to_TO set_VB off_RP current_JJ tax_NN assets_NNS against_IN current_JJ tax_NN liabilities_NNS and_CC when_WRB they_PRP relate_VBP to_TO income_NN taxes_NNS levied_VBN by_IN the_DT same_JJ taxation_NN authority_NN and_CC the_DT Group_NNP intends_VBZ to_TO settle_VB its_PRP$ current_JJ tax_NN assets_NNS and_CC liabilities_NNS on_IN a_DT net_JJ basis_NN ._.
Deferred_JJ tax_NN is_VBZ calculated_VBN at_IN the_DT tax_NN rates_NNS that_WDT are_VBP expected_VBN to_TO apply_VB in_IN the_DT period_NN when_WRB the_DT liability_NN is_VBZ settled_VBN or_CC the_DT asset_NN is_VBZ realized_VBN ._.
Deferred_JJ tax_NN is_VBZ charged_VBN or_CC credited_VBN to_TO the_DT income_NN statement_NN ,_, except_IN when_WRB it_PRP relates_VBZ to_TO items_NNS charged_VBN or_CC credited_VBN directly_RB to_TO equity_NN ,_, in_IN which_WDT case_NN the_DT deferred_JJ tax_NN is_VBZ also_RB dealt_VBN with_IN in_IN equity_NN ._.
56_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 57_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS s_VBZ Employee_NNP benefits_NNS Retirement_NNP obligations_NNS defined_VBD contribution_NN plans_NNS The_DT Group_NNP operates_VBZ personal_JJ defined_VBN contribution_NN plans_NNS for_IN employees_NNS ._.
A_DT defined_VBN contribution_NN plan_NN is_VBZ a_DT pension_NN plan_NN under_IN which_WDT the_DT Group_NNP pays_VBZ fixed_VBN percentage_NN contributions_NNS into_IN a_DT separate_JJ entity_NN ._.
The_DT Group_NNP has_VBZ no_DT legal_JJ or_CC constructive_JJ obligations_NNS to_TO pay_VB further_JJ contributions_NNS if_IN the_DT fund_NN does_VBZ not_RB hold_VB sufficient_JJ assets_NNS to_TO pay_VB all_DT employees_NNS the_DT benefits_NNS relating_VBG to_TO employee_NN service_NN in_IN the_DT current_JJ and_CC prior_JJ periods_NNS ._.
The_DT Group_NNP pays_VBZ contributions_NNS to_TO publicly_RB or_CC privately_RB administered_VBN pension_NN insurance_NN plans_VBZ on_IN a_DT mandatory_JJ ,_, contractual_JJ or_CC voluntary_JJ basis_NN ._.
The_DT Group_NNP has_VBZ no_DT further_JJ payment_NN obligations_NNS once_IN the_DT contributions_NNS have_VBP been_VBN paid_VBN ._.
The_DT contributions_NNS are_VBP recognized_VBN as_IN employee_NN benefit_NN expense_NN when_WRB they_PRP are_VBP due_JJ ._.
Prepaid_JJ contributions_NNS are_VBP recognized_VBN as_IN an_DT asset_NN to_TO the_DT extent_NN that_IN a_DT cash_NN refund_NN or_CC a_DT reduction_NN in_IN future_JJ payments_NNS is_VBZ available_JJ ._.
Retirement_NNP obligations_NNS defined_VBD benefit_NN plans_NNS The_DT Group_NNP operates_VBZ defined_VBN benefit_NN plans_NNS SERPs_NNS for_IN certain_JJ senior_JJ employees_NNS ._.
The_DT liability_NN recognized_VBN in_IN the_DT balance_NN sheet_NN in_IN respect_NN of_IN these_DT plans_NNS shown_VBN in_IN Note_NN 27_CD is_VBZ the_DT present_JJ value_NN of_IN the_DT defined_VBN benefit_NN obligations_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
Assets_NNS relating_VBG to_TO a_DT closed_JJ defined_VBN benefit_NN plan_NN are_VBP held_VBN in_IN a_DT Rabbi_NNP Trust_NNP ,_, the_DT legal_JJ form_NN of_IN which_WDT is_VBZ such_JJ that_IN the_DT assets_NNS held_VBD to_TO cover_VB the_DT pension_NN liabilities_NNS are_VBP available_JJ to_TO the_DT general_JJ creditors_NNS of_IN the_DT company_NN on_IN winding_VBG up_RP and_CC are_VBP therefore_RB shown_VBN on_IN the_DT balance_NN sheet_NN Note_VB 24_CD ._.
Changes_NNS in_IN the_DT present_JJ value_NN of_IN the_DT benefit_NN obligation_NN are_VBP recognized_VBN in_IN the_DT income_NN statement_NN ._.
Further_JJ information_NN on_IN the_DT Groups_NNS defined_VBN benefit_NN plans_NNS can_MD be_VB found_VBN in_IN Note_NN 29_CD Retirement_NNP obligations_NNS ._.
Share-based_JJ compensation_NN The_DT Group_NNP has_VBZ applied_VBN the_DT requirements_NNS of_IN IFRS_NNP 2_CD ,_, Share-based_JJ Payment_NN ._.
In_IN accordance_NN with_IN the_DT transitional_JJ provisions_NNS ,_, IFRS_NNP 2_CD has_VBZ been_VBN applied_VBN to_TO all_DT grants_NNS of_IN equity_NN instruments_NNS after_IN November_NNP 7_CD ,_, 2002_CD that_WDT were_VBD unvested_JJ at_IN December_NNP 31_CD ,_, 2004_CD ._.
The_DT Group_NNP operates_VBZ equity-settled_JJ ,_, share-based_JJ compensation_NN plans_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT employee_NN services_NNS received_VBN in_IN exchange_NN for_IN the_DT grant_NN of_IN the_DT options_NNS is_VBZ calculated_VBN using_VBG the_DT Black-Scholes_NNP model_NN ._.
In_IN accordance_NN with_IN IFRS_NNP 2_CD Share-based_JJ Payments_NNS ,_, the_DT resulting_VBG cost_NN is_VBZ recognized_VBN as_IN an_DT expense_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT vesting_JJ period_NN of_IN the_DT options_NNS ._.
The_DT value_NN of_IN the_DT charge_NN is_VBZ adjusted_VBN to_TO reflect_VB expected_VBN and_CC actual_JJ levels_NNS of_IN options_NNS vesting_NN ._.
The_DT Group_NNP also_RB provides_VBZ employees_NNS with_IN the_DT option_NN to_TO purchase_VB ordinary_JJ shares_NNS of_IN Shire_NNP :_: under_IN the_DT Sharesave_NNP Scheme_NNP at_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS :_: and_CC under_IN the_DT Employee_NNP Share_NNP Purchase_NNP Plan_NNP at_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT proceeds_NNS received_VBD ,_, net_NN of_IN any_DT directly_RB attributable_JJ transaction_NN costs_NNS ,_, are_VBP credited_VBN to_TO share_VB capital_NN nominal_JJ value_NN and_CC share_NN premium_NN when_WRB the_DT options_NNS are_VBP exercised_VBN ._.
Termination_NN benefits_NNS Termination_NN benefits_NNS are_VBP payable_JJ when_WRB employment_NN is_VBZ terminated_VBN before_IN the_DT normal_JJ retirement_NN date_NN ,_, or_CC whenever_WRB an_DT employee_NN accepts_VBZ voluntary_JJ redundancy_NN in_IN exchange_NN for_IN these_DT benefits_NNS ._.
The_DT Group_NNP recognizes_VBZ termination_NN benefits_NNS when_WRB it_PRP is_VBZ demonstrably_RB committed_VBN to_TO either_DT :_: i_FW terminating_VBG the_DT employment_NN of_IN current_JJ employees_NNS according_VBG to_TO a_DT detailed_JJ formal_JJ plan_NN without_IN possibility_NN of_IN withdrawal_NN :_: or_CC ii_FW providing_VBG termination_NN benefits_NNS as_IN a_DT result_NN of_IN an_DT offer_NN made_VBD to_TO encourage_VB voluntary_JJ redundancy_NN ._.
Benefits_NNS falling_VBG due_RB more_JJR than_IN 12_CD months_NNS after_IN the_DT balance_NN sheet_NN date_NN are_VBP discounted_VBN to_TO present_JJ value_NN ._.
t_NN Provisions_NNS Provisions_NNS for_IN restructuring_VBG costs_NNS and_CC legal_JJ claims_NNS are_VBP recognized_VBN when_WRB the_DT Group_NNP has_VBZ a_DT present_JJ legal_JJ or_CC constructive_JJ obligation_NN as_IN a_DT result_NN of_IN past_JJ events_NNS :_: it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_DT an_DT outflow_NN of_IN resources_NNS will_MD be_VB required_VBN to_TO settle_VB the_DT obligation_NN :_: the_DT amount_NN can_MD be_VB reliably_RB estimated_VBN and_CC when_WRB a_DT detailed_JJ formal_JJ plan_NN for_IN the_DT restructuring_NN has_VBZ been_VBN communicated_VBN to_TO affected_JJ parties_NNS ._.
Provisions_NNS are_VBP measured_VBN at_IN the_DT Directors_NNS best_JJS estimate_NN of_IN the_DT expenditure_NN required_VBN to_TO settle_VB the_DT obligation_NN at_IN the_DT balance_NN sheet_NN date_NN ,_, and_CC are_VBP discounted_VBN to_TO present_JJ value_NN where_WRB the_DT effect_NN is_VBZ material_NN ._.
Restructuring_NN provisions_NNS comprise_VBP lease_NN termination_NN penalties_NNS and_CC employee_NN termination_NN payments_NNS ._.
Provisions_NNS are_VBP not_RB recognized_VBN for_IN future_JJ operating_NN losses_NNS ._.
Where_WRB there_EX are_VBP a_DT number_NN of_IN similar_JJ obligations_NNS ,_, the_DT likelihood_NN that_IN an_DT outflow_NN will_MD be_VB required_VBN in_IN settlement_NN is_VBZ determined_VBN by_IN considering_VBG the_DT class_NN of_IN obligations_NNS as_IN a_DT whole_NN ._.
A_DT provision_NN is_VBZ recognized_VBN even_RB if_IN the_DT likelihood_NN of_IN an_DT outflow_NN with_IN respect_NN to_TO any_DT one_CD item_NN included_VBN in_IN the_DT same_JJ class_NN of_IN obligations_NNS may_MD be_VB small_JJ ._.
u_NNP Dividend_NN distribution_NN Dividend_NN distribution_NN to_TO the_DT Companys_NNPS shareholders_NNS is_VBZ recognized_VBN as_IN a_DT liability_NN in_IN the_DT Groups_NNS financial_JJ statements_NNS in_IN the_DT period_NN in_IN which_WDT the_DT shareholders_NNS right_RB to_TO receive_VB payment_NN is_VBZ established_VBN ._.
This_DT occurs_VBZ in_IN the_DT period_NN in_IN which_WDT the_DT dividends_NNS are_VBP approved_VBN by_IN the_DT Companys_NNP shareholders_NNS ,_, or_CC in_IN the_DT case_NN of_IN an_DT interim_JJ dividend_NN ,_, when_WRB the_DT dividend_NN is_VBZ paid_VBN ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 57_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 58_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS v_VBP Non-current_JJ assets_NNS held_VBN for_IN sale_NN Non-current_JJ assets_NNS and_CC disposal_NN groups_NNS classified_VBN as_IN held_VBN for_IN sale_NN are_VBP measured_VBN at_IN the_DT lower_JJR of_IN carrying_VBG amount_NN and_CC fair_JJ value_NN less_RBR costs_NNS to_TO sell_VB ._.
Non-current_JJ assets_NNS and_CC disposal_NN groups_NNS are_VBP classified_VBN as_IN held_VBN for_IN sale_NN if_IN their_PRP$ carrying_VBG amount_NN will_MD be_VB recovered_VBN through_IN a_DT sale_NN transaction_NN rather_RB than_IN continuing_VBG use_NN ._.
This_DT condition_NN is_VBZ considered_VBN met_VBD only_RB when_WRB the_DT sale_NN is_VBZ highly_RB probable_JJ and_CC the_DT asset_NN or_CC disposal_NN group_NN is_VBZ available_JJ for_IN immediate_JJ sale_NN in_IN its_PRP$ present_JJ condition_NN ._.
Management_NN must_MD be_VB committed_VBN to_TO the_DT sale_NN ,_, which_WDT should_MD be_VB expected_VBN to_TO qualify_VB for_IN recognition_NN as_IN a_DT completed_VBN sale_NN within_IN one_CD year_NN from_IN the_DT date_NN of_IN classification_NN ._.
w_VB Government_NNP grants_NNS Government_NNP grants_NNS relating_VBG to_TO property_NN ,_, plant_NN and_CC equipment_NN are_VBP treated_VBN as_IN deferred_JJ income_NN and_CC released_VBN to_TO profit_VB and_CC loss_NN over_IN the_DT expected_VBN useful_JJ lives_NNS of_IN the_DT assets_NNS concerned_VBN ._.
3_CD Change_NNP in_IN reporting_VBG entity_NN On_IN November_NNP 25_CD ,_, 2005_CD ,_, Shire_NNP plc_NN ,_, a_DT public_JJ limited_JJ company_NN incorporated_VBN in_IN England_NNP and_CC Wales_NNP Shire_NNP ,_, became_VBD the_DT holding_VBG company_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN SPG_NNP pursuant_JJ to_TO a_DT Scheme_NN of_IN Arrangement_NN under_IN Section_NN 425_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD that_WDT was_VBD approved_VBN by_IN the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP and_CC the_DT shareholders_NNS of_IN SPG_NNP the_DT Scheme_NNP of_IN Arrangement_NNP ._.
Pursuant_JJ to_TO the_DT Scheme_NN of_IN Arrangement_NN ,_, ordinary_JJ shares_NNS ,_, each_DT having_VBG a_DT nominal_JJ value_NN of_IN 3.50_CD ,_, of_IN Shire_NNP Shire_NNP Ordinary_NNP Shares_NNP were_VBD exchanged_VBN for_IN ordinary_JJ shares_NNS ,_, each_DT having_VBG a_DT nominal_JJ value_NN of_IN 0.05_CD of_IN SPG_NNP SPG_NNP Ordinary_NNP Shares_NNP ,_, on_IN a_DT one-for-one_JJ basis_NN ._.
As_IN a_DT result_NN of_IN the_DT Scheme_NNP of_IN Arrangement_NNP ,_, SPG_NNP is_VBZ now_RB a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP and_CC has_VBZ been_VBN re-registered_VBN as_IN a_DT private_JJ company_NN under_IN the_DT name_NN Shire_NNP Pharmaceuticals_NNP Limited_NNP ._.
The_DT Shire_NNP Ordinary_NNP Shares_NNP carry_VBP substantially_RB the_DT same_JJ rights_NNS as_IN did_VBD the_DT SPG_NNP Ordinary_NNP Shares_NNP ._.
The_DT Scheme_NN of_IN Arrangement_NN did_VBD not_RB involve_VB any_DT payment_NN for_IN the_DT new_JJ Shire_NNP Ordinary_NNP Shares_NNP ._.
Shires_NNP Board_NNP of_IN Directors_NNS ,_, management_NN and_CC corporate_JJ governance_NN arrangements_NNS immediately_RB following_VBG the_DT Scheme_NN of_IN Arrangement_NN were_VBD the_DT same_JJ as_IN SPG_NNP immediately_RB before_IN the_DT effectiveness_NN of_IN the_DT Scheme_NN of_IN Arrangement_NN ._.
The_DT consolidated_JJ assets_NNS and_CC liabilities_NNS of_IN Shire_NNP immediately_RB after_IN the_DT Scheme_NN of_IN Arrangement_NN were_VBD the_DT same_JJ as_IN the_DT consolidated_JJ assets_NNS and_CC liabilities_NNS of_IN SPG_NNP immediately_RB prior_RB thereto_RB ._.
In_IN consequence_NN of_IN the_DT implementation_NN of_IN the_DT Scheme_NNP of_IN Arrangement_NNP ,_, American_NNP Depositary_NNP Shares_NNP ADSs_NNP representing_VBG ordinary_JJ shares_NNS of_IN SPG_NNP were_VBD replaced_VBN by_IN ADSs_NNS representing_VBG ordinary_JJ shares_NNS of_IN Shire_NNP on_IN a_DT one-for-one_JJ basis_NN ._.
Shire_NNP was_VBD incorporated_VBN on_IN June_NNP 27_CD ,_, 2005_CD ._.
Prior_RB to_TO November_NNP 25_CD ,_, 2005_CD Shire_NNP had_VBD not_RB commenced_VBN trading_NN or_CC made_VBN any_DT profits_NNS or_CC trading_NN losses_NNS ._.
On_IN November_NNP 28_CD ,_, 2005_CD the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP approved_VBD a_DT reduction_NN of_IN Shires_NNP share_NN capital_NN to_TO take_VB effect_NN on_IN November_NNP 29_CD ,_, 2005_CD ,_, when_WRB the_DT nominal_JJ value_NN of_IN each_DT Shire_NNP ordinary_JJ share_NN was_VBD reduced_VBN from_IN 3.50_CD to_TO 0.05_CD ._.
This_DT reduction_NN increased_VBD the_DT distributable_JJ reserves_NNS potentially_RB available_JJ to_TO Shire_VB to_TO approximately_RB $_$ 2.95_CD billion_CD ,_, which_WDT the_DT Directors_NNS of_IN Shire_NNP can_MD utilise_VB for_IN future_JJ dividend_NN payments_NNS at_IN their_PRP$ discretion_NN ._.
The_DT corporate_JJ restructuring_NN has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT reverse_JJ acquisition_NN ._.
Accordingly_RB ,_, the_DT historical_JJ financial_JJ statements_NNS prior_RB to_TO the_DT reorganization_NN are_VBP labeled_VBN as_IN those_DT of_IN Shire_NNP ,_, but_CC represent_VBP the_DT operations_NNS of_IN SPG_NNP ._.
For_IN periods_NNS prior_RB to_TO the_DT corporate_JJ restructuring_NN ,_, the_DT equity_NN of_IN Shire_NNP represents_VBZ the_DT historical_JJ equity_NN of_IN SPG_NNP ._.
After_IN the_DT Scheme_NN of_IN Arrangement_NN ,_, shareholders_NNS equity_NN represents_VBZ the_DT equity_NN of_IN Shire_NNP ._.
The_DT effect_NN on_IN share_NN capital_NN ,_, the_DT share_NN premium_NN account_NN ,_, the_DT capital_NN reserve_NN and_CC other_JJ reserve_NN is_VBZ shown_VBN in_IN the_DT Shareholders_NNS funds_NNS and_CC statement_NN of_IN shareholders_NNS equity_NN table_NN in_IN Note_NN 33_CD ._.
The_DT capital_NN reduction_NN has_VBZ resulted_VBN in_IN a_DT new_JJ distributable_JJ reserve_NN the_DT Capital_NNP Reduction_NNP Reserve_NNP ._.
The_DT increase_NN in_IN the_DT value_NN of_IN common_JJ stock_NN at_IN January_NNP 1_CD ,_, 2005_CD from_IN $_$ 36.1_CD million_CD to_TO $_$ 41.8_CD million_CD on_IN restatement_NN is_VBZ due_JJ to_TO differences_NNS between_IN the_DT historic_JJ exchange_NN rates_NNS used_VBN to_TO convert_VB SPGs_NNP Sterling_NNP denominated_VBD nominal_JJ share_NN capital_NN into_IN US_NNP Dollars_NNPS ,_, and_CC the_DT exchange_NN rate_NN at_IN the_DT time_NN of_IN the_DT corporate_JJ restructuring_NN ._.
Earnings_NNS per_IN share_NN are_VBP unaffected_JJ by_IN the_DT reorganization_NN ._.
All_DT SPG_NNP stock_NN options_NNS granted_VBN to_TO Directors_NNS and_CC employees_NNS under_IN stock_NN option_NN plans_NNS that_WDT were_VBD in_IN existence_NN immediately_RB prior_RB to_TO the_DT Scheme_NN of_IN Arrangement_NN were_VBD exchangeable_JJ for_IN stock_NN options_NNS in_IN Shire_NNP on_IN a_DT one-for-one_JJ basis_NN with_IN no_DT change_NN in_IN any_DT of_IN the_DT terms_NNS or_CC conditions_NNS ._.
The_DT number_NN of_IN stock_NN options_NNS for_IN which_WDT this_DT exchange_NN did_VBD not_RB take_VB place_NN was_VBD not_RB material_NN ._.
58_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 59_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 4_CD Financial_NNP risk_NN management_NN Financial_NNP risk_NN factors_NNS The_DT Groups_NNS activities_NNS expose_VB it_PRP to_TO a_DT variety_NN of_IN financial_JJ risks_NNS :_: market_NN risk_NN including_VBG foreign_JJ exchange_NN risk_NN and_CC price_NN risk_NN :_: cash_NN flow_NN and_CC fair_JJ value_NN interest_NN rate_NN risk_NN :_: credit_NN risk_NN :_: and_CC liquidity_NN risk_NN ._.
The_DT Groups_NNS overall_JJ risk_NN management_NN program_NN focuses_VBZ on_IN the_DT unpredictability_NN of_IN financial_JJ markets_NNS and_CC seeks_VBZ to_TO minimize_VB potential_JJ adverse_JJ effects_NNS on_IN the_DT Groups_NNS financial_JJ performance_NN ._.
The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO hedge_VB certain_JJ risk_NN exposures_NNS ._.
Financial_NNP Risk_NNP management_NN is_VBZ carried_VBN out_RP by_IN a_DT central_JJ treasury_NN department_NN Group_NNP Treasury_NNP under_IN policies_NNS approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS ._.
Group_NNP Treasury_NNP identifies_VBZ ,_, evaluates_VBZ and_CC hedges_NNS financial_JJ risks_NNS in_IN close_JJ co-operation_NN with_IN the_DT Groups_NNS operating_VBG units_NNS ._.
All_DT Group_NNP Treasury_NNP operations_NNS are_VBP conducted_VBN within_IN a_DT framework_NN of_IN policies_NNS and_CC procedures_NNS reviewed_VBN and_CC approved_VBN by_IN the_DT Board_NNP ._.
As_IN a_DT matter_NN of_IN policy_NN ,_, the_DT Group_NNP does_VBZ not_RB undertake_VB speculative_JJ transactions_NNS that_WDT would_MD increase_VB currency_NN or_CC interest_NN rate_NN exposure_NN ._.
a_DT Market_NN risk_NN Foreign_JJ exchange_NN risk_NN The_DT Groups_NNS net_JJ income_NN and_CC financial_JJ position_NN ,_, as_IN expressed_VBN in_IN US_NNP Dollars_NNPS ,_, are_VBP exposed_VBN to_TO movements_NNS in_IN foreign_JJ exchange_NN rates_NNS against_IN the_DT US_NNP Dollar_NNP ._.
The_DT main_JJ trading_NN currencies_NNS of_IN the_DT Group_NNP are_VBP the_DT US_NNP Dollar_NNP ,_, Pounds_NNP Sterling_NNP ,_, the_DT Euro_NNP and_CC the_DT Canadian_JJ Dollar_NN ._.
Foreign_JJ exchange_NN risk_NN arises_VBZ when_WRB future_JJ commercial_JJ transactions_NNS ,_, recognized_VBN assets_NNS ,_, liabilities_NNS and_CC net_JJ investments_NNS in_IN subsidiaries_NNS are_VBP denominated_VBN in_IN a_DT currency_NN that_WDT is_VBZ not_RB the_DT subsidiarys_NNS functional_JJ currency_NN ._.
The_DT exposure_NN to_TO foreign_JJ exchange_NN is_VBZ managed_VBN and_CC monitored_VBN by_IN Group_NNP Treasury_NNP ._.
Exposures_NNS are_VBP generally_RB managed_VBN through_IN natural_JJ hedging_NN via_IN the_DT currency_NN denomination_NN of_IN cash_NN balances_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD five_CD outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN of_IN $_$ 206_CD million_CD to_TO manage_VB the_DT risk_NN associated_VBN with_IN inter-company_JJ loans_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD there_EX were_VBD no_DT material_NN unrealized_JJ gains_NNS or_CC losses_NNS on_IN these_DT contracts_NNS ._.
Price_NN risk_NN As_IN of_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP has_VBZ $_$ 34.1_CD million_CD 2004_CD :_: $_$ 401.4_CD million_CD of_IN financial_JJ assets_NNS comprizing_VBG private_JJ companies_NNS ,_, publicly_RB quoted_VBN equities_NNS ,_, institutional_JJ and_CC managed_VBD cash_NN funds_NNS and_CC commercial_JJ paper_NN ._.
The_DT publicly_RB quoted_VBN assets_NNS are_VBP exposed_VBN to_TO market_NN risk_NN ._.
No_DT financial_JJ instruments_NNS or_CC derivatives_NNS have_VBP been_VBN employed_VBN to_TO hedge_VB this_DT risk_NN ._.
b_NN Cash_NN flow_NN and_CC fair_JJ value_NN interest_NN rate_NN risk_NN The_DT Groups_NNS income_NN and_CC operating_NN cash_NN flows_NNS are_VBP substantially_RB independent_JJ of_IN changes_NNS in_IN market_NN interest_NN rates_NNS ._.
The_DT majority_NN of_IN the_DT Groups_NNS debt_NN was_VBD repaid_VBN during_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD and_CC therefore_RB the_DT Groups_NNS interest_NN charge_NN is_VBZ low_JJ ._.
Consequently_RB the_DT Group_NNP has_VBZ limited_VBN exposure_NN to_TO interest_NN rate_NN movements_NNS ._.
In_IN 2005_CD the_DT average_JJ interest_NN rate_NN received_VBN on_IN cash_NN and_CC liquid_JJ investments_NNS was_VBD approximately_RB 2.9_CD %_NN per_IN annum_NN 2004_CD :_: 1.44_CD %_NN ._.
The_DT largest_JJS proportion_NN of_IN investments_NNS was_VBD in_IN US_NNP Dollar_NNP liquidity_NN funds_NNS ._.
No_DT financial_JJ instruments_NNS or_CC derivatives_NNS have_VBP been_VBN employed_VBN to_TO hedge_VB this_DT exposure_NN ._.
c_NN Credit_NN risk_NN The_DT Groups_NNS revenues_NNS are_VBP mainly_RB derived_VBN from_IN agreements_NNS with_IN major_JJ pharmaceutical_JJ companies_NNS and_CC relationships_NNS with_IN pharmaceutical_JJ wholesale_JJ distributors_NNS and_CC retail_JJ pharmacy_NN chains_NNS ._.
Such_JJ clients_NNS typically_RB have_VBP significant_JJ cash_NN resources_NNS and_CC as_IN such_JJ the_DT risk_NN is_VBZ considered_VBN minimal_JJ ._.
The_DT Group_NNP has_VBZ taken_VBN positive_JJ steps_NNS to_TO manage_VB any_DT credit_NN risk_NN associated_VBN with_IN these_DT transactions_NNS ._.
The_DT Group_NNP operates_VBZ clearly_RB defined_VBN credit_NN evaluation_NN procedures_NNS ._.
For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, there_EX were_VBD three_CD customers_NNS in_IN the_DT US_NNP who_WP accounted_VBD for_IN 69_CD %_NN of_IN the_DT Groups_NNS total_VBP revenues_NNS ._.
Financial_NNP instruments_NNS that_WDT potentially_RB expose_VBP the_DT Group_NNP to_TO concentrations_NNS of_IN credit_NN risk_NN consist_VBP primarily_RB of_IN short-term_JJ cash_NN investments_NNS and_CC trade_NN accounts_NNS receivable_JJ ._.
Excess_JJ cash_NN is_VBZ invested_VBN in_IN short-term_JJ money_NN market_NN instruments_NNS ,_, including_VBG bank_NN and_CC building_NN society_NN term_NN deposits_NNS ,_, commercial_JJ paper_NN and_CC other_JJ debt_NN securities_NNS from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
These_DT investments_NNS typically_RB bear_VBP minimal_JJ risk_NN ._.
d_LS Liquidity_NN risk_NN Prudent_JJ liquidity_NN risk_NN management_NN implies_VBZ maintaining_VBG sufficient_JJ cash_NN and_CC marketable_JJ securities_NNS ,_, the_DT availability_NN of_IN funding_VBG through_IN an_DT adequate_JJ amount_NN of_IN committed_JJ credit_NN facilities_NNS ,_, and_CC the_DT ability_NN to_TO close_VB out_RP market_NN positions_NNS ._.
The_DT Group_NNP ordinarily_RB finances_VBZ its_PRP$ activities_NNS through_IN cash_NN generated_VBD from_IN operating_VBG activities_NNS ,_, private_JJ and_CC public_JJ offerings_NNS of_IN equity_NN and_CC debt_NN securities_NNS and_CC the_DT proceeds_NNS of_IN asset_NN or_CC investment_NN disposals_NNS ._.
The_DT Group_NNP anticipates_VBZ that_IN its_PRP$ operating_NN cash_NN flow_NN together_RB with_IN available_JJ cash_NN ,_, cash_NN equivalents_NNS and_CC short-term_JJ investments_NNS will_MD be_VB sufficient_JJ to_TO meet_VB its_PRP$ anticipated_JJ future_NN operating_NN expenses_NNS ,_, capital_NN expenditures_NNS and_CC debt_NN service_NN and_CC lease_NN obligations_NNS as_IN they_PRP become_VBP due_JJ over_IN the_DT next_JJ 12_CD months_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 59_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 60_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 5_CD Critical_JJ accounting_NN estimates_NNS and_CC key_JJ sources_NNS of_IN estimation_NN uncertainty_NN The_DT preparation_NN of_IN consolidated_JJ financial_JJ statements_NNS ,_, in_IN conformity_NN with_IN IFRS_NNP accounting_NN principles_NNS ,_, requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS ,_, the_DT disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC reported_VBD amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
The_DT estimates_NNS and_CC assumptions_NNS that_WDT have_VBP a_DT significant_JJ risk_NN of_IN causing_VBG a_DT material_NN adjustment_NN to_TO the_DT carrying_VBG amounts_NNS of_IN assets_NNS and_CC liabilities_NNS within_IN the_DT next_JJ financial_JJ year_NN are_VBP discussed_VBN below_IN ._.
a_DT Estimated_JJ impairment_NN of_IN goodwill_NN The_DT Group_NNP tests_NNS annually_RB whether_IN goodwill_NN has_VBZ suffered_VBN any_DT impairment_NN ,_, in_IN accordance_NN with_IN the_DT accounting_NN policy_NN stated_VBN in_IN Note_NN 2_CD h._NN The_DT recoverable_JJ amounts_NNS of_IN cash-generating_JJ units_NNS have_VBP been_VBN determined_VBN based_VBN on_IN value-in-use_JJ calculations_NNS ._.
These_DT calculations_NNS require_VBP the_DT use_NN of_IN estimates_NNS ._.
The_DT Group_NNP uses_VBZ discounted_JJ cash_NN flow_NN models_NNS to_TO value_VB the_DT recoverable_JJ amounts_NNS of_IN cash-generating_JJ units_NNS ,_, which_WDT require_VBP assumptions_NNS about_IN the_DT timing_NN and_CC amount_NN of_IN future_JJ cash_NN inflows_NNS and_CC outflows_NNS ,_, risk_NN ,_, the_DT cost_NN of_IN capital_NN and_CC terminal_NN values_NNS ._.
Each_DT of_IN these_DT assumptions_NNS is_VBZ significant_JJ to_TO the_DT value_NN of_IN the_DT intangible_JJ asset_NN ._.
A_DT prolonged_JJ general_JJ economic_JJ downturn_NN ,_, new_JJ products_NNS ,_, loss_NN of_IN IP_NNP protection_NN ,_, sustained_VBD government_NN pressure_NN on_IN prices_NNS and_CC ,_, specifically_RB ,_, competitive_JJ pricing_NN ,_, could_MD create_VB an_DT imbalance_NN of_IN industry_NN supply_NN and_CC demand_NN ,_, or_CC otherwise_RB diminish_VB volumes_NNS or_CC profits_NNS ._.
Such_JJ events_NNS ,_, combined_VBN with_IN changes_NNS in_IN interest_NN rates_NNS ,_, could_MD adversely_RB affect_VB the_DT Groups_NNS valuation_NN of_IN the_DT estimated_JJ future_JJ net_JJ cash_NN flows_VBZ generated_VBN by_IN its_PRP$ cash-generating_JJ units_NNS ._.
As_IN a_DT result_NN ,_, future_JJ operating_NN results_NNS could_MD be_VB materially_RB and_CC adversely_RB affected_VBN by_IN additional_JJ impairment_NN charges_NNS related_VBN to_TO the_DT recoverability_NN of_IN goodwill_NN ._.
The_DT carrying_VBG amount_NN of_IN goodwill_NN at_IN the_DT balance_NN sheet_NN date_NN was_VBD $_$ 2,209_CD million_CD ,_, after_IN an_DT impairment_NN loss_NN of_IN $_$ 527_CD million_CD was_VBD recognized_VBN during_IN 2005_CD ._.
Details_NNS of_IN the_DT impairment_NN loss_NN calculation_NN are_VBP provided_VBN in_IN Note_NN 17_CD ._.
b_NN Valuation_NN of_IN intangible_JJ assets_NNS general_JJ The_DT Group_NNP has_VBZ acquired_VBN and_CC continues_VBZ to_TO acquire_VB significant_JJ intangible_JJ assets_NNS ,_, recorded_VBN at_IN acquisition_NN cost_NN or_CC fair_JJ value_NN and_CC amortised_VBN over_IN the_DT assets_NNS useful_JJ economic_JJ lives_NNS ._.
Managements_NNS estimate_NN of_IN the_DT useful_JJ life_NN considers_VBZ ,_, inter_VB alia_NN ,_, the_DT following_VBG factors_NNS :_: the_DT expected_VBN use_NN of_IN the_DT asset_NN by_IN the_DT Group_NNP :_: any_DT legal_JJ ,_, regulatory_JJ ,_, or_CC contractual_JJ provisions_NNS that_WDT may_MD limit_VB the_DT useful_JJ life_NN and_CC the_DT effects_NNS of_IN demand_NN :_: competition_NN :_: levels_NNS of_IN maintenance_NN expenditure_NN required_VBN :_: and_CC other_JJ economic_JJ factors_NNS such_JJ as_IN the_DT stability_NN of_IN the_DT industry_NN ,_, known_VBN technological_JJ advances_NNS ,_, legislative_JJ action_NN that_WDT results_VBZ in_IN an_DT uncertain_JJ or_CC changing_VBG regulatory_JJ environment_NN ,_, and_CC expected_VBN changes_NNS in_IN distribution_NN channels_NNS ._.
There_EX is_VBZ a_DT high_JJ occurrence_NN of_IN transactions_NNS involving_VBG the_DT transfer_NN of_IN intangible_JJ assets_NNS between_IN companies_NNS in_IN the_DT health_NN care_NN field_NN ,_, and_CC valuations_NNS are_VBP usually_RB based_VBN on_IN discounted_JJ cash_NN flow_NN analysis_NN ._.
The_DT Group_NNP uses_VBZ a_DT discounted_JJ cash_NN flow_NN model_NN to_TO value_NN intangible_JJ assets_NNS acquired_VBN ,_, which_WDT requires_VBZ assumptions_NNS about_IN the_DT timing_NN and_CC amount_NN of_IN future_JJ cash_NN inflows_NNS and_CC outflows_NNS ,_, risk_NN ,_, the_DT cost_NN of_IN capital_NN ,_, and_CC terminal_NN values_NNS ._.
The_DT Group_NNP engages_VBZ independent_JJ valuation_NN experts_NNS who_WP review_VBP critical_JJ assumptions_NNS for_IN significant_JJ acquisitions_NNS of_IN intangibles_NNS ._.
The_DT Group_NNP reviews_VBZ intangible_JJ assets_NNS for_IN impairment_NN periodically_RB in_IN accordance_NN with_IN IAS_NNP 36_CD Impairment_NN of_IN Assets_NNS ._.
Such_JJ events_NNS ,_, combined_VBN with_IN changes_NNS in_IN interest_NN rates_NNS ,_, could_MD adversely_RB affect_VB the_DT Groups_NNS valuation_NN of_IN the_DT estimated_JJ future_JJ net_JJ cash_NN flows_VBZ generated_VBN by_IN its_PRP$ intangible_JJ assets_NNS ._.
As_IN a_DT result_NN ,_, future_JJ operating_NN results_NNS could_MD be_VB materially_RB and_CC adversely_RB affected_VBN by_IN additional_JJ impairment_NN charges_NNS related_VBN to_TO the_DT recoverability_NN of_IN intangible_JJ assets_NNS ._.
c_NN Valuation_NN of_IN intangible_JJ assets_NNS TKT_NNP acquisition_NN The_DT fair_JJ value_NN of_IN all_DT of_IN the_DT identifiable_JJ intangible_JJ assets_NNS acquired_VBN through_IN the_DT acquisition_NN of_IN TKT_NNP has_VBZ been_VBN determined_VBN using_VBG an_DT income_NN approach_NN on_IN a_DT project-by-project_JJ basis_NN ,_, by_IN independent_JJ valuation_NN specialists_NNS ._.
This_DT method_NN starts_VBZ with_IN a_DT forecast_NN of_IN all_DT of_IN the_DT expected_JJ future_JJ net_JJ cash_NN flows_VBZ either_CC generated_VBD or_CC saved_VBD as_IN a_DT result_NN of_IN ownership_NN of_IN the_DT intellectual_JJ property_NN ,_, the_DT customer_NN relationships_NNS and_CC the_DT other_JJ intangible_JJ assets_NNS ._.
These_DT cash_NN flows_NNS are_VBP then_RB adjusted_VBN to_TO present_JJ value_NN by_IN applying_VBG an_DT appropriate_JJ discount_NN rate_NN that_WDT reflects_VBZ the_DT risk_NN factors_NNS associated_VBN with_IN the_DT cash_NN flow_NN streams_NNS ._.
The_DT forecast_NN of_IN future_JJ cash_NN flows_VBZ requires_VBZ various_JJ assumptions_NNS to_TO be_VB made_VBN ,_, including_VBG :_: revenue_NN that_WDT is_VBZ reasonably_RB likely_JJ to_TO result_VB from_IN the_DT sale_NN of_IN products_NNS including_VBG the_DT estimated_VBN number_NN of_IN units_NNS to_TO be_VB sold_VBN ,_, estimated_VBN selling_NN prices_NNS ,_, estimated_VBN market_NN penetration_NN and_CC estimated_VBN market_NN share_NN and_CC year-over-year_JJ growth_NN rates_NNS over_IN the_DT product_NN life_NN cycles_NNS :_: royalty_NN or_CC license_NN fees_NNS saved_VBN by_IN owning_VBG the_DT intellectual_JJ property_NN associated_VBN with_IN the_DT products_NNS :_: cost_NN of_IN sales_NNS for_IN the_DT products_NNS using_VBG historical_JJ data_NNS ,_, industry_NN data_NNS or_CC other_JJ sources_NNS of_IN market_NN data_NNS :_: sales_NNS and_CC marketing_NN expense_NN using_VBG historical_JJ data_NNS ,_, industry_NN data_NNS or_CC other_JJ sources_NNS of_IN market_NN data_NNS :_: general_JJ and_CC administrative_JJ expenses_NNS :_: research_NN and_CC development_NN expenses_NNS :_: and_CC the_DT estimated_VBN life_NN of_IN the_DT products_NNS ._.
60_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 61_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 5_CD Critical_JJ accounting_NN estimates_NNS and_CC key_JJ sources_NNS of_IN estimation_NN uncertainty_NN continued_VBD The_DT valuations_NNS are_VBP based_VBN on_IN information_NN at_IN the_DT time_NN of_IN the_DT acquisition_NN and_CC the_DT expectations_NNS and_CC assumptions_NNS that_WDT have_VBP been_VBN deemed_VBN reasonable_JJ by_IN the_DT Groups_NNS management_NN ._.
No_DT assurance_NN can_MD be_VB given_VBN ,_, however_RB ,_, that_IN the_DT underlying_VBG assumptions_NNS or_CC events_NNS associated_VBN with_IN such_JJ assets_NNS will_MD occur_VB as_IN projected_VBN ._.
For_IN these_DT reasons_NNS ,_, among_IN others_NNS ,_, the_DT actual_JJ cash_NN flows_NNS may_MD vary_VB from_IN forecasts_NNS of_IN future_JJ cash_NN flows_NNS ._.
d_LS Valuation_NN of_IN financial_JJ assets_NNS and_CC equity_NN accounted_VBD investments_NNS The_DT Group_NNP has_VBZ investments_NNS in_IN certain_JJ public_JJ and_CC private_JJ pharmaceutical_JJ and_CC biotechnology_NN companies_NNS and_CC partnerships_NNS ._.
These_DT investments_NNS are_VBP designated_VBN as_IN either_DT available-for-sale_JJ ,_, joint_JJ venture_NN investments_NNS or_CC associate_JJ companies_NNS ._.
Those_DT investments_NNS designated_VBN as_IN available-for-sale_NN are_VBP held_VBN at_IN fair_JJ value_NN ,_, in_IN accordance_NN with_IN IAS_NNP 39_CD ,_, with_IN any_DT unrealized_JJ movements_NNS in_IN fair_JJ value_NN being_VBG recognized_VBN directly_RB within_IN equity_NN ._.
Associates_NNPS and_CC joint_JJ ventures_NNS are_VBP accounted_VBN for_IN under_IN the_DT equity_NN method_NN ,_, with_IN the_DT companys_NNS share_NN or_CC profit_NN or_CC loss_NN after_IN tax_NN presented_VBN as_IN a_DT separate_JJ item_NN on_IN the_DT face_NN of_IN the_DT income_NN statement_NN ._.
e_LS Sales_NNS deductions_NNS Sales_NNS deductions_NNS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP and_CC other_JJ government_NN agencies_NNS ,_, contractual_JJ rebates_NNS with_IN healthmaintenance_NN organizations_NNS HMOs_NNS ,_, product_NN returns_NNS ,_, trade_NN discounts_NNS ,_, wholesaler_NN chargebacks_NNS and_CC allowances_NNS for_IN the_DT coupon_NN sampling_VBG program_NN ._.
Statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS and_CC contractual_JJ rebates_NNS with_IN HMOs_NNS are_VBP based_VBN on_IN price_NN differentials_NNS between_IN a_DT base_NN price_NN and_CC the_DT selling_NN price_NN ._.
Rebates_NNS generally_RB increase_VB as_IN a_DT percentage_NN of_IN the_DT selling_NN price_NN over_IN the_DT life_NN of_IN the_DT product_NN as_IN prices_NNS increase_NN ._.
Provisions_NNS for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS of_IN future_JJ utilization_NN derived_VBN from_IN historical_JJ trends_NNS ._.
Revisions_NNS or_CC clarification_NN from_IN Centres_NNP for_IN Medicare_NNP and_CC Medicaid_NNP Services_NNPS CMS_NNP related_VBN to_TO state_NN Medicaid_NNP and_CC other_JJ government_NN program_NN reimbursement_NN practices_NNS with_IN retroactive_JJ application_NN can_MD result_VB in_IN changes_NNS to_TO managements_NNS estimates_NNS of_IN the_DT rebates_NNS reported_VBD in_IN prior_JJ periods_NNS ._.
However_RB ,_, at_IN the_DT time_NN of_IN sale_NN ,_, the_DT prices_NNS of_IN the_DT Groups_NNS products_NNS are_VBP fixed_VBN and_CC consequently_RB the_DT rebates_NNS can_MD be_VB reasonably_RB determined_VBN at_IN the_DT outset_NN of_IN each_DT transaction_NN it_PRP undertakes_VBZ with_IN its_PRP$ customers_NNS and_CC ,_, therefore_RB ,_, these_DT factors_NNS would_MD not_RB impact_VB the_DT recording_NN of_IN revenues_NNS in_IN accordance_NN with_IN IFRS_NNP ._.
Provisions_NNS for_IN product_NN returns_NNS and_CC trade_NN discounts_NNS to_TO customers_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS based_VBN upon_IN past_JJ activity_NN levels_NNS :_: the_DT duration_NN of_IN time_NN in_IN the_DT processing_NN of_IN deductions_NNS :_: and_CC other_JJ factors_NNS such_JJ as_IN the_DT launch_NN of_IN a_DT new_JJ drug_NN ,_, the_DT loss_NN of_IN patent_NN protection_NN or_CC new_JJ competition_NN ._.
Where_WRB such_JJ factors_NNS are_VBP relevant_JJ ,_, the_DT Group_NNP develops_VBZ provisions_NNS for_IN returns_NNS based_VBN on_IN wholesaler_NN customer_NN channel_NN checks_NNS for_IN slow-moving_JJ product_NN and_CC a_DT separate_JJ management_NN review_NN of_IN estimated_VBN customer_NN inventory_NN levels_NNS ,_, by_IN product_NN ._.
To_TO the_DT extent_NN that_IN the_DT Group_NNP is_VBZ unable_JJ to_TO estimate_VB returns_NNS ,_, recognition_NN of_IN revenue_NN is_VBZ deferred_VBN until_IN either_CC the_DT product_NN is_VBZ sold_VBN to_TO the_DT pharmacy_NN or_CC until_IN the_DT Group_NNP receives_VBZ payment_NN from_IN the_DT wholesaler_NN ._.
The_DT Groups_NNS policy_NN is_VBZ to_TO accept_VB customer_NN returns_NNS in_IN the_DT following_VBG circumstances_NNS :_: a_DT expiration_NN of_IN product_NN ,_, b_NN product_NN damaged_VBN while_IN in_IN the_DT possession_NN of_IN the_DT Group_NNP ,_, or_CC c_NN specific_JJ sales_NNS terms_NNS ,_, at_IN product_NN launch_NN ,_, that_IN allow_VBP for_IN unconditional_JJ return_NN of_IN product_NN guaranteed_VBN sales_NNS ._.
Customer_NN return_NN periods_NNS range_VBP from_IN one_CD to_TO twenty-four_CD months_NNS with_IN an_DT average_JJ return_NN period_NN of_IN six_CD months_NNS ._.
In_IN addition_NN ,_, the_DT Group_NNP monitors_VBZ customer_NN inventory_NN levels_NNS ,_, based_VBN on_IN estimated_VBN prescription_NN demand_NN ,_, and_CC limits_VBZ the_DT amount_NN of_IN product_NN shipped_VBN to_TO a_DT customer_NN when_WRB there_EX appears_VBZ to_TO be_VB a_DT protracted_JJ pattern_NN of_IN customer_NN ordering_VBG that_IN exceeds_VBZ the_DT Groups_NNS estimate_NN of_IN underlying_VBG demand_NN ._.
The_DT practice_NN of_IN monitoring_VBG inventory_NN levels_NNS allows_VBZ the_DT Group_NNP to_TO more_RBR accurately_RB predict_VB customer_NN returns_NNS ._.
The_DT actual_JJ experience_NN and_CC the_DT level_NN of_IN these_DT deductions_NNS to_TO revenue_NN may_MD deviate_VB from_IN the_DT estimate_NN ._.
The_DT Group_NNP revises_VBZ its_PRP$ estimates_NNS every_DT period_NN and_CC may_MD be_VB required_VBN to_TO adjust_VB the_DT estimate_NN in_IN a_DT subsequent_JJ period_NN ._.
There_EX have_VBP been_VBN no_DT material_NN adjustments_NNS to_TO the_DT estimates_NNS recognized_VBN related_VBN to_TO the_DT Groups_NNS provisions_NNS for_IN sales_NNS rebates_NNS or_CC returns_NNS ,_, in_IN the_DT period_NN presented_VBN ._.
f_LS Income_NN taxes_NNS The_DT Group_NNP operates_VBZ in_IN numerous_JJ countries_NNS where_WRB its_PRP$ income_NN tax_NN returns_NNS are_VBP subject_JJ to_TO audits_NN and_CC adjustments_NNS ._.
Because_IN the_DT Group_NNP operates_VBZ globally_RB ,_, the_DT nature_NN of_IN the_DT audit_NN items_NNS are_VBP often_RB very_RB complex_JJ ._.
The_DT Group_NNP employs_VBZ internal_JJ and_CC external_JJ tax_NN professionals_NNS to_TO minimize_VB audit_NN adjustment_NN amounts_NNS where_WRB possible_JJ ._.
The_DT Group_NNP also_RB has_VBZ significant_JJ deferred_VBN assets_NNS due_JJ to_TO net_JJ operating_NN losses_NNS NOLs_NNS in_IN the_DT United_NNP States_NNPS ,_, Canada_NNP and_CC other_JJ countries_NNS ._.
The_DT realization_NN of_IN these_DT assets_NNS is_VBZ not_RB assured_VBN and_CC is_VBZ dependent_JJ on_IN the_DT generation_NN of_IN sufficient_JJ taxable_JJ income_NN in_IN the_DT future_NN ._.
Management_NN has_VBZ exercised_VBN judgement_NN in_IN determining_VBG the_DT extent_NN of_IN the_DT realization_NN of_IN these_DT losses_NNS based_VBN upon_IN estimates_NNS of_IN future_JJ taxable_JJ income_NN in_IN the_DT various_JJ jurisdictions_NNS in_IN which_WDT these_DT NOLs_NNS exist_VBP ._.
Where_WRB there_EX is_VBZ an_DT expectation_NN that_WDT on_IN the_DT balance_NN of_IN probabilities_NNS there_RB will_MD not_RB be_VB sufficient_JJ taxable_JJ profits_NNS to_TO utilise_VB these_DT NOLs_NNS a_DT provision_NN is_VBZ made_VBN against_IN these_DT deferred_VBN tax_NN assets_NNS ._.
If_IN actual_JJ events_NNS differ_VBP from_IN managements_NNS estimates_NNS ,_, or_CC to_TO the_DT extent_NN that_IN these_DT estimates_NNS are_VBP adjusted_VBN in_IN the_DT future_NN ,_, any_DT changes_NNS to_TO the_DT valuation_NN allowance_NN could_MD materially_RB impact_VB the_DT Groups_NNS financial_JJ position_NN and_CC results_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 61_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 62_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 5_CD Critical_JJ accounting_NN estimates_NNS and_CC key_JJ sources_NNS of_IN estimation_NN uncertainty_NN continued_VBD g_JJ Litigation_NN The_DT Group_NNP accounts_NNS for_IN litigation_NN losses_NNS in_IN accordance_NN with_IN IAS_NNP 37_CD Provisions_NNS ,_, Contingent_NNP Liabilities_NNPS and_CC Contingent_NNP Assets_NNPS ._.
Under_IN IAS_NNP 37_CD ,_, provisions_NNS are_VBP recorded_VBN for_IN probable_JJ litigation_NN losses_NNS when_WRB management_NN is_VBZ able_JJ to_TO reliably_RB estimate_VB the_DT loss_NN ._.
The_DT amount_NN recognized_VBN as_IN a_DT provision_NN is_VBZ managements_NNS best_JJS estimate_NN of_IN the_DT expenditure_NN required_VBN to_TO settle_VB the_DT present_JJ obligation_NN at_IN the_DT balance_NN sheet_NN date_NN :_: in_IN other_JJ words_NNS the_DT amount_NN that_IN an_DT entity_NN would_MD rationally_RB pay_VB to_TO settle_VB the_DT obligation_NN at_IN the_DT balance_NN sheet_NN date_NN or_CC transfer_VB it_PRP to_TO a_DT third_JJ party_NN at_IN that_DT time_NN ._.
These_DT estimates_NNS are_VBP developed_VBN substantially_RB earlier_JJR than_IN the_DT ultimate_JJ loss_NN is_VBZ known_VBN and_CC the_DT estimates_NNS are_VBP refined_VBN each_DT accounting_NN period_NN ,_, as_IN additional_JJ information_NN becomes_VBZ known_VBN ._.
In_IN instances_NNS where_WRB there_EX is_VBZ a_DT continuous_JJ range_NN of_IN possible_JJ outcomes_NNS ,_, and_CC each_DT point_NN in_IN that_DT range_NN is_VBZ as_IN likely_JJ as_IN any_DT other_JJ ,_, the_DT mid-point_NN of_IN the_DT range_NN is_VBZ recorded_VBN as_IN a_DT loss_NN ._.
The_DT best_JJS estimates_NNS are_VBP reviewed_VBN quarterly_JJ and_CC the_DT estimates_NNS are_VBP changed_VBN when_WRB expectations_NNS are_VBP revised_VBN ._.
Any_DT outcome_NN upon_IN settlement_NN that_IN deviates_VBZ from_IN the_DT Groups_NNS best_JJS estimate_NN may_MD result_VB in_IN an_DT additional_JJ expense_NN in_IN a_DT future_JJ accounting_NN period_NN ._.
h_NN TKT_NNP acquisition_NN The_DT acquisition_NN of_IN TKT_NNP has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT purchase_NN business_NN combination_NN in_IN accordance_NN with_IN IFRS_NNP 3_CD ,_, Business_NNP Combinations_NNPS ._.
Under_IN the_DT purchase_NN method_NN of_IN accounting_NN ,_, the_DT Group_NNP has_VBZ measured_VBN the_DT cost_NN of_IN the_DT business_NN combination_NN as_IN the_DT aggregate_NN of_IN the_DT assets_NNS acquired_VBN ,_, the_DT liabilities_NNS assumed_VBD from_IN TKT_NNP at_IN the_DT date_NN of_IN acquisition_NN at_IN their_PRP$ respective_JJ fair_JJ values_NNS ,_, and_CC any_DT costs_NNS directly_RB attributable_JJ to_TO the_DT business_NN combination_NN ._.
The_DT valuation_NN of_IN in-process_JJ R&D_NNP ,_, the_DT inventory_NN acquired_VBN with_IN TKT_NNP and_CC the_DT amount_NN payable_JJ to_TO those_DT TKT_NNP shareholders_NNS who_WP have_VBP asserted_VBN appraisal_NN rights_NNS in_IN relation_NN to_TO the_DT Groups_NNS acquisition_NN of_IN TKT_NNP on_IN July_NNP 27_CD ,_, 2005_CD are_VBP based_VBN on_IN managements_NNS best_JJS estimates_NNS ._.
Finished_VBN goods_NNS were_VBD fair_JJ valued_VBN at_IN estimated_VBN selling_NN price_NN less_CC the_DT sum_NN of_IN costs_NNS of_IN disposal_NN and_CC a_DT reasonable_JJ profit_NN allowance_NN for_IN the_DT selling_NN effort_NN of_IN the_DT company_NN ._.
Work_NN in-process_NN was_VBD fair_JJ valued_VBN on_IN the_DT same_JJ basis_NN less_RBR costs_NNS to_TO complete_VB ._.
All_DT cost_NN of_IN product_NN sales_NNS of_IN REPLAGAL_NNP ,_, since_IN the_DT acquisition_NN ,_, are_VBP at_IN the_DT fair_JJ value_NN of_IN the_DT inventory_NN acquired_VBN ._.
The_DT fair_JJ value_NN of_IN certain_JJ pre-acquisition_JJ contingencies_NNS ,_, in_IN particular_JJ those_DT relating_VBG to_TO the_DT Purported_NNP Class_NNP Action_NNP Shareholder_NN Suit_NN see_VBP Note_NN 35_CD are_VBP yet_RB to_TO be_VB determined_VBN ._.
The_DT Group_NNP currently_RB does_VBZ not_RB have_VB sufficient_JJ information_NN to_TO measure_VB the_DT contingencies_NNS reliably_RB ._.
6_CD Segment_NN information_NN Primary_JJ reporting_NN format_NN business_NN segments_NNS For_IN management_NN purposes_NNS ,_, the_DT Group_NNP is_VBZ organised_VBN into_IN two_CD main_JJ reporting_NN segments_NNS pharmaceutical_JJ products_NNS and_CC royalties_NNS ._.
Certain_JJ revenues_NNS and_CC profits_NNS from_IN product_NN licensing_NN ,_, development_NN and_CC other_JJ items_NNS are_VBP not_RB included_VBN within_IN these_DT two_CD segments_NNS and_CC are_VBP therefore_RB presented_VBN as_IN unallocated_JJ ._.
The_DT Group_NNP was_VBD also_RB previously_RB involved_VBN in_IN a_DT vaccines_NNS business_NN Biologics_NNP ,_, that_IN operation_NN was_VBD disposed_VBN of_IN during_IN 2004_CD ._.
Pharmaceutical_NNP products_NNS Royalties_NNP Unallocated_NNP Group_NNP 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Continuing_VBG operations_NNS Revenue_NN external_JJ customers_NNS 1,327,660_CD 242,910_CD 28,746_CD 1,599,316_CD Segment_NN result_NN :_: Operating_NN loss_NN profit_NN 42,072_CD 140,179_CD 23,378_CD 158,873_CD Finance_NNP costs_NNS 17,420_CD Investment_NN revenues_NNS 35,300_CD Share_NN of_IN post_NN tax_NN profit_NN from_IN :_: associates_NNS 6,325_CD joint_JJ ventures_NNS 5,325_CD Loss_NN before_IN tax_NN 141,993_CD Taxation_NNP 38,510_CD Loss_NN for_IN the_DT year_NN from_IN continuing_VBG operations_NNS 180,503_CD Discontinued_VBN operations_NNS Profit_NN on_IN disposal_NN of_IN operations_NNS 3,125_CD Profit_NN before_IN income_NN tax_NN 3,125_CD Taxation_NNP Profit_NN for_IN the_DT year_NN from_IN discontinued_VBN operations_NNS 3,125_CD 62_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 63_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 6_CD Segment_NN information_NN continued_VBD Pharmaceutical_NNP products_NNS Royalties_NNP Unallocated_NNP Group_NNP 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Balance_NNP Sheet_NNP Segment_NNP assets_NNS 4,211,231_CD 926,368_CD 5,137,599_CD Investment_NN in_IN equity_NN accounted_VBD :_: joint_JJ ventures_NNS 5,954_CD associates_NNS 17,069_CD Group_NNP assets_NNS deferred_VBN tax_NN 67,283_CD Total_JJ assets_NNS 4,211,231_CD 926,368_CD 5,227,905_CD Segment_NN liabilities_NNS 1,017,081_CD 1,017,081_CD Group_NNP liabilities_NNS deferred_VBN tax_NN 127,691_CD Total_JJ liabilities_NNS 1,017,081_CD 1,144,772_CD Other_JJ segment_NN items_NNS Capital_NNP expenditure_NN 638,538_CD 638,538_CD Depreciation_NN 23,003_CD 23,003_CD Amortization_NNP 49,516_CD 49,516_CD Impairment_NN charges_NNS 154,735_CD 383,089_CD 537,824_CD Share-based_JJ payments_NNS 27,383_CD 27,383_CD Provisions_NNS 20,420_CD 20,420_CD Reorganization_NN costs_NNS 2,301_CD 2,301_CD Primary_JJ reporting_NN format_NN business_NN segments_NNS Pharmaceutical_NNP products_NNS Royalties_NNP Biologics_NNP Unallocated_NNP Group_NNP 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Continuing_VBG operations_NNS Revenue_NN external_JJ customers_NNS 1,112,457_CD 230,364_CD 20,386_CD 1,363,207_CD Segment_NN result_NN :_: Operating_NN profit_NN 43,344_CD 230,364_CD 17,078_CD 290,786_CD Interest_NN expense_NN and_CC similar_JJ charges_NNS 14,771_CD Interest_NN income_NN 21,901_CD Share_NN of_IN post_NN tax_NN profit_NN from_IN :_: associates_NNS 75_CD joint_JJ ventures_NNS 4,433_CD Profit_NN before_IN income_NN tax_NN 302,424_CD Taxation_NNP 141,623_CD Profit_NN for_IN the_DT year_NN from_IN continuing_VBG operations_NNS 160,801_CD Discontinued_VBN operations_NNS Revenue_NN external_JJ customers_NNS 3,626_CD 3,626_CD Segment_NN result_NN Loss_NN from_IN discontinued_VBN operations_NNS 20,135_CD 20,135_CD Loss_NN on_IN disposal_NN of_IN operations_NNS 44,157_CD 44,157_CD Loss_NN before_IN income_NN tax_NN 64,292_CD 64,292_CD Taxation_NNP Loss_NN for_IN the_DT year_NN from_IN discontinued_VBN operations_NNS 64,292_CD 64,292_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 63_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 64_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 6_CD Segment_NN information_NN continued_VBD Pharmaceutical_NNP products_NNS Royalties_NNP Biologics_NNP Unallocated_NNP Group_NNP 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Balance_NNP Sheet_NNP Segment_NNP assets_NNS 3,299,958_CD 1,311,163_CD 4,611,121_CD Investment_NN in_IN equity_NN accounted_VBD :_: joint_JJ ventures_NNS 6,179_CD associates_NNS 24,669_CD Group_NNP assets_NNS deferred_VBN tax_NN 85,041_CD Total_JJ assets_NNS 3,299,958_CD 1,311,163_CD 4,727,010_CD Segment_NN liabilities_NNS 482,078_CD 482,078_CD Total_JJ liabilities_NNS 482,078_CD 482,078_CD Other_JJ segment_NN items_NNS Capital_NNP expenditure_NN 101,997_CD 12,715_CD 114,712_CD Depreciation_NN 22,668_CD 2,033_CD 24,701_CD Amortization_NNP 42,138_CD 42,138_CD Impairment_NN charges_NNS 153,789_CD 153,789_CD Share-based_JJ payments_NNS 15,815_CD 15,815_CD Provisions_NNS 23,125_CD 43,161_CD 66,286_CD Reorganization_NN costs_NNS 55,505_CD 55,505_CD On_IN September_NNP 9_CD ,_, 2004_CD the_DT Group_NNP completed_VBD its_PRP$ disposal_NN of_IN the_DT vaccines_NNS Biologics_NNPS business_NN ,_, which_WDT was_VBD a_DT separate_JJ business_NN segment_NN and_CC was_VBD part_NN of_IN the_DT North_NNP America_NNP geographic_JJ segment_NN Note_NN 14_CD ._.
Secondary_JJ reporting_NN format_NN geographical_JJ segments_NNS The_DT Groups_NNS operations_NNS are_VBP located_VBN in_IN the_DT US_NNP and_CC Canada_NNP North_NNP America_NNP and_CC throughout_IN the_DT rest_NN of_IN the_DT world_NN primarily_RB the_DT UK_NNP and_CC other_JJ European_NNP Union_NNP countries_NNS ._.
The_DT revenue_NN analysis_NN in_IN the_DT following_VBG table_NN is_VBZ based_VBN on_IN the_DT location_NN of_IN the_DT customer_NN ,_, which_WDT is_VBZ not_RB materially_RB different_JJ from_IN the_DT location_NN where_WRB the_DT assets_NNS are_VBP located_VBN ._.
Capital_NNP expenditure_NN is_VBZ allocated_VBN based_VBN on_IN where_WRB the_DT assets_NNS are_VBP located_VBN ._.
Capital_NNP expenditures_VBZ on_IN plant_NN ,_, Segment_NN property_NN and_CC equipment_NN Revenue_NN assets_NNS and_CC intangible_JJ assets_NNS 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Continuing_VBG operations_NNS North_NNP America_NNP 1,233,511_CD 3,357,313_CD 616,647_CD Rest_VBP of_IN the_DT world_NN 365,805_CD 1,847,569_CD 21,891_CD 1,599,316_CD 5,204,882_CD 638,538_CD Investment_NN in_IN equity_NN accounted_VBD :_: joint_JJ ventures_NNS 5,954_CD associates_NNS 17,069_CD Total_JJ 1,599,316_CD 5,227,905_CD 638,538_CD Secondary_JJ reporting_NN format_NN geographical_JJ segments_NNS Capital_NNP expenditures_VBZ on_IN plant_NN ,_, Segment_NN property_NN and_CC equipment_NN Revenue_NN assets_NNS and_CC intangible_JJ assets_NNS 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Continuing_VBG operations_NNS North_NNP America_NNP 1,086,087_CD 3,006,662_CD 33,962_CD Rest_VBP of_IN the_DT world_NN 277,120_CD 1,689,500_CD 68,035_CD 1,363,207_CD 4,696,162_CD 101,997_CD Discontinued_VBN operations_NNS North_NNP America_NNP 3,626_CD 12,715_CD Investment_NN in_IN equity_NN accounted_VBD :_: joint_JJ ventures_NNS 6,179_CD associates_NNS 24,669_CD Total_JJ 1,366,833_CD 4,727,010_CD 114,712_CD 64_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 65_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 6_CD Segment_NN information_NN continued_VBD Analysis_NNP of_IN revenue_NN by_IN category_NN continuing_VBG operations_NNS 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Continuing_VBG operations_NNS Product_NNP sales_NNS 1,327,660_CD 1,112,457_CD Royalties_NNS 242,910_CD 230,364_CD Licensing_NN and_CC development_NN 15,002_CD 13,479_CD Other_JJ revenues_NNS 13,744_CD 6,907_CD 1,599,316_CD 1,363,207_CD Investment_NN revenues_NNS 35,300_CD 21,901_CD 1,634,616_CD 1,385,108_CD Discontinued_VBN operations_NNS 3,626_CD Total_JJ revenue_NN including_VBG investment_NN revenues_NNS 1,634,616_CD 1,388,734_CD For_IN discontinued_VBN operations_NNS see_VBP Note_NN 14_CD ._.
7_CD Loss_NN profit_NN for_IN the_DT year_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD The_DT following_JJ items_NNS have_VBP been_VBN included_VBN in_IN arriving_VBG at_IN the_DT loss_NN profit_NN from_IN continuing_VBG operations_NNS :_: Staff_NN costs_NNS :_: wages_NNS and_CC salaries_NNS 234,425_CD 179,174_CD social_JJ security_NN costs_NNS 20,674_CD 15,333_CD pensions_NNS costs_NNS defined_VBN contribution_NN plans_NNS 13,461_CD 8,722_CD pensions_NNS costs_NNS defined_VBN benefit_NN plans_NNS 607_CD 284_CD share-based_JJ payments_NNS to_TO Directors_NNS and_CC employees_NNS 27,383_CD 15,815_CD 296,550_CD 219,328_CD Inventories_NNS :_: cost_NN of_IN inventories_NNS recognized_VBN as_IN expense_NN included_VBN in_IN cost_NN of_IN sales_NNS 184,353_CD 119,943_CD inventory_NN write_VB down_RP included_VBN in_IN cost_NN of_IN sales_NNS 9,432_CD 3,788_CD Depreciation_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN :_: owned_VBN assets_NNS 20,099_CD 20,140_CD under_IN finance_NN leases_NNS 2,904_CD 2,528_CD Impairment_NN of_IN goodwill_NN 526,956_CD 132,576_CD Impairment_NN of_IN intangible_JJ assets_NNS 4,410_CD 19,626_CD Impairment_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 6,458_CD 1,587_CD Amortization_NN of_IN intangible_JJ assets_NNS included_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS all_DT acquired_VBN 49,516_CD 42,138_CD Operating_NN lease_NN rentals_NNS :_: property_NN ,_, plant_NN and_CC machinery_NN 14,445_CD 6,563_CD other_JJ 2,673_CD 3,495_CD Profit_NN on_IN disposal_NN of_IN financial_JJ assets_NNS 4,100_CD 14,805_CD Impairment_NN of_IN financial_JJ assets_NNS 1,974_CD 17,455_CD Net_JJ foreign_JJ exchange_NN losses_NNS 10,212_CD 2,466_CD Reorganization_NN costs_NNS 2,301_CD 55,505_CD Integration_NN costs_NNS 11,727_CD Government_NN grants_NNS towards_IN research_NN 26_CD Auditors_NNS remuneration_NN for_IN audit_NN services_NNS 5,121_CD 5,401_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 65_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 66_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 7_CD Loss_NN profit_NN for_IN the_DT year_NN continued_VBD Accounts_NNPS payable_JJ to_TO Deloitte_NNP &_CC Touche_NNP LLP_NNP and_CC their_PRP$ associates_NNS by_IN the_DT Group_NNP in_IN respect_NN of_IN non-audit_JJ services_NNS were_VBD $_$ 2.8_CD million_CD 2004_CD :_: $_$ 4.9_CD million_CD ._.
A_DT more_JJR detailed_JJ analysis_NN of_IN auditors_NNS remuneration_NN on_IN a_DT worldwide_JJ basis_NN is_VBZ provided_VBN below_RB ._.
2005_CD 2004_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD i_FW Audit_NNP fees_NNS 2,731_CD 3,253_CD ii_FW Audit-related_JJ fees_NNS 2,390_CD 2,148_CD iii_FW Tax_NNP fees_NNS 2,066_CD 4,734_CD iv_NN All_DT other_JJ fees_NNS 708_CD 183_CD Total_JJ fees_NNS 7,895_CD 10,318_CD Notes_NNS i_FW Audit_NNP fees_NNS consisted_VBD of_IN audit_NN work_NN only_RB the_DT Independent_NNP Registered_NNP Public_NNP Accountant_NNP can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN statutory_JJ audits_NN ,_, and_CC included_VBD the_DT audit_NN of_IN managements_NNS assessment_NN that_IN the_DT Group_NNP maintained_VBD effective_JJ internal_JJ control_NN over_IN 10-K_JJ financial_JJ reporting_NN and_CC the_DT audit_NN of_IN the_DT effectiveness_NN of_IN the_DT Groups_NNS internal_JJ control_NN over_IN 10-K_JJ financial_JJ reporting_NN ._.
ii_FW Audit-related_JJ fees_NNS consist_VBP of_IN work_NN generally_RB only_RB the_DT Independent_NNP Registered_NNP Public_NNP Accountant_NNP can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN procedures_NNS relating_VBG to_TO regulatory_JJ filings_NNS ._.
iii_FW Tax_NNP fees_NNS consisted_VBD principally_RB of_IN assistance_NN with_IN matters_NNS related_VBN to_TO compliance_NN ,_, planning_NN and_CC advice_NN in_IN various_JJ tax_NN jurisdictions_NNS ._.
iv_NN All_DT other_JJ fees_NNS relate_VBP to_TO assisting_VBG the_DT remuneration_NN committee_NN and_CC corporate_JJ responsibility_NN ._.
A_DT description_NN of_IN the_DT work_NN of_IN the_DT audit_NN committee_NN is_VBZ set_VBN out_RP in_IN the_DT Audit_NNP Committee_NNP Report_NNP on_IN pages_NNS 31_CD to_TO 32_CD ._.
The_DT loss_NN for_IN the_DT financial_JJ year_NN under_IN UK_NNP GAAP_NNP dealt_VBD with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN was_VBD $_$ 363,000_CD 2004_CD :_: Not_RB Applicable_JJ ._.
The_DT loss_NN for_IN the_DT financial_JJ year_NN ended_VBD December_NNP 31_CD ,_, 2004_CD under_IN UK_NNP GAAP_NNP dealt_VBD with_IN in_IN the_DT accounts_NNS of_IN the_DT previous_JJ holding_VBG company_NN ,_, Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN ,_, was_VBD $_$ 32,061,087_CD ._.
As_IN provided_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN in_IN respect_NN of_IN the_DT Company_NN accounts_VBZ shown_VBN on_IN pages_NNS 106_CD to_TO 112_CD ._.
8_CD Investment_NN revenue_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Interest_NN on_IN bank_NN deposits_NNS and_CC managed_VBD cash_NN funds_NNS 35,300_CD 21,901_CD 9_CD Finance_NNP costs_NNS 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Interest_NN expense_NN and_CC similar_JJ charges_NNS :_: convertible_JJ loan_NN notes_NNS 12,197_CD obligations_NNS under_IN finance_NN leases_NNS 360_CD 329_CD interest_NN provision_NN for_IN dissenting_VBG shareholders_NNS 7,690_CD other_JJ interest_NN payable_JJ 4,334_CD 97_CD 12,384_CD 12,623_CD Net_JJ foreign_JJ exchange_NN transaction_NN losses_NNS 5,036_CD 2,148_CD 17,420_CD 14,771_CD All_DT items_NNS relate_VBP materially_RB to_TO continuing_VBG operations_NNS ._.
In_IN August_NNP 2004_CD ,_, $_$ 370.1_CD million_CD of_IN the_DT 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS due_JJ 2011_CD were_VBD redeemed_VBN at_IN cost_NN by_IN the_DT note_NN holders_NNS and_CC as_IN a_DT result_NN debt_NN issuance_NN costs_NNS of_IN $_$ 7.4_CD million_CD were_VBD expensed_VBN in_IN the_DT year_NN ._.
These_DT costs_NNS were_VBD being_VBG amortised_VBN through_IN the_DT income_NN statement_NN over_IN the_DT life_NN of_IN the_DT loan_NN notes_NNS ._.
These_DT costs_NNS were_VBD partly_RB offset_VBN by_IN a_DT reduction_NN in_IN interest_NN payable_JJ for_IN the_DT period_NN from_IN redemption_NN of_IN the_DT loan_NN notes_VBZ up_RP to_TO December_NNP 31_CD ,_, 2004_CD ._.
66_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 67_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 10_CD Taxation_NNP 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Analysis_NN of_IN charge_NN in_IN the_DT year_NN Current_JJ tax_NN charge_NN continuing_VBG operations_NNS 70,097_CD 146,782_CD discontinued_VBN operations_NNS Deferred_JJ tax_NN income_NN expense_NN 20_CD continuing_VBG operations_NNS 31,587_CD 18,590_CD discontinued_VBN operations_NNS recognition_NN of_IN a_DT deferred_JJ tax_NN asset_NN within_IN goodwill_NN 23,749_CD Taxation_NNP 38,510_CD 141,623_CD Corporation_NNP tax_NN is_VBZ calculated_VBN at_IN 30_CD %_NN 2004_CD :_: 30_CD %_NN of_IN the_DT estimated_VBN assessable_JJ profit_NN in_IN the_DT year_NN ._.
Taxation_NNP for_IN other_JJ jurisdictions_NNS is_VBZ calculated_VBN at_IN the_DT rates_NNS prevailing_VBG in_IN the_DT respective_JJ jurisdictions_NNS ._.
The_DT effective_JJ tax_NN rate_NN for_IN the_DT year_NN is_VBZ -27_CD %_NN ._.
The_DT difference_NN between_IN this_DT and_CC the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP of_IN 30_CD %_NN is_VBZ explained_VBN below_IN :_: 2005_CD 2004_CD Loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN $_$ 000_CD 141,993_CD 302,424_CD %_NN %_NN Tax_NN at_IN the_DT UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 2004_CD :_: 30_CD %_NN 30.0_CD 30.0_CD Effects_NNPS of_IN :_: adjustments_NNS to_TO tax_NN in_IN respect_NN of_IN prior_JJ periods_NNS 0.4_CD 5.9_CD permanent_JJ differences_NNS 29.8_CD 6.1_CD non_NN deductible_JJ goodwill_NN 111.4_CD 13.4_CD stock_NN option_NN benefit_NN 1.2_CD change_NN in_IN opening_VBG tax_NN rates_NNS 1.6_CD movement_NN on_IN deferred_JJ tax_NN 22.2_CD 6.4_CD capital_NN taxes_NNS and_CC withholding_NN taxes_NNS 0.1_CD different_JJ tax_NN rates_NNS on_IN overseas_JJ earnings_NNS 1.6_CD 3.0_CD other_JJ 1.5_CD 0.3_CD Effective_JJ tax_NN rate_NN for_IN the_DT year_NN 27.1_CD 46.8_CD The_DT Group_NNP earns_VBZ profits_NNS in_IN various_JJ territories_NNS ,_, which_WDT have_VBP different_JJ tax_NN rates_NNS compared_VBN to_TO the_DT UK_NNP ._.
The_DT tax_NN credit_NN expense_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD consists_VBZ of_IN a_DT UK_NNP taxation_NN credit_NN of_IN $_$ 50.1_CD million_CD 2004_CD :_: $_$ 0.3_CD million_CD expense_NN and_CC overseas_JJ tax_NN expenses_NNS of_IN $_$ 88.6_CD million_CD 2004_CD :_: $_$ 141.3_CD million_CD expense_NN ._.
No_DT tax_NN deduction_NN is_VBZ available_JJ on_IN the_DT impairment_NN of_IN goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
Of_IN the_DT charge_NN to_TO current_JJ tax_NN ,_, $_$ nil_JJ 2004_CD :_: $_$ nil_JJ related_VBN to_TO profits_NNS arising_VBG in_IN the_DT vaccines_NNS business_NN Biologics_NNS which_WDT was_VBD disposed_VBN of_IN during_IN 2004_CD ._.
No_DT tax_NN charge_NN or_CC credit_NN arose_VBD on_IN the_DT disposal_NN ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 67_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 68_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 11_CD Business_NN acquisitions_NNS TKT_NNP acquisition_NN On_IN July_NNP 27_CD ,_, 2005_CD the_DT Group_NNP completed_VBD its_PRP$ acquisition_NN of_IN TKT_NNP in_IN an_DT all-cash_JJ transaction_NN ._.
The_DT acquisition_NN was_VBD effected_VBN by_IN merging_VBG a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP with_IN and_CC into_IN TKT_NNP ,_, with_IN TKT_NNP continuing_VBG as_IN the_DT surviving_VBG corporation_NN ._.
As_IN consideration_NN ,_, the_DT Group_NNP paid_VBD to_TO TKTs_NNS stockholders_NNS $_$ 37_CD in_IN cash_NN for_IN each_DT share_NN of_IN TKT_NNP common_JJ stock_NN outstanding_JJ at_IN the_DT time_NN of_IN the_DT acquisition_NN ,_, less_JJR any_DT applicable_JJ withholding_NN taxes_NNS ._.
The_DT total_JJ cash_NN consideration_NN for_IN the_DT acquisition_NN of_IN TKT_NNP is_VBZ expected_VBN to_TO be_VB approximately_RB $_$ 1.6_CD billion_CD ,_, subject_JJ to_TO change_VB as_RB may_MD be_VB required_VBN by_IN the_DT appraisal_NN rights_NNS process_NN see_VBP below_IN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD shareholders_NNS owning_VBG approximately_RB 24.8_CD million_CD TKT_NNP shares_NNS being_VBG 69_CD %_NN of_IN the_DT 36.2_CD million_CD TKT_NNP shares_NNS outstanding_JJ at_IN the_DT acquisition_NN date_NN had_VBD accepted_VBN the_DT offer_NN and_CC $_$ 917.9_CD million_CD has_VBZ been_VBN paid_VBN to_TO them_PRP :_: $_$ 83.9_CD million_CD was_VBD paid_VBN in_IN connection_NN with_IN TKT_NNP stock_NN options_NNS :_: and_CC $_$ 170.1_CD million_CD in_IN connection_NN with_IN convertible_JJ notes_NNS outstanding_JJ at_IN the_DT date_NN of_IN acquisition_NN ._.
In_IN connection_NN with_IN the_DT Groups_NNS merger_NN with_IN TKT_NNP ,_, former_JJ holders_NNS of_IN approximately_RB 11.7_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN submitted_VBN written_VBN demands_NNS to_TO the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP for_IN appraisal_NN of_IN these_DT shares_NNS and_CC ,_, as_IN a_DT result_NN ,_, elected_VBN not_RB to_TO accept_VB the_DT $_$ 37_CD per_IN share_NN merger_NN consideration_NN ._.
On_IN October_NNP 10_CD ,_, 2005_CD ,_, at_IN the_DT request_NN of_IN one_CD of_IN the_DT holders_NNS to_TO tender_VB 365,000_CD shares_NNS at_IN the_DT merger_NN price_NN of_IN $_$ 37_CD per_IN share_NN ,_, TKT_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT holders_NNS demand_NN ._.
On_IN October_NNP 12_CD ,_, 2005_CD ,_, the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP granted_VBD this_DT motion_NN ,_, and_CC the_DT holder_NN tendered_VBD the_DT shares_NNS at_IN the_DT merger_NN consideration_NN of_IN $_$ 37_CD per_IN share_NN ._.
Therefore_RB ,_, as_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, former_JJ holders_NNS of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN maintained_VBD written_VBN demands_NNS for_IN appraisal_NN of_IN these_DT shares_NNS and_CC have_VBP elected_VBN not_RB to_TO accept_VB the_DT $_$ 37_CD merger_NN consideration_NN ._.
In_IN November_NNP 2005_CD ,_, the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP approved_VBD a_DT consolidation_NN order_NN filed_VBN by_IN TKT_NNP whereby_WRB actions_NNS brought_VBN by_IN all_DT petitioners_NNS have_VBP been_VBN consolidated_VBN as_IN one_CD case_NN ._.
To_TO the_DT extent_NN that_IN the_DT remaining_VBG demands_NNS were_VBD validly_RB asserted_VBN in_IN accordance_NN with_IN the_DT applicable_JJ requirements_NNS of_IN Delaware_NNP law_NN and_CC the_DT former_JJ holders_NNS perfect_JJ their_PRP$ rights_NNS thereunder_NN ,_, such_JJ former_JJ holders_NNS will_MD be_VB entitled_VBN to_TO receive_VB the_DT fair_JJ value_NN of_IN the_DT shares_NNS as_IN determined_VBN by_IN the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP ._.
The_DT determination_NN of_IN fair_JJ value_NN will_MD be_VB made_VBN excluding_VBG any_DT element_NN of_IN value_NN arising_VBG from_IN the_DT transaction_NN ,_, such_JJ as_IN cost_NN savings_NNS or_CC business_NN synergies_NNS ._.
The_DT Delaware_NNP Court_NNP of_IN Chancery_NNP may_MD ascribe_VB a_DT valuation_NN to_TO the_DT shares_NNS that_WDT is_VBZ greater_JJR than_IN ,_, less_JJR than_IN or_CC equal_JJ to_TO $_$ 37_CD per_IN share_NN and_CC may_MD award_NN interest_NN on_IN the_DT amount_NN determined_VBN in_IN the_DT appraisal_NN process_NN ._.
The_DT total_JJ consideration_NN for_IN the_DT acquisition_NN of_IN TKT_NNP ,_, including_VBG amounts_NNS payable_JJ in_IN respect_NN of_IN stock_NN options_NNS and_CC convertible_JJ securities_NNS ,_, is_VBZ approximately_RB $_$ 1.6_CD billion_CD at_IN the_DT merger_NN price_NN of_IN $_$ 37_CD per_IN share_NN ._.
This_DT could_MD change_VB if_IN Shire_NNP is_VBZ required_VBN to_TO pay_VB a_DT different_JJ amount_NN of_IN consideration_NN in_IN respect_NN of_IN the_DT approximately_RB 11.3_CD million_CD shares_NNS for_IN which_WDT holders_NNS have_VBP asserted_VBN appraisal_NN rights_NNS ._.
Until_IN such_JJ time_NN as_IN the_DT appraisal_NN process_NN is_VBZ complete_JJ ,_, the_DT Group_NNP is_VBZ unable_JJ to_TO determine_VB the_DT extent_NN of_IN its_PRP$ liability_NN ._.
The_DT liability_NN to_TO dissenting_VBG shareholders_NNS shown_VBN in_IN the_DT Balance_NNP Sheet_NNP as_IN at_IN December_NNP 31_CD ,_, 2005_CD consists_VBZ of_IN $_$ 419.9_CD million_CD based_VBN on_IN the_DT merger_NN consideration_NN of_IN $_$ 37_CD per_IN share_NN for_IN the_DT 11.3_CD million_CD shares_NNS outstanding_JJ plus_CC a_DT provision_NN for_IN interest_NN of_IN $_$ 7.7_CD million_CD that_WDT may_MD be_VB awarded_VBN by_IN the_DT Court_NNP ._.
For_IN accounting_VBG purposes_NNS ,_, the_DT acquisition_NN of_IN TKT_NNP has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT purchase_NN business_NN combination_NN in_IN accordance_NN with_IN IFRS_NNP 3_CD ,_, Business_NNP Combinations_NNPS ._.
Financial_NNP statements_NNS and_CC reported_VBD results_NNS of_IN operations_NNS of_IN the_DT Group_NNP issued_VBN after_IN completion_NN of_IN the_DT acquisition_NN will_MD reflect_VB these_DT values_NNS ,_, with_IN the_DT results_NNS of_IN TKT_NNP included_VBD from_IN July_NNP 27_CD ,_, 2005_CD in_IN the_DT income_NN statement_NN ._.
The_DT cost_NN of_IN the_DT acquisition_NN was_VBD made_VBN up_RP as_IN follows_VBZ :_: $_$ 000_CD Common_JJ stock_NN Number_NN of_IN shares_NNS of_IN TKT_NNP common_JJ stock_NN non-dissenting_JJ 24,809,126_CD Price_NN per_IN TKT_NNP share_NN $_$ 37.00_CD 917,937_CD Number_NN of_IN shares_NNS of_IN TKT_NNP common_JJ stock_NN dissenting_VBG 11,349,150_CD Price_NN per_IN TKT_NNP share_NN $_$ 37.00_CD 419,919_CD Total_JJ number_NN of_IN shares_NNS of_IN TKT_NNP common_JJ stock_NN outstanding_JJ as_IN at_IN July_NNP 27_CD ,_, 2005_CD 36,158,276_CD Amount_NNP payable_JJ to_TO TKTs_NNS shareholders_NNS at_IN $_$ 37_CD per_IN share_NN 1,337,856_CD Stock_NNP options_NNS Cash_NN cost_NN of_IN settling_VBG TKT_NNP stock_NN options_NNS 83,877_CD Convertible_JJ notes_NNS Nominal_JJ value_NN of_IN convertible_JJ loan_NN notes_NNS as_IN at_IN July_NNP 27_CD ,_, 2005_CD in_IN $_$ 000s_CD 85,000_CD Conversion_NNP ratio_NN into_IN TKT_NNP common_JJ stock_NN 18.49_CD Total_JJ shares_NNS payable_JJ upon_IN conversion_NN 4,597,080_CD Price_NN per_IN TKT_NNP share_NN $_$ 37.00_CD Cost_NN of_IN settling_VBG convertible_JJ notes_NNS 170,092_CD Direct_JJ costs_NNS of_IN acquisition_NN 37,491_CD Total_JJ cost_NN of_IN the_DT acquisition_NN 1,629,316_CD 68_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 69_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 11_CD Business_NN acquisitions_NNS continued_VBD The_DT total_JJ cost_NN of_IN the_DT acquisition_NN stated_VBD above_IN has_VBZ been_VBN allocated_VBN on_IN a_DT provisional_JJ basis_NN according_VBG to_TO the_DT Groups_NNS estimate_NN of_IN the_DT fair_JJ value_NN of_IN assets_NNS acquired_VBN and_CC liabilities_NNS assumed_VBD ._.
The_DT fair_JJ values_NNS of_IN certain_JJ pre-acquisition_JJ contingencies_NNS ,_, in_IN particular_JJ those_DT relating_VBG to_TO the_DT Purported_NNP Class_NNP Action_NNP Shareholder_NN Suit_NN see_VBP Note_NN 35_CD for_IN further_JJ details_NNS are_VBP yet_RB to_TO be_VB determined_VBN ._.
The_DT Group_NNP currently_RB does_VBZ not_RB have_VB sufficient_JJ information_NN to_TO measure_VB the_DT fair_JJ value_NN of_IN these_DT contingencies_NNS reliably_RB ._.
The_DT fair_JJ values_NNS of_IN assets_NNS acquired_VBN and_CC liabilities_NNS assumed_VBD will_MD be_VB determined_VBN as_RB soon_RB as_IN possible_JJ and_CC ,_, in_IN any_DT event_NN ,_, no_RB later_RB than_IN one_CD year_NN from_IN the_DT acquisition_NN date_NN if_IN such_JJ fair_JJ values_NNS can_MD be_VB measured_VBN reliably_RB in_IN this_DT time_NN frame_NN ._.
To_TO the_DT extent_NN that_WDT estimates_VBZ need_NN to_TO be_VB adjusted_VBN ,_, the_DT Group_NNP will_MD do_VB so_RB in_IN future_NN periods_NNS in_IN accordance_NN with_IN IFRS_NNP 3_CD ._.
The_DT cost_NN of_IN the_DT acquisition_NN has_VBZ been_VBN allocated_VBN as_IN follows_VBZ :_: Book_NNP Fair_NNP value_NN Fair_NN value_NN adjustments_NNS value_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD Assets_NNPS Current_JJ assets_NNS :_: Cash_NN and_CC cash_NN equivalents_NNS 56,814_CD 56,814_CD Restricted_VBN cash_NN 8,173_CD 8,173_CD Short-term_JJ investments_NNS 46,896_CD 46,896_CD Accounts_NNPS receivable_JJ 28,361_CD 28,361_CD Inventories_NNS 12,890_CD 88,879_CD 101,769_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 7,997_CD 7,997_CD Total_JJ current_JJ assets_NNS 161,131_CD 88,879_CD 250,010_CD Property_NN ,_, plant_NN and_CC equipment_NN 57,297_CD 57,297_CD Goodwill_NNP 39,038_CD 39,038_CD Other_JJ intangible_JJ assets_NNS 20,210_CD 1,043,790_CD 1,064,000_CD Other_JJ non-current_JJ assets_NNS 3,281_CD 3,281_CD Total_JJ assets_NNS 280,957_CD 1,093,631_CD 1,374,588_CD Liabilities_NNP Current_NNP liabilities_NNS :_: Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 35,365_CD 1,574_CD 33,791_CD Deferred_JJ tax_NN liability_NN 178,637_CD 178,637_CD Other_JJ current_JJ liabilities_NNS 24,471_CD 24,471_CD Total_JJ current_JJ liabilities_NNS 59,836_CD 177,063_CD 236,899_CD Other_JJ long-term_JJ liabilities_NNS 1,806_CD 1,806_CD Total_JJ liabilities_NNS 61,642_CD 177,063_CD 238,705_CD Contingent_JJ liabilities_NNS Net_JJ assets_NNS 219,315_CD 916,568_CD 1,135,883_CD Goodwill_NNP 493,433_CD Total_JJ consideration_NN 1,629,316_CD Book_NNP values_NNS are_VBP stated_VBN in_IN US_NNP GAAP_NNP and_CC have_VBP not_RB been_VBN re-stated_VBN to_TO IFRS_NNP on_IN the_DT grounds_NNS of_IN materiality_NN ._.
The_DT goodwill_NN arising_VBG on_IN the_DT acquisition_NN of_IN TKT_NNP is_VBZ attributed_VBN to_TO the_DT anticipated_VBN profitability_NN of_IN TKTs_NNS products_NNS and_CC the_DT anticipated_JJ future_NN operating_VBG synergies_NNS from_IN the_DT combination_NN ._.
TKT_NNP contributed_VBD $_$ 42.0_CD million_CD of_IN revenue_NN and_CC $_$ 39.5_CD million_CD to_TO the_DT Groups_NNS loss_NN before_IN tax_NN for_IN the_DT period_NN between_IN the_DT date_NN of_IN acquisition_NN and_CC the_DT balance_NN sheet_NN date_NN ._.
If_IN the_DT acquisition_NN of_IN TKT_NNP had_VBD been_VBN completed_VBN on_IN the_DT first_JJ day_NN of_IN the_DT financial_JJ year_NN ,_, Group_NNP revenues_NNS for_IN the_DT period_NN would_MD have_VB been_VBN $_$ 1,652.9_CD million_CD ,_, and_CC the_DT Group_NNP loss_NN before_IN tax_NN from_IN continuing_VBG operations_NNS would_MD have_VB been_VBN $_$ 257.7_CD million_CD ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 69_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 70_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 12_CD Business_NN integration_NN In_IN connection_NN with_IN the_DT acquisition_NN of_IN TKT_NNP ,_, the_DT Groups_NNS management_NN approved_VBD and_CC initiated_VBD plans_NNS to_TO restructure_VB the_DT operations_NNS of_IN the_DT enlarged_JJ Group_NNP to_TO eliminate_VB duplicate_VB costs_NNS ._.
Integration_NN costs_NNS represent_VBP incremental_JJ costs_NNS incurred_VBN by_IN the_DT Group_NNP directly_RB related_VBN to_TO the_DT absorption_NN of_IN the_DT TKT_NNP business_NN into_IN the_DT Group_NNP ,_, including_VBG expenditures_NNS for_IN consulting_NN and_CC systems_NNS integration_NN ._.
The_DT charges_NNS have_VBP been_VBN presented_VBN as_IN selling_NN ,_, general_JJ and_CC administrative_JJ costs_NNS in_IN the_DT consolidated_JJ income_NN statement_NN and_CC are_VBP accounted_VBN for_IN solely_RB within_IN the_DT Pharmaceutical_NNP products_NNS reporting_VBG segment_NN ._.
Integration_NN costs_NNS recorded_VBN and_CC paid_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD were_VBD :_: Costs_NNS recorded_VBN in_IN year_NN to_TO Paid_VBN in_IN year_NN to_TO December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN 2005_CD 2005_CD liability_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 2,011_CD 2,011_CD Retention_NNP payments_NNS for_IN key_JJ TKT_NNP employees_NNS 7,031_CD 1,097_CD 5,934_CD IT_PRP costs_VBZ 1,049_CD 1,049_CD Other_JJ 1,636_CD 1,436_CD 200_CD Total_JJ 11,727_CD 5,593_CD 6,134_CD 13_CD Reorganizations_NNS Sale_NNP of_IN the_DT drug_NN formulation_NN business_NN On_IN December_NNP 22_CD ,_, 2005_CD the_DT Group_NNP sold_VBD its_PRP$ drug_NN formulation_NN business_NN to_TO Supernus_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Supernus_NNP ,_, a_DT newly-formed_JJ specialty_NN pharmaceutical_JJ company_NN funded_VBN by_IN two_CD venture_NN capital_NN companies_NNS ._.
The_DT disposal_NN resulted_VBD in_IN :_: a_DT profit_NN on_IN disposal_NN of_IN $_$ 3.6_CD million_CD ._.
Proceeds_NNS from_IN the_DT sale_NN included_VBD an_DT equity_NN interest_NN of_IN less_JJR than_IN 10_CD %_NN in_IN Supernus_NNP ,_, which_WDT has_VBZ been_VBN included_VBN in_IN investments_NNS in_IN private_JJ companies_NNS see_VBP Note_NN 22_CD at_IN its_PRP$ fair_JJ value_NN of_IN $_$ 3.9_CD million_CD ._.
The_DT fair_JJ value_NN was_VBD determined_VBN by_IN reference_NN to_TO the_DT cash_NN invested_VBN in_IN Supernus_NNP by_IN the_DT venture_NN capital_NN companies_NNS :_: the_DT transfer_NN of_IN the_DT lease_NN on_IN the_DT East_NNP Gude_NNP Drive_NNP ,_, Rockville_NNP premises_NNS to_TO Supernus_NNP ,_, with_IN the_DT Group_NNP being_VBG released_VBN from_IN all_DT obligations_NNS under_IN the_DT lease_NN by_IN the_DT landlord_NN :_: an_DT ongoing_JJ projects_NNS agreement_NN relating_VBG to_TO work_VB Supernus_NNP will_MD continue_VB to_TO provide_VB to_TO the_DT Group_NNP for_IN a_DT transitional_JJ period_NN ending_VBG on_IN or_CC about_IN March_NNP 31_CD ,_, 2006_CD on_IN certain_JJ Shire_NNP projects_NNS until_IN the_DT projects_NNS are_VBP moved_VBN to_TO third-party_JJ suppliers_NNS :_: and_CC the_DT severance_NN of_IN 28_CD employees_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, 16_CD had_VBD left_VBN the_DT Group_NNP ,_, and_CC the_DT remaining_VBG employees_NNS are_VBP expected_VBN to_TO leave_VB by_IN March_NNP 31_CD ,_, 2006_CD ._.
Severance_NN payments_NNS are_VBP being_VBG made_VBN to_TO the_DT former_JJ employees_NNS over_IN a_DT 42_CD week_NN period_NN ,_, as_IN required_VBN by_IN local_JJ regulations_NNS ._.
The_DT disposal_NN has_VBZ been_VBN reflected_VBN in_IN the_DT consolidated_JJ income_NN statement_NN as_IN follows_VBZ :_: SG&A_NNP expense_NN R&D_NNP expense_NN $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 1,216_CD Gain_NNP on_IN disposal_NN 3,561_CD Other_JJ costs_NNS 192_CD 3,561_CD 1,408_CD All_DT items_NNS are_VBP recorded_VBN in_IN the_DT Pharmaceutical_NNP products_NNS segment_NN ._.
North_JJ American_JJ site_NN consolidation_NN The_DT Group_NNP began_VBD a_DT consolidation_NN of_IN its_PRP$ North_JJ American_JJ sites_NNS in_IN 2004_CD ,_, with_IN the_DT aim_NN of_IN decreasing_VBG the_DT number_NN of_IN sites_NNS from_IN 16_CD to_TO four_CD ,_, including_VBG the_DT opening_NN of_IN a_DT new_JJ US_NNP headquarters_NN office_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
The_DT Group_NNP recorded_VBD reorganization_NN costs_NNS of_IN $_$ 55.5_CD million_CD in_IN 2004_CD ,_, and_CC $_$ 2.3_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
Following_VBG the_DT closure_NN of_IN the_DT Newport_NNP site_NN in_IN July_NNP 2005_CD ,_, the_DT site_NN consolidation_NN is_VBZ now_RB complete_JJ and_CC no_DT further_JJ reorganization_NN costs_NNS are_VBP expected_VBN ._.
The_DT primary_JJ costs_NNS associated_VBN with_IN the_DT site_NN consolidation_NN include_VBP :_: severance_NN costs_NNS relating_VBG to_TO 137_CD employees_NNS :_: retention_NN payments_NNS to_TO key_JJ employees_NNS :_: 70_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 71_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 13_CD Reorganizations_NNS continued_VBD relocation_NN costs_NNS relating_VBG to_TO 85_CD employees_NNS who_WP were_VBD moved_VBN to_TO Wayne_NNP ,_, Pennsylvania_NNP :_: costs_NNS of_IN duplicate_VBP facilities_NNS including_VBG lease_NN exit_NN costs_NNS :_: and_CC other_JJ incremental_JJ costs_NNS associated_VBN with_IN the_DT site_NN closures_NNS ,_, such_JJ as_IN legal_JJ ,_, consultancy_NN ,_, the_DT write_VB down_IN of_IN property_NN ,_, plant_NN and_CC equipment_NN and_CC information_NN technology_NN costs_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, 137_CD employees_NNS had_VBD left_VBN the_DT Group_NNP ._.
In_IN addition_NN ,_, all_DT 85_CD of_IN those_DT employees_NNS who_WP had_VBD agreed_VBN to_TO relocate_VB had_VBD relocated_VBN ._.
The_DT following_JJ table_NN presents_VBZ the_DT cost_NN of_IN the_DT reorganization_NN recorded_VBN to_TO date_NN and_CC the_DT total_JJ costs_NNS of_IN the_DT reorganization_NN ._.
Total_JJ costs_NNS Total_JJ costs_NNS incurred_VBN to_TO incurred_VBN to_TO Total_JJ estimated_VBN December_NNP 31_CD ,_, December_NNP 31_CD ,_, costs_NNS of_IN 2004_CD 2005_CD reorganization_NN $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN and_CC relocation_NN costs_NNS 33.8_CD 1.6_CD 35.4_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1.2_CD Consultancy_NN costs_VBZ 2.9_CD 0.5_CD 3.4_CD Duplicate_NNP facilities_NNS 12.1_CD 0.2_CD 12.3_CD Information_NN technology_NN costs_VBZ 2.1_CD 2.1_CD Other_JJ costs_NNS 3.4_CD 3.4_CD 55.5_CD 2.3_CD 57.8_CD These_DT charges_NNS are_VBP included_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ costs_NNS in_IN the_DT consolidated_JJ income_NN statement_NN and_CC are_VBP accounted_VBN for_IN solely_RB within_IN the_DT Pharmaceutical_NNP products_NNS reporting_VBG segment_NN ._.
As_IN noted_VBN above_IN ,_, certain_JJ of_IN the_DT costs_NNS associated_VBN with_IN the_DT reorganization_NN will_MD be_VB paid_VBN in_IN subsequent_JJ periods_NNS ._.
The_DT following_VBG provides_VBZ a_DT reconciliation_NN of_IN the_DT liability_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD ._.
Costs_NNS recorded_VBD Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2005_CD 2005_CD liability_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN and_CC relocation_NN costs_NNS 1.9_CD 1.6_CD 2.9_CD 0.6_CD Consultancy_NN costs_NNS 0.5_CD 0.5_CD Duplicate_NNP facilities_NNS 11.0_CD 0.2_CD 4.0_CD 7.2_CD 12.9_CD 2.3_CD 7.4_CD 7.8_CD Current_JJ liabilities_NNS 1.9_CD 2.1_CD 0.6_CD 3.4_CD Other_JJ long-term_JJ liabilities_NNS 11.0_CD 0.2_CD 6.8_CD 4.4_CD 12.9_CD 2.3_CD 7.4_CD 7.8_CD The_DT remaining_VBG relocation_NN costs_NNS are_VBP expected_VBN to_TO be_VB paid_VBN in_IN 2006_CD ._.
The_DT liability_NN for_IN the_DT duplicate_VB facilities_NNS will_MD be_VB paid_VBN over_IN the_DT remaining_VBG life_NN of_IN the_DT relevant_JJ leases_NNS ,_, which_WDT all_DT expire_VBP before_IN October_NNP 31_CD ,_, 2012_CD ._.
The_DT following_VBG provides_VBZ a_DT reconciliation_NN of_IN the_DT liability_NN as_IN at_IN December_NNP 31_CD ,_, 2004_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2004_CD 2004_CD liability_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN and_CC relocation_NN costs_NNS 33.8_CD 31.9_CD 1.9_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1.2_CD Consultancy_NN costs_VBZ 2.9_CD 2.9_CD Duplicate_NNP facilities_NNS 12.1_CD 1.1_CD 11.0_CD Information_NN technology_NN costs_VBZ 2.1_CD 2.1_CD Other_JJ costs_NNS 3.4_CD 3.4_CD 55.5_CD 42.6_CD 12.9_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 71_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 72_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 14_CD Discontinued_VBN operations_NNS Disposal_NNP of_IN the_DT vaccines_NNS business_NN Biologics_NNPS On_IN September_NNP 9_CD ,_, 2004_CD the_DT Group_NNP completed_VBD the_DT disposition_NN of_IN its_PRP$ vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP ._.
The_DT total_JJ consideration_NN for_IN the_DT sale_NN was_VBD $_$ 120_CD million_CD comprizing_VBG $_$ 30_CD million_CD of_IN cash_NN received_VBN at_IN completion_NN ,_, $_$ 30_CD million_CD of_IN cash_NN held_VBN in_IN escrow_NN and_CC due_JJ on_IN the_DT first_JJ anniversary_NN of_IN completion_NN and_CC $_$ 60_CD million_CD received_VBN at_IN completion_NN in_IN the_DT form_NN of_IN 4,931,864_CD subscription_NN receipts_NNS of_IN IDB_NNP ._.
If_IN ,_, prior_RB to_TO January_NNP 10_CD ,_, 2005_CD ,_, IDB_NNP were_VBD to_TO raise_VB up_RP to_TO $_$ 60_CD million_CD from_IN equity_NN related_VBN issuances_NNS ,_, then_RB it_PRP was_VBD required_VBN under_IN the_DT terms_NNS of_IN the_DT sale_NN agreement_NN to_TO redeem_VB the_DT subscription_NN receipts_NNS from_IN the_DT Group_NNP for_IN $_$ 60_CD million_CD ._.
Accordingly_RB ,_, following_VBG the_DT completion_NN of_IN such_PDT a_DT fund_NN raising_VBG on_IN January_NNP 7_CD ,_, 2005_CD ,_, IDB_NNP redeemed_VBD the_DT subscription_NN receipts_NNS from_IN the_DT Group_NNP for_IN $_$ 60_CD million_CD in_IN cash_NN ._.
On_IN the_DT first_JJ anniversary_NN of_IN completion_NN ,_, the_DT Group_NNP received_VBD the_DT $_$ 30_CD million_CD of_IN cash_NN held_VBN in_IN escrow_NN ._.
As_IN part_NN of_IN the_DT transaction_NN ,_, the_DT Group_NNP entered_VBD into_IN an_DT agreement_NN to_TO provide_VB IDB_NNP with_IN a_DT loan_NN facility_NN of_IN up_RB to_TO $_$ 100_CD million_CD ,_, which_WDT could_MD be_VB drawn_VBN down_RB over_IN the_DT four_CD years_NNS following_VBG completion_NN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD IDB_NNP had_VBD drawn_VBN down_IN the_DT entire_JJ $_$ 100_CD million_CD loan_NN ._.
It_PRP was_VBD required_VBN that_IN this_DT facility_NN be_VB used_VBN by_IN IDB_NNP to_TO fund_VB the_DT development_NN of_IN injectable_JJ flu_NN and_CC pipeline_NN products_NNS within_IN the_DT vaccines_NNS business_NN acquired_VBD from_IN the_DT Group_NNP ._.
Drawings_NNS under_IN the_DT loan_NN facility_NN are_VBP segregated_VBN into_IN two_CD components_NNS :_: i_FW Drawings_NNPS for_IN injectable_JJ flu_NN development_NN of_IN $_$ 70.6_CD million_CD which_WDT are_VBP repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ non-Canadian_JJ injectable_JJ flu_NN products_NNS ,_, subject_JJ to_TO minimum_JJ annual_JJ repayments_NNS in_IN respect_NN of_IN the_DT first_JJ $_$ 30_CD million_CD of_IN the_DT drawing_NN ,_, to_TO be_VB made_VBN between_IN 2007_CD and_CC 2017_CD :_: and_CC ii_FW Drawings_NNPS for_IN pipeline_NN development_NN of_IN $_$ 29.4_CD million_CD which_WDT are_VBP repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ pipeline_NN products_NNS and_CC have_VBP no_DT fixed_VBN repayment_NN schedule_NN ._.
The_DT transaction_NN gave_VBD rise_NN to_TO an_DT overall_JJ loss_NN on_IN disposition_NN of_IN the_DT vaccines_NNS business_NN of_IN $_$ 41.1_CD million_CD ,_, recorded_VBN as_IN a_DT loss_NN on_IN disposition_NN at_IN completion_NN in_IN 2004_CD of_IN $_$ 44.2_CD million_CD and_CC a_DT subsequent_JJ provision_NN release_NN of_IN $_$ 3.1_CD million_CD being_VBG recognized_VBN during_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
This_DT net_JJ loss_NN on_IN disposition_NN of_IN $_$ 41.1_CD million_CD comprises_VBZ a_DT gain_NN on_IN disposition_NN of_IN net_JJ assets_NNS of_IN $_$ 28.9_CD million_CD together_RB with_IN a_DT provision_NN for_IN a_DT loss_NN of_IN $_$ 70_CD million_CD out_IN of_IN the_DT $_$ 100_CD million_CD loan_NN facility_NN available_JJ to_TO IDB_NNP ._.
This_DT provision_NN was_VBD made_VBN on_IN the_DT basis_NN that_IN those_DT loan_NN repayments_NNS based_VBN solely_RB on_IN future_JJ sales_NNS of_IN flu_NN and_CC pipeline_NN products_NNS in_IN development_NN provided_VBN no_DT certainty_NN of_IN recovery_NN ._.
The_DT historical_JJ consolidated_JJ financial_JJ statements_NNS have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT vaccines_NNS business_NN as_IN a_DT discontinued_VBN operation_NN for_IN all_DT periods_NNS presented_VBN ._.
The_DT results_NNS of_IN the_DT discontinued_VBN operation_NN have_VBP been_VBN removed_VBN from_IN all_DT periods_NNS on_IN a_DT line-by-line_JJ basis_NN from_IN product_NN sales_NNS revenue_NN to_TO income_NN from_IN continuing_VBG operations_NNS ._.
The_DT net_JJ loss_NN from_IN the_DT discontinued_VBN operation_NN together_RB with_IN the_DT loss_NN on_IN disposal_NN ,_, are_VBP shown_VBN as_IN separate_JJ line_NN items_NNS below_IN ._.
Operating_VBG results_NNS of_IN the_DT discontinued_VBN operations_NNS are_VBP summarized_VBN below_IN ._.
2004_CD $_$ 000_CD Product_NN sales_NNS 3,626_CD Total_JJ revenues_NNS 3,626_CD Costs_NNS and_CC expenses_NNS :_: Cost_NN of_IN sales_NNS 8,304_CD Research_NNP and_CC development_NN 9,222_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 5,614_CD Total_JJ operating_NN expenses_NNS 23,140_CD Operating_NN loss_NN 19,514_CD Other_JJ expense_NN ,_, net_JJ 621_CD Loss_NN from_IN discontinued_VBN operations_NNS before_IN tax_NN 20,135_CD Taxation_NNP Loss_NN from_IN discontinued_VBN operations_NNS after_IN tax_NN 20,135_CD Loss_NN on_IN disposal_NN before_IN tax_NN 44,157_CD Taxation_NNP Loss_NN on_IN disposal_NN after_IN tax_NN 44,157_CD Loss_NN for_IN the_DT year_NN from_IN discontinued_VBN operations_NNS 64,292_CD 72_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 73_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 14_CD Discontinued_VBN operations_NNS continued_VBD The_DT following_JJ table_NN summarizes_VBZ the_DT assets_NNS and_CC liabilities_NNS attributed_VBD to_TO the_DT discontinued_VBN operations_NNS at_IN the_DT disposal_NN date_NN ._.
2004_CD $_$ 000_CD Goodwill_NNP 4,476_CD Property_NN ,_, plant_NN and_CC equipment_NN 74,799_CD Inventories_NNS 6,481_CD Trade_NNP and_CC other_JJ receivables_NN 11,036_CD Cash_NN and_CC cash_NN equivalents_NNS 2,069_CD Borrowings_NNS 1,476_CD Trade_NNP and_CC other_JJ payables_NNS 13,514_CD Loan_NN provision_NN 70,000_CD Other_JJ provisions_NNS 8,492_CD Acquisition_NNP costs_NNS 6,706_CD Loss_NN on_IN sale_NN 44,157_CD 124,912_CD Satisfied_VBN by_IN :_: Cash_NN consideration_NN 34,912_CD Deferred_JJ consideration_NN 30,000_CD Subscription_NNP receipts_NNS 60,000_CD 124,912_CD At_IN December_NNP 31_CD ,_, 2004_CD the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT discontinued_VBN vaccines_NNS operation_NN were_VBD $_$ nil_JJ ._.
Cash_NN flows_VBZ from_IN discontinued_VBN operations_NNS :_: 2004_CD $_$ 000_CD Operating_NN cash_NN flows_VBZ 30,525_CD Investing_VBG cash_NN flows_NNS 12,715_CD Financing_NN cash_NN flows_VBZ Foreign_JJ currency_NN translation_NN 10_CD Total_JJ cash_NN flows_VBZ 43,250_CD 15_CD Dividends_NNPS 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Equity_NNP shares_NNS :_: first_JJ interim_JJ dividend_NN of_IN 1.0475_CD pence_NN 1.8246_CD equivalent_JJ per_IN share_NN paid_VBN on_IN October_NNP 13_CD ,_, 2005_CD 2004_CD :_: 1.00_CD pence_NN 1.82_CD equivalent_JJ paid_VBN on_IN October_NNP 14_CD ,_, 2004_CD 9,403_CD 8,905_CD 2004_CD second_JJ interim_JJ dividend_NN of_IN 2.00_CD pence_NN 3.85_CD equivalent_JJ per_IN share_NN paid_VBN on_IN April_NNP 14_CD ,_, 2005_CD 2004_CD :_: nil_NN 19,057_CD 28,460_CD 8,905_CD Proposed_VBN second_JJ interim_JJ dividend_NN 2.5356_CD pence_NN 4.419_CD equivalent_JJ per_IN share_NN 22,020_CD 19,057_CD In_IN accordance_NN with_IN IAS10_NNP Events_NNS after_IN the_DT Balance_NNP Sheet_NNP Date_NNP ,_, the_DT proposed_VBN second_JJ interim_JJ dividend_NN has_VBZ not_RB been_VBN included_VBN as_IN a_DT liability_NN in_IN these_DT financial_JJ statements_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 73_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 74_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 16_CD Loss_NN earnings_NNS per_IN ordinary_JJ share_NN EPS_NNP Basic_JJ EPS_NNP is_VBZ calculated_VBN by_IN dividing_VBG the_DT loss_NN earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT year_NN ,_, excluding_VBG those_DT held_VBN in_IN the_DT employee_NN share_NN trust_NN Note_VB 32_CD ,_, which_WDT are_VBP treated_VBN as_IN canceled_VBN ._.
For_IN diluted_VBN EPS_NNP ,_, the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS in_IN issue_NN is_VBZ adjusted_VBN to_TO assume_VB conversion_NN of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS ._.
For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD share_NN options_NNS to_TO purchase_VB approximately_RB 20.7_CD million_CD ordinary_JJ shares_NNS and_CC warrants_NNS to_TO purchase_VB 1.3_CD million_CD ordinary_JJ shares_NNS were_VBD not_RB dilutive_JJ and_CC were_VBD therefore_RB excluded_VBN from_IN the_DT computation_NN of_IN diluted_VBN EPS_NNP ._.
The_DT $_$ 370_CD million_CD loan_NN note_NN convertible_JJ debt_NN was_VBD excluded_VBN from_IN the_DT calculation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN diluted_VBN EPS_NNP in_IN 2004_CD as_IN it_PRP was_VBD not_RB dilutive_JJ ._.
Reconciliations_NNS of_IN the_DT earnings_NNS and_CC weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN the_DT calculations_NNS are_VBP set_VBN out_RP below_IN ._.
Weighted_JJ average_JJ Loss_NN number_NN of_IN Per_IN share_NN 2005_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ and_CC diluted_JJ EPS_NNP Loss_NN attributable_JJ to_TO ordinary_JJ shareholders_NNS 177,378_CD 500,243,137_CD 35.5_CD Weighted_VBN average_JJ Earnings_NNS number_NN of_IN Per_IN share_NN 2004_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ EPS_NNP Earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS 96,509_CD 496,306,604_CD 19.4_CD Effect_NN of_IN dilutive_JJ securities_NNS Share_NN options_NNS 3,035,620_CD 0.1_CD Warrants_NNS 66,792_CD Diluted_NNP EPS_NNP 96,509_CD 499,409,016_CD 19.3_CD Loss_NN earnings_NNS per_IN share_NN from_IN continuing_VBG and_CC discontinued_VBN operations_NNS :_: Weighted_JJ average_JJ Loss_NN number_NN of_IN Per_IN share_NN 2005_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ and_CC Diluted_JJ EPS_NNP Loss_NN from_IN continuing_VBG operations_NNS 180,503_CD 500,243,137_CD 36.1_CD Gain_NN from_IN discontinued_VBN operations_NNS 3,125_CD 500,243,137_CD 0.6_CD Weighted_VBN average_JJ Earnings_NNS number_NN of_IN Per_IN share_NN 2004_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ EPS_NNP Profit_NN from_IN continuing_VBG operations_NNS 160,801_CD 496,306,604_CD 32.4_CD Loss_NN from_IN discontinued_VBN operations_NNS 64,292_CD 496,306,604_CD 13.0_CD Diluted_NNP EPS_NNP Profit_NN from_IN continuing_VBG operations_NNS 160,801_CD 499,409,016_CD 32.1_CD Loss_NN from_IN discontinued_VBN operations_NNS 64,292_CD 499,409,016_CD 12.9_CD 74_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 75_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 17_CD Goodwill_NNP 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Net_JJ book_NN value_NN At_IN January_NNP 1_CD ,_, 2,246,220_CD 2,381,287_CD Recognised_VBN on_IN acquisition_NN of_IN subsidiary_NN 493,433_CD Impairment_NNP 526,956_CD 132,576_CD Disposals_NNPS 4,476_CD Exchange_NNP differences_NNS 3,237_CD 1,985_CD At_IN December_NNP 31_CD ,_, 2,209,460_CD 2,246,220_CD Goodwill_NNP is_VBZ allocated_VBN to_TO the_DT Groups_NNS cash-generating_JJ units_NNS CGUs_NNS that_WDT are_VBP expected_VBN to_TO benefit_VB from_IN that_DT business_NN combination_NN ._.
The_DT carrying_VBG amount_NN of_IN goodwill_NN has_VBZ been_VBN allocated_VBN as_IN follows_VBZ :_: Pharmaceutical_NNP products_NNS Royalties_NNP Total_NNP 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD North_NNP America_NNP 1,320,888_CD 440,346_CD 1,761,234_CD Rest_VBP of_IN the_DT world_NN 21,393_CD 426,833_CD 448,226_CD Total_JJ 1,342,281_CD 867,179_CD 2,209,460_CD Pharmaceutical_NNP products_NNS Royalties_NNP Total_NNP 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD North_NNP America_NNP 971,301_CD 636,026_CD 1,607,327_CD Rest_VBP of_IN the_DT world_NN 24,651_CD 614,242_CD 638,893_CD Total_JJ 995,952_CD 1,250,268_CD 2,246,220_CD The_DT Group_NNP tests_NNS goodwill_NN annually_RB for_IN impairment_NN or_CC more_JJR frequently_RB if_IN there_EX are_VBP indications_NNS that_WDT goodwill_NN might_MD be_VB impaired_VBN ._.
The_DT recoverable_JJ amount_NN of_IN a_DT CGU_NNP is_VBZ determined_VBN based_VBN on_IN value-in-use_JJ calculations_NNS ._.
These_DT calculations_NNS use_VBP cash_NN flow_NN projections_NNS based_VBN on_IN financial_JJ budgets_NNS approved_VBN by_IN management_NN covering_VBG up_RP to_TO five_CD years_NNS ._.
For_IN certain_JJ CGUs_NNS ,_, projections_NNS of_IN up_RB to_TO fifteen_CD years_NNS are_VBP used_VBN to_TO fully_RB model_VB relevant_JJ product_NN lifecycles_NNS ._.
Cash_NN flows_VBZ beyond_IN the_DT projected_VBN period_NN are_VBP extrapolated_VBN using_VBG the_DT estimated_VBN growth_NN rates_NNS stated_VBD below_IN ._.
The_DT growth_NN rate_NN does_VBZ not_RB exceed_VB the_DT long-term_JJ average_JJ growth_NN rate_NN for_IN the_DT business_NN in_IN which_WDT the_DT CGU_NNP operates_VBZ ._.
These_DT assumptions_NNS have_VBP been_VBN used_VBN for_IN the_DT analysis_NN of_IN each_DT CGU_NNP within_IN the_DT business_NN segment_NN ._.
Key_NNP assumptions_NNS used_VBN for_IN value-in-use_JJ calculations_NNS :_: Pharmaceutical_NNP Pharmaceutical_NNP products_NNS products_NNS Royalties_NNS Royalties_NNS 2005 2004 2005 2004_CD i_FW Gross_NNP margin_NN 86_CD %_NN 87_CD %_NN ii_FW Growth_NN rate_NN 2_CD %_NN 2_CD %_NN 25_CD %_NN 9_CD %_NN iii_FW Discount_NNP rate_NN 19_CD %_NN 19_CD %_NN 10_CD %_NN 10_CD %_NN Notes_NNS i_FW Budgeted_VBN gross_JJ margin_NN ._.
ii_FW Weighted_VBN average_JJ growth_NN rate_NN used_VBN to_TO extrapolate_VB cash_NN flows_NNS beyond_IN the_DT projection_NN period_NN of_IN ten_CD years_NNS as_IN appropriate_JJ ._.
iii_FW Pre-tax_JJ discount_NN rate_NN applied_VBN to_TO the_DT pre-tax_JJ cash_NN flow_NN projections_NNS ._.
Management_NNP determined_VBD budgeted_VBN gross_JJ margin_NN based_VBN on_IN past_JJ performance_NN and_CC its_PRP$ expectations_NNS for_IN the_DT market_NN development_NN ._.
The_DT weighted_JJ average_JJ growth_NN rates_NNS used_VBN are_VBP consistent_JJ with_IN the_DT forecasts_NNS included_VBD in_IN industry_NN reports_NNS ._.
The_DT discount_NN rates_NNS used_VBN are_VBP pre-tax_JJ and_CC reflect_VBP specific_JJ risks_NNS relating_VBG to_TO the_DT relevant_JJ segments_NNS ._.
The_DT Group_NNP recognized_VBD $_$ 493_CD million_CD as_IN goodwill_NN on_IN acquisition_NN of_IN TKT_NNP see_VBP Note_VB 11_CD ,_, in_IN accordance_NN with_IN IFRS_NNP 3_CD ,_, Business_NNP Combinations_NNPS ._.
This_DT goodwill_NN is_VBZ recorded_VBN in_IN the_DT Pharmaceutical_NNP products_NNS operating_VBG segment_NN ._.
At_IN December_NNP 31_CD ,_, 2005_CD an_DT impairment_NN charge_NN of_IN $_$ 527_CD million_CD was_VBD made_VBN in_IN relation_NN to_TO goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
A_DT discounted_JJ cash_NN flow_NN model_NN was_VBD used_VBN to_TO estimate_VB the_DT recoverable_JJ value_NN of_IN the_DT business_NN and_CC the_DT impairment_NN is_VBZ included_VBN within_IN net_JJ operating_NN expenses_NNS in_IN the_DT consolidated_JJ income_NN statement_NN ._.
A_DT range_NN of_IN pre-tax_JJ discount_NN rates_NNS between_IN 10_CD %_NN 19_CD %_NN was_VBD applied_VBN to_TO probabilityadjusted_JJ forecasts_NNS ._.
The_DT impairment_NN reflected_VBD lower_JJR projected_VBD sales_NNS in_IN the_DT BioChem_NNP subsidiary_NN ,_, and_CC lower_JJR estimates_NNS of_IN cashflows_NNS from_IN 3TC_NNP royalties_NNS as_IN increased_VBN competition_NN in_IN the_DT anti-viral_JJ market_NN is_VBZ anticipated_VBN ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 75_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 76_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 17_CD Goodwill_NNP continued_VBD At_IN December_NNP 31_CD ,_, 2004_CD an_DT impairment_NN charge_NN was_VBD made_VBN in_IN relation_NN to_TO goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
A_DT discounted_JJ cash_NN flow_NN model_NN was_VBD used_VBN to_TO estimate_VB the_DT recoverable_JJ value_NN of_IN the_DT business_NN and_CC the_DT impairment_NN is_VBZ included_VBN within_IN net_JJ operating_NN expenses_NNS in_IN the_DT consolidated_JJ income_NN statement_NN ._.
A_DT range_NN of_IN pre-tax_JJ discount_NN rates_NNS between_IN 10_CD %_NN 19_CD %_NN was_VBD applied_VBN to_TO probability-adjusted_JJ forecasts_NNS ._.
The_DT impairment_NN reflected_VBD lower_JJR sales_NNS in_IN the_DT BioChem_NNP subsidiary_NN following_VBG the_DT suspension_NN of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP in_IN February_NNP 2005_CD :_: lower_JJR estimates_NNS of_IN cashflows_NNS from_IN 3TC_NNP royalties_NNS :_: and_CC lower_JJR estimates_NNS of_IN cashflows_NNS from_IN TROXATYL_NNP and_CC SPD_NNP 754_CD following_VBG their_PRP$ out-licensing_NN ._.
Disposals_NNS of_IN goodwill_NN in_IN 2004_CD related_VBN to_TO the_DT vaccines_NNS business_NN see_VBP Note_NN 14_CD ._.
18_CD Other_JJ intangible_JJ assets_NNS Intellectual_NNP Software_NNP and_CC property_NN other_JJ Total_JJ $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ book_NN value_NN At_IN January_NNP 1_CD ,_, 2005_CD 312,563_CD 9,695_CD 322,258_CD Additions_NNPS all_DT acquired_VBN 54,261_CD 18,898_CD 73,159_CD Acquired_VBN on_IN acquisition_NN of_IN subsidiary_NN 1,064,000_CD 1,064,000_CD Amortization_NNP 43,420_CD 6,096_CD 49,516_CD Impairments_NNP 4,410_CD 4,410_CD Exchange_NNP differences_NNS 11,373_CD 559_CD 10,814_CD At_IN December_NNP 31_CD ,_, 2005_CD 1,371,621_CD 23,056_CD 1,394,677_CD Patents_NNP and_CC trademarks_NNS are_VBP amortised_VBN over_IN their_PRP$ useful_JJ lives_NNS ,_, which_WDT is_VBZ on_IN average_JJ 16_CD years_NNS ._.
Intellectual_NNP Software_NNP and_CC property_NN other_JJ Total_JJ $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ book_NN value_NN At_IN January_NNP 1_CD ,_, 2004_CD 318,552_CD 318,552_CD Additions_NNPS all_DT acquired_VBN 49,183_CD 12,084_CD 61,267_CD Amortization_NNP 39,749_CD 2,389_CD 42,138_CD Impairments_NNP 19,626_CD 19,626_CD Disposals_NNPS 4,936_CD 4,936_CD Exchange_NNP differences_NNS 9,139_CD 9,139_CD At_IN December_NNP 31_CD ,_, 2004_CD 312,563_CD 9,695_CD 322,258_CD During_IN 2005_CD ,_, the_DT Group_NNP acquired_VBD $_$ 1,064_CD million_CD of_IN other_JJ identifiable_JJ intangible_JJ assets_NNS ,_, at_IN fair_JJ value_NN ,_, as_IN part_NN of_IN the_DT acquisition_NN of_IN TKT_NNP see_VBP Note_VB 11_CD ._.
The_DT weighted_JJ average_JJ amortization_NN period_NN of_IN these_DT assets_NNS is_VBZ 18_CD years_NNS ._.
These_DT assets_NNS relate_VBP to_TO in-process_JJ R&D_NNP $_$ 673_CD million_CD intellectual_JJ property_NN $_$ 272_CD million_CD ,_, customer_NN relationships_NNS $_$ 97_CD million_CD and_CC other_JJ finite-lived_JJ assets_NNS $_$ 22_CD million_CD ._.
During_IN 2005_CD the_DT Group_NNP disposed_VBD of_IN no_DT intangible_JJ assets_NNS 2004_CD :_: $_$ 4.9_CD million_CD ._.
All_DT motor_NN vehicles_NNS ,_, amounting_VBG to_TO $_$ 7.3_CD million_CD 2004_CD :_: $_$ 6.5_CD million_CD are_VBP held_VBN under_IN finance_NN leases_NNS ._.
Depreciation_NN expense_NN of_IN $_$ 3.5_CD million_CD 2004_CD :_: $_$ 2.7_CD million_CD has_VBZ been_VBN charged_VBN in_IN cost_NN of_IN sales_NNS ,_, and_CC $_$ 19.5_CD million_CD 2004_CD :_: $_$ 20_CD million_CD in_IN net_JJ operating_NN expenses_NNS ._.
20_CD Deferred_JJ tax_NN Deferred_VBN tax_NN is_VBZ calculated_VBN in_IN full_JJ on_IN temporary_JJ differences_NNS under_IN the_DT liability_NN method_NN using_VBG a_DT tax_NN rate_NN of_IN 30_CD %_NN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP offset_VBN when_WRB there_EX is_VBZ a_DT legally_RB enforceable_JJ right_NN to_TO offset_VB current_JJ tax_NN assets_NNS against_IN current_JJ tax_NN liabilities_NNS and_CC when_WRB the_DT deferred_JJ taxes_NNS relate_VBP to_TO the_DT same_JJ fiscal_JJ authority_NN ._.
The_DT offset_VBN amounts_NNS are_VBP as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Deferred_VBN tax_NN assets_NNS :_: deferred_JJ tax_NN asset_NN to_TO be_VB recovered_VBN after_IN more_JJR than_IN 12_CD months_NNS 85,730_CD 49,942_CD deferred_VBN tax_NN asset_NN to_TO be_VB recovered_VBN within_IN 12_CD months_NNS 323,294_CD 75,887_CD 409,024_CD 125,829_CD Deferred_JJ tax_NN liabilities_NNS :_: deferred_JJ tax_NN liability_NN to_TO be_VB incurred_VBN after_IN more_JJR than_IN 12_CD months_NNS 18,447_CD 39,698_CD deferred_VBN tax_NN liability_NN to_TO be_VB incurred_VBN within_IN 12_CD months_NNS 450,985_CD 1,090_CD 469,432_CD 40,788_CD Net_JJ deferred_JJ tax_NN liability_NN asset_NN 60,408_CD 85,041_CD These_DT amounts_NNS are_VBP disclosed_VBN in_IN the_DT balance_NN sheet_NN as_IN follows_VBZ :_: Deferred_JJ tax_NN asset_NN 67,283_CD 85,041_CD Deferred_JJ tax_NN liability_NN 127,691_CD 60,408_CD 85,041_CD The_DT gross_JJ movement_NN on_IN the_DT deferred_JJ tax_NN account_NN is_VBZ as_IN follows_VBZ :_: At_IN January_NNP 1_CD ,_, 85,041_CD 76,341_CD Acquisition_NNP of_IN subsidiary_NN 178,637_CD Income_NNP statement_NN credit_NN 31,587_CD 5,159_CD Movement_NNP booked_VBN to_TO equity_NN 1,721_CD Foreign_NNP exchange_NN 120_CD 3,541_CD At_IN December_NNP 31_CD ,_, 60,408_CD 85,041_CD As_IN of_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP has_VBZ not_RB made_VBN a_DT UK_NNP tax_NN provision_NN on_IN approximately_RB $_$ 1.7_CD billion_CD 2004_CD :_: $_$ 1.4_CD billion_CD of_IN unremitted_JJ earnings_NNS of_IN its_PRP$ international_JJ subsidiaries_NNS ._.
The_DT Group_NNP does_VBZ not_RB provide_VB for_IN income_NN taxes_NNS on_IN the_DT unremitted_JJ earnings_NNS of_IN subsidiaries_NNS located_VBN outside_IN the_DT UK_NNP ,_, where_WRB such_JJ earnings_NNS have_VBP been_VBN retained_VBN indefinitely_RB for_IN reinvestment_NN ,_, or_CC where_WRB it_PRP is_VBZ managements_NNS intention_NN that_IN the_DT earnings_NNS will_MD be_VB remitted_VBN in_IN a_DT tax_NN free_JJ liquidation_NN ,_, or_CC as_IN dividends_NNS with_IN taxes_NNS substantially_RB offset_VBN by_IN foreign_JJ tax_NN credits_NNS ._.
It_PRP is_VBZ not_RB practical_JJ to_TO determine_VB the_DT amount_NN of_IN unrecognised_JJ deferred_JJ tax_NN liabilities_NNS for_IN temporary_JJ differences_NNS related_VBN to_TO these_DT investments_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 77_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 78_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 20_CD Deferred_JJ tax_NN continued_VBN The_DT movement_NN in_IN deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS during_IN the_DT year_NN ,_, without_IN taking_VBG into_IN consideration_NN the_DT offsetting_VBG of_IN balances_NNS within_IN the_DT same_JJ tax_NN jurisdiction_NN ,_, is_VBZ as_IN follows_VBZ :_: Deferred_JJ tax_NN assets_NNS :_: Share-based_JJ Tax_NNP losses_NNS ACA_NNP STTD_NNP payments_NNS Total_JJ 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD At_IN January_NNP 1_CD ,_, 2005_CD 69,810_CD 53,718_CD 2,301_CD 125,829_CD Acquisition_NNP of_IN subsidiary_NN 151,314_CD 134,786_CD 286,100_CD Charged_VBN to_TO the_DT income_NN statement_NN 85,428_CD 75,039_CD 6,720_CD 3,669_CD Charge_NNP to_TO equity_NN 1,721_CD 1,721_CD Exchange_NNP differences_NNS 378 153 426 957_CD At_IN December_NNP 31_CD ,_, 2005_CD 135,318_CD 263,390_CD 10,316_CD 409,024_CD Share-based_JJ Tax_NNP losses_NNS ACA_NNP STTD_NNP payments_NNS Total_JJ 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD At_IN January_NNP 1_CD ,_, 2004_CD 80,476_CD 32,505_CD 2,301_CD 115,282_CD Charged_VBN to_TO the_DT income_NN statement_NN 14,003_CD 20,477_CD 6,474_CD Exchange_NNP differences_NNS 3,337_CD 736_CD 4,073_CD At_IN December_NNP 31_CD ,_, 2004_CD 69,810_CD 53,718_CD 2,301_CD 125,829_CD Accelerated_VBN capital_NN allowances_NNS short-term_JJ timing_NN differences_NNS ._.
Deferred_JJ tax_NN liabilities_NNS :_: Total_JJ 2005_CD $_$ 000_CD At_IN January_NNP 1_CD ,_, 2005_CD 40,788_CD Acquisition_NNP of_IN subsidiary_NN 464,737_CD Credited_VBN to_TO the_DT income_NN statement_NN 35,256_CD Exchange_NNP differences_NNS 837_CD At_IN December_NNP 31_CD ,_, 2005_CD 469,432_CD At_IN December_NNP 31_CD ,_, 2005_CD the_DT deferred_JJ tax_NN liabilities_NNS materially_RB related_VBN to_TO accelerated_VBN capital_NN allowances_NNS ._.
Total_JJ 2004_CD $_$ 000_CD At_IN January_NNP 1_CD ,_, 2004_CD 38,941_CD Credited_VBN to_TO the_DT income_NN statement_NN 1,315_CD Exchange_NNP differences_NNS 532_CD At_IN December_NNP 31_CD ,_, 2004_CD 40,788_CD At_IN December_NNP 31_CD ,_, 2004_CD the_DT deferred_JJ tax_NN liabilities_NNS materially_RB related_VBN to_TO accelerated_VBN capital_NN allowances_NNS ._.
78_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 79_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 20_CD Deferred_JJ tax_NN continued_VBN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Group_NNP will_MD realize_VB the_DT benefits_NNS of_IN the_DT recognized_VBN deferred_VBN tax_NN assets_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realizable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
Unrecognised_JJ deferred_VBN tax_NN assets_NNS :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Tax_NNP losses_NNS 148,642_CD 181,335_CD Other_JJ timing_NN differences_NNS 86,535_CD 24,500_CD 235,177_CD 205,835_CD 21_CD Investments_NNP accounted_VBD for_IN using_VBG equity_NN method_NN Joint_NNP Associates_NNP ventures_NNS Total_JJ 2005 2005 2005 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD At_IN January_NNP 1_CD ,_, 2005_CD 24,669_CD 6,179_CD 30,848_CD Additions_NNPS 2,093_CD 2,093_CD Share_NN post_NN tax_NN loss_NN profit_NN 6,325_CD 5,325_CD 1,000_CD Dividends_NNS received_VBD 3,774_CD 4,710_CD 8,484_CD Impairments_NNP Exchange_NNP differences_NNS 406 840 434_CD At_IN December_NNP 31_CD ,_, 2005_CD 17,069_CD 5,954_CD 23,023_CD Joint_NNP Associates_NNPS ventures_NNS Total_JJ 2005 2005 2005 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD At_IN January_NNP 1_CD ,_, 2004_CD 25,656_CD 5,028_CD 30,684_CD Additions_NNPS 2,436_CD 2,436_CD Share_NN post_NN tax_NN profit_NN 75_CD 4,433_CD 4,508_CD Dividends_NNS received_VBD 1,450_CD 4,043_CD 5,493_CD Impairments_NNP 3,971_CD 3,971_CD Exchange_NNP differences_NNS 1,923_CD 761_CD 2,684_CD At_IN December_NNP 31_CD ,_, 2004_CD 24,669_CD 6,179_CD 30,848_CD Investments_NNP in_IN joint_JJ ventures_NNS consist_VBP of_IN a_DT 50_CD %_NN share_NN of_IN the_DT commercialization_NN partnership_NN with_IN GlaxoSmithKline_NNP GSK_NNP ,_, through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP ._.
Investments_NNP in_IN associates_NNS consist_VBP primarily_RB of_IN investments_NNS in_IN the_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP and_CC the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP together_RB The_DT Funds_NNS ._.
The_DT Funds_NNS are_VBP limited_VBN partnerships_NNS with_IN a_DT December_NNP 31_CD ,_, year-end_JJ formed_VBN under_IN the_DT laws_NNS of_IN the_DT Province_NNP of_IN Quebec_NNP ,_, Canada_NNP ,_, investing_VBG in_IN healthcare_NN research_NN and_CC development_NN companies_NNS ,_, in_IN which_WDT the_DT Group_NNP owns_VBZ 30_CD %_NN and_CC 11_CD %_NN of_IN the_DT issued_VBN shares_NNS respectively_RB ._.
At_IN December_NNP 31_CD ,_, 2005_CD the_DT Funds_NNPS net_JJ assets_NNS totalled_VBD approximately_RB $_$ 71_CD million_CD 2004_CD :_: $_$ 107_CD million_CD ._.
The_DT Group_NNP is_VBZ involved_VBN as_IN a_DT limited_JJ partner_NN and_CC the_DT general_JJ partner_NN of_IN the_DT Funds_NNPS :_: the_DT Groups_NNS involvement_NN in_IN the_DT Funds_NNS dates_NNS from_IN between_IN 1997_CD and_CC 2000_CD ._.
The_DT Groups_NNS exposure_NN to_TO loss_NN as_IN a_DT result_NN of_IN its_PRP$ involvement_NN with_IN the_DT Funds_NNPS is_VBZ limited_VBN to_TO the_DT carrying_VBG value_NN of_IN the_DT investment_NN ,_, $_$ 12.7_CD million_CD at_IN December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 18.3_CD million_CD and_CC its_PRP$ commitment_NN to_TO further_JJ investment_NN of_IN $_$ 1.7_CD million_CD 2004_CD :_: $_$ 2.9_CD million_CD ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, the_DT Group_NNP recorded_VBD an_DT impairment_NN of_IN $_$ 4.0_CD million_CD against_IN the_DT investment_NN in_IN the_DT Funds_NNPS following_VBG reviews_NNS of_IN the_DT Funds_NNPS investment_NN portfolios_NNS that_WDT identified_VBD other-than-temporary_JJ declines_NNS in_IN the_DT value_NN of_IN certain_JJ private_JJ and_CC publicly_RB quoted_VBN securities_NNS held_VBN by_IN the_DT Funds_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 79_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 80_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 21_CD Investments_NNPS accounted_VBD for_IN using_VBG equity_NN method_NN continued_VBD Aggregated_JJ amounts_NNS relating_VBG to_TO associates_NNS ,_, all_DT of_IN which_WDT are_VBP unlisted_JJ ,_, are_VBP shown_VBN below_IN :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Assets_NNPS 112,910_CD 157,727_CD Liabilities_NNPS 256 174 112_CD ,654_CD 157,553_CD Revenue_NN 1,259_CD 1,227_CD Post_NNP tax_NN loss_NN 42,387_CD 12,163_CD Aggregated_NNP amounts_NNS relating_VBG to_TO the_DT joint_JJ venture_NN are_VBP shown_VBN below_IN :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Non-current_JJ assets_NNS Current_JJ assets_NNS 12,848_CD 13,448_CD Non-current_JJ liabilities_NNS Current_JJ liabilities_NNS 940_CD 1,090_CD 11,908_CD 12,358_CD Revenue_NN 32,544_CD 36,060_CD Operating_NN expenses_NNS 21,894_CD 27,194_CD 10,650_CD 8,866_CD Taxation_NNP Post_NNP tax_NN profit_NN 10,650_CD 8,866_CD 22_CD Investments_NNP 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Available-for-sale_JJ investments_NNS Investments_NNP in_IN private_JJ companies_NNS 9,008_CD 2,451_CD Available-for-sale_JJ securities_NNS 18,131_CD 74,099_CD 27,139_CD 76,550_CD Trading_NN investments_NNS Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 6,947_CD 175,186_CD Commercial_JJ paper_NN 149,659_CD 6,947_CD 324,845_CD The_DT fair_JJ value_NN of_IN available-for-sale_JJ investments_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD was_VBD $_$ 27.1_CD million_CD 2004_CD :_: $_$ 92.4_CD million_CD ._.
There_EX were_VBD no_DT material_NN differences_NNS between_IN fair_JJ value_NN and_CC book_NN value_NN of_IN the_DT trading_NN investments_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD ._.
2004_CD :_: none_NN Available-for-sale_JJ investments_NNS Investments_NNP in_IN private_JJ companies_NNS During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD additions_NNS to_TO investments_NNS in_IN private_JJ companies_NNS included_VBD a_DT $_$ 3.9_CD million_CD investment_NN in_IN Supernus_NNP Pharmaceuticals_NNP ,_, Inc._NNP less_JJR than_IN 10_CD %_NN of_IN total_JJ equity_NN ,_, as_IN part_NN consideration_NN for_IN the_DT sale_NN of_IN the_DT drug_NN formulation_NN business_NN ._.
The_DT fair_JJ value_NN of_IN the_DT investment_NN was_VBD determined_VBN by_IN reference_NN to_TO cash_VB invested_VBN in_IN Supernus_NNP by_IN the_DT other_JJ investors_NNS ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP recorded_VBD impairments_NNS of_IN $_$ 1.6_CD million_CD against_IN its_PRP$ investments_NNS in_IN private_JJ companies_NNS based_VBN on_IN a_DT decline_NN in_IN the_DT estimates_NNS of_IN their_PRP$ fair_JJ value_NN that_IN the_DT Group_NNP believes_VBZ are_VBP other-than-temporary_JJ ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Group_NNP recorded_VBD impairments_NNS of_IN $_$ 15.9_CD million_CD against_IN these_DT investments_NNS based_VBN on_IN changes_NNS in_IN the_DT estimates_NNS of_IN their_PRP$ fair_JJ value_NN ._.
The_DT changes_NNS in_IN fair_JJ values_NNS which_WDT resulted_VBD in_IN the_DT write-downs_NNS referred_VBD to_TO above_IN were_VBD based_VBN on_IN the_DT Groups_NNS estimates_NNS ,_, derived_VBN from_IN financial_JJ and_CC other_JJ publicly_RB available_JJ information_NN such_JJ as_IN press_NN releases_NNS and_CC recent_JJ capital_NN raising_VBG activities_NNS ._.
80_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 81_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 22_CD Investments_NNPS continued_VBD Available-for-sale_JJ securities_NNS During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP sold_VBD an_DT investment_NN in_IN an_DT available-for-sale_JJ security_NN ,_, valued_VBN at_IN $_$ 6.0_CD million_CD ,_, realizing_VBG a_DT gain_NN on_IN the_DT sale_NN of_IN $_$ 3.9_CD million_CD ._.
Also_RB during_IN the_DT year_NN the_DT Group_NNP received_VBD $_$ 60_CD million_CD on_IN the_DT redemption_NN by_IN IDB_NNP of_IN its_PRP$ subscription_NN receipts_NNS ,_, for_IN no_DT gain_NN or_CC loss_NN on_IN sale_NN ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Group_NNP sold_VBD an_DT investment_NN in_IN an_DT available-for-sale_JJ security_NN ,_, valued_VBN at_IN $_$ 11.9_CD million_CD ,_, realizing_VBG a_DT gain_NN on_IN the_DT sale_NN of_IN $_$ 14.8_CD million_CD ._.
Other-than-temporary_JJ impairment_NN The_DT Group_NNP recorded_VBD other-than-temporary_JJ impairments_NNS of_IN $_$ 0.4_CD million_CD against_IN its_PRP$ available-for-sale_JJ securities_NNS in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
At_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Group_NNP had_VBD no_DT available_JJ for_IN sale_NN investments_NNS in_IN a_DT significant_JJ unrealized_JJ loss_NN position_NN for_IN which_WDT other-than-temporary_JJ impairments_NNS have_VBP not_RB been_VBN recognized_VBN ._.
24_CD Trade_NNP and_CC other_JJ receivables_NN 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Trade_NNP receivables_NN 339,671_CD 226,812_CD Less_RBR :_: provision_NN for_IN impairment_NN 9,747_CD 4,266_CD Trade_NNP receivables_NN net_NN 329,924_CD 222,546_CD Loans_NNPS granted_VBD 14_CD 30,000_CD 30,000_CD Interest_NN receivable_NN 1,491_CD 394_CD Prepayments_NNS and_CC accrued_VBN income_NN 30,245_CD 32,794_CD Other_JJ debtors_NNS 29,601_CD 13,496_CD Cash_NN held_VBN in_IN escrow_NN 14_CD 30,000_CD SERP_NNP 29_CD 8,852_CD 9,482_CD Total_JJ 430,113_CD 338,712_CD Less_RBR :_: non-current_JJ portion_NN 42,907_CD 38,895_CD Current_JJ portion_NN 387,206_CD 299,817_CD Further_JJ details_NNS of_IN the_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP asset_NN are_VBP provided_VBN in_IN Note_NN 29_CD ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT cash_NN at_IN bank_NN and_CC non-current_JJ marketable_JJ securities_NNS held_VBN in_IN a_DT Rabbi_NNP Trust_NNP ._.
The_DT legal_JJ form_NN of_IN the_DT trust_NN is_VBZ such_JJ that_IN the_DT assets_NNS held_VBD to_TO cover_VB the_DT pension_NN liabilities_NNS are_VBP available_JJ to_TO the_DT general_JJ creditors_NNS of_IN the_DT Group_NNP on_IN winding_VBG up_RP ._.
Accordingly_RB ,_, the_DT assets_NNS held_VBN by_IN the_DT trust_NN are_VBP not_RB plan_VB assets_NNS and_CC are_VBP recorded_VBN on_IN the_DT balance_NN sheet_NN ._.
A_DT related_JJ liability_NN is_VBZ shown_VBN in_IN Note_NN 27_CD ._.
The_DT average_JJ credit_NN period_NN taken_VBN on_IN sales_NNS of_IN goods_NNS is_VBZ 37_CD days_NNS ._.
An_DT allowance_NN has_VBZ been_VBN made_VBN for_IN doubtful_JJ accounts_NNS and_CC sales_NNS discounts_NNS of_IN $_$ 9.7_CD Million_NNP 2004_CD :_: $_$ 4.3_CD million_CD ._.
This_DT allowance_NN has_VBZ been_VBN determined_VBN by_IN specific_JJ review_NN of_IN outstanding_JJ receivables_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT Directors_NNS consider_VBP that_IN the_DT carrying_VBG amount_NN of_IN trade_NN and_CC other_JJ receivables_NN approximates_VBZ to_TO their_PRP$ fair_JJ value_NN ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 81_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 82_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 25_CD Borrowings_NNS 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Non-current_JJ 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011 116 116_CD Finance_NNP lease_NN liabilities_NNS 4,588_CD 4,126_CD 4,704_CD 4,242_CD Current_JJ Finance_NNP lease_NN liabilities_NNS 2,667_CD 2,420_CD Total_JJ borrowings_NNS 7,371_CD 6,662_CD All_DT borrowings_NNS in_IN both_DT the_DT current_JJ and_CC previous_JJ years_NNS are_VBP denominated_VBN in_IN US_NNP Dollars_NNPS ._.
The_DT Directors_NNS consider_VBP that_IN the_DT carrying_VBG amount_NN of_IN borrowing_VBG approximates_VBZ their_PRP$ fair_JJ value_NN ._.
Subject_JJ to_TO the_DT conditions_NNS below_IN ,_, non-current_JJ borrowings_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Convertible_JJ loan_NN notes_NNS :_: i_FW After_IN five_CD years_NNS 116_CD 116_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS :_: ii_FW Between_IN one_CD and_CC two_CD years_NNS 2,667_CD 2,420_CD Between_IN two_CD and_CC three_CD years_NNS 1,921_CD 1,706_CD 4,588_CD 4,126_CD 4,704_CD 4,242_CD i_FW 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD The_DT guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ,_, were_VBD issued_VBN in_IN August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN the_DT Company_NN ._.
The_DT convertible_JJ notes_NNS were_VBD guaranteed_VBN by_IN Shire_NNP and_CC were_VBD convertible_JJ into_IN redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB immediately_RB exchanged_VBN for_IN :_: i_FW Shire_FW ordinary_JJ shares_NNS ,_, ii_FW Shire_FW ADSs_FW or_CC iii_FW at_IN the_DT Issuers_NNPS option_NN ,_, a_DT cash_NN amount_NN based_VBN upon_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_NN prices_NNS of_IN Shires_NNP ordinary_JJ shares_NNS on_IN the_DT fourth_JJ through_IN eighth_JJ business_NN days_NNS following_VBG conversion_NN ._.
At_IN the_DT choice_NN of_IN investors_NNS ,_, each_DT $_$ 1,000_CD of_IN nominal_JJ value_NN notes_NNS was_VBD convertible_JJ into_IN 49.62_CD Shire_NNP ordinary_JJ shares_NNS subject_JJ to_TO adjustment_NN or_CC 16.54_CD Shire_NNP ADSs_NNP subject_NN to_TO adjustment_NN at_IN any_DT time_NN up_RP to_TO August_NNP 21_CD ,_, 2011_CD ._.
Alternatively_RB ,_, investors_NNS had_VBD the_DT right_NN to_TO receive_VB repayment_NN of_IN the_DT nominal_JJ principal_NN in_IN cash_NN either_CC at_IN the_DT maturity_NN date_NN of_IN August_NNP 21_CD ,_, 2011_CD or_CC by_IN exercising_VBG a_DT put_NN option_NN on_IN any_DT of_IN the_DT three_CD put_VBD dates_NNS being_VBG August_NNP 21_CD ,_, 2004_CD ,_, August_NNP 21_CD ,_, 2006_CD and_CC August_NNP 21_CD ,_, 2008_CD ._.
On_IN August_NNP 21_CD ,_, 2004_CD ,_, upon_IN exercise_NN of_IN the_DT put_NN option_NN by_IN substantially_RB all_DT of_IN the_DT convertible_JJ note_NN holders_NNS ,_, the_DT Group_NNP redeemed_VBD $_$ 370.1_CD million_CD at_IN par_NN ,_, from_IN available_JJ funds_NNS ._.
The_DT obligation_NN to_TO pay_VB the_DT remaining_VBG $_$ 116,000_CD of_IN the_DT convertible_JJ loan_NN notes_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, 2005_CD is_VBZ due_JJ in_IN 2011_CD ,_, subject_JJ to_TO the_DT exercise_NN of_IN the_DT put_NN option_NN referred_VBD to_TO above_IN ._.
ii_FW Finance_NNP leases_VBZ 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Finance_NNP lease_NN liabilities_NNS minimum_JJ lease_NN payments_NNS :_: Not_RB later_RB than_IN 1_CD year_NN 2,933_CD 2,588_CD Later_RB than_IN 1_CD year_NN and_CC not_RB later_RB than_IN 5_CD years_NNS 5,046_CD 4,806_CD Later_RB than_IN 5_CD years_NNS 7,979_CD 7,394_CD Future_NNP finance_NN charges_NNS on_IN finance_NN leases_NNS 724_CD 848_CD Present_JJ value_NN of_IN finance_NN lease_NN liabilities_NNS 7,255_CD 6,546_CD The_DT Groups_NNS finance_NN leases_NNS are_VBP in_IN respect_NN of_IN motor_NN vehicles_NNS ,_, and_CC do_VB not_RB impose_VB any_DT significant_JJ restrictions_NNS on_IN the_DT Group_NNP ._.
82_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 83_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 26_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS IAS_NNP 32_CD 39_CD disclosure_NN for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD The_DT Group_NNP is_VBZ exposed_VBN to_TO movements_NNS in_IN foreign_JJ exchange_NN rates_NNS against_IN the_DT US_NNP Dollar_NNP for_IN trading_VBG transactions_NNS and_CC the_DT translation_NN of_IN net_JJ assets_NNS ,_, liabilities_NNS and_CC earnings_NNS of_IN non-US_JJ subsidiaries_NNS ._.
The_DT main_JJ trading_NN currencies_NNS of_IN the_DT Group_NNP are_VBP the_DT US_NNP Dollar_NNP ,_, the_DT Canadian_JJ Dollar_NN ,_, Pounds_NNP Sterling_NNP ,_, the_DT Euro_NNP and_CC Swedish_NNP Krona_NNP ._.
The_DT exposure_NN to_TO foreign_JJ exchange_NN risk_NN is_VBZ managed_VBN and_CC monitored_VBN by_IN the_DT treasury_NN function_NN ._.
At_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD five_CD outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN of_IN $_$ 206_CD million_CD equivalent_JJ to_TO manage_VB the_DT currency_NN risk_NN associated_VBN with_IN inter-company_JJ loans_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT fair_JJ value_NN of_IN these_DT currency_NN derivatives_NNS showed_VBD an_DT unrealized_JJ gain_NN of_IN $_$ 2.6_CD million_CD ._.
The_DT change_NN in_IN fair_JJ value_NN has_VBZ been_VBN taken_VBN to_TO the_DT income_NN statement_NN in_IN the_DT year_NN ._.
FRS_NNP 13_CD disclosures_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2004_CD The_DT Financial_NNP risk_NN management_NN review_NN in_IN Note_NN 4_CD provides_VBZ an_DT explanation_NN of_IN the_DT role_NN that_WDT financial_JJ instruments_NNS have_VBP had_VBN during_IN the_DT prior_JJ year_NN ._.
The_DT explanation_NN summarizes_VBZ the_DT objectives_NNS and_CC policies_NNS for_IN holding_VBG or_CC issuing_VBG financial_JJ instruments_NNS and_CC similar_JJ contracts_NNS ,_, and_CC the_DT strategies_NNS for_IN achieving_VBG those_DT objectives_NNS that_WDT have_VBP been_VBN followed_VBN during_IN the_DT year_NN ._.
Interest_NN rate_NN profile_NN The_DT currency_NN and_CC interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS cash_NN ,_, cash_NN equivalents_NNS ,_, restricted_VBN cash_NN and_CC current_JJ financial_JJ assets_NNS excluding_VBG short-term_JJ debtors_NNS as_IN at_IN December_NNP 31_CD ,_, 2004_CD are_VBP shown_VBN below_IN :_: Weighted_NNP Weighted_NNP Weighted_NNP average_JJ average_JJ average_JJ interest_NN interest_NN interest_NN Financial_NNP Financial_NNP period_NN rate_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Days_NNS %_NN %_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD US_NNP Dollars_NNPS 678_CD 2.01_CD 2.05_CD 1,263,166_CD 42,712_CD 1,305,878_CD Pounds_NNP Sterling_NNP 4.11_CD 37,789_CD 37,789_CD Euro_NNP 0.30_CD 16,803_CD 16,803_CD Canadian_JJ Dollars_NNPS 2.52_CD 97,461_CD 97,461_CD Other_JJ 0.25_CD 18_CD 18_CD 1,415,237_CD 42,712_CD 1,457,949_CD The_DT benchmark_NN rates_NNS for_IN floating_VBG rate_NN assets_NNS are_VBP primarily_RB :_: US_NNP Dollar_NNP seven-day_JJ ,_, one-month_JJ and_CC three-month_JJ London_NNP Interbank_NNP Bid_NNP Rate_NNP LIBID_NNP ,_, and_CC Pounds_NNP Sterling_NNP seven-day_JJ LIBID_NNP ._.
The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN December_NNP 31_CD ,_, 2004_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD US_NNP Dollars_NNPS convertible_JJ debt_NN 116_CD 116_CD finance_NN leases_NNS 6,546_CD 6,546_CD 6,662_CD 6,662_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 83_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 84_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 26_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Currency_NNP exposures_NNS The_DT Group_NNP aims_VBZ to_TO minimize_VB currency_NN related_VBN exposures_NNS arising_VBG from_IN its_PRP$ net_JJ investments_NNS overseas_RB in_IN other_JJ words_NNS ,_, its_PRP$ structural_JJ currency_NN exposures_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG from_IN structural_JJ currency_NN exposures_NNS are_VBP recognized_VBN in_IN the_DT consolidated_JJ statement_NN of_IN total_JJ recognized_VBN income_NN ._.
The_DT table_NN below_IN shows_NNS the_DT Groups_NNS transactional_JJ or_CC non-structural_JJ currency_NN exposures_NNS that_WDT give_VBP rise_VB to_TO the_DT net_JJ currency_NN gains_NNS and_CC losses_NNS recognized_VBN in_IN the_DT income_NN statement_NN ._.
Such_JJ exposures_NNS comprise_VBP the_DT monetary_JJ assets_NNS and_CC monetary_JJ liabilities_NNS of_IN the_DT Group_NNP that_WDT are_VBP not_RB denominated_VBN in_IN the_DT functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN involved_VBN ,_, other_JJ than_IN certain_JJ non-US_JJ Dollar_NN borrowings_NNS treated_VBN as_IN hedges_NNS of_IN net_JJ investments_NNS in_IN overseas_JJ operations_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2004_CD these_DT exposures_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS US_NNP Pounds_NNP Canadian_NNP Dollars_NNP Sterling_NNP Euro_NNP Dollars_NNP Other_JJ Total_NNP Functional_NNP currency_NN of_IN Group_NNP operation_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD US_NNP Dollars_NNPS 341,790_CD 38,156_CD 67_CD 4_CD 303,563_CD Pounds_NNP Sterling_NNP 907,197_CD 21,801_CD 2_CD 286_CD 885,112_CD Euro_NNP 516_CD 1,004_CD 1,520_CD Canadian_JJ Dollars_NNPS 298,264_CD 182,924_CD 38_CD 481,226_CD 609,449_CD 523,710_CD 16,317_CD 69 282 101_CD ,843_CD Borrowing_NN facilities_NNS The_DT Group_NNP had_VBD no_DT undrawn_JJ committed_JJ borrowing_NN facilities_NNS at_IN December_NNP 31_CD ,_, 2004_CD ._.
Fair_NNP values_VBZ The_DT quoted_VBN market_NN price_NN of_IN the_DT convertible_JJ loan_NN stock_NN 2011_CD as_RB at_IN December_NNP 31_CD ,_, 2004_CD was_VBD $_$ 100.53_CD compared_VBN with_IN an_DT issue_NN price_NN of_IN $_$ 100_CD ._.
If_IN the_DT remaining_VBG loan_NN is_VBZ not_RB converted_VBN into_IN equity_NN ,_, it_PRP would_MD be_VB repayable_JJ at_IN $_$ 100_CD per_IN note_NN ._.
The_DT total_JJ fair_JJ value_NN of_IN the_DT debt_NN as_IN at_IN December_NNP 31_CD ,_, 2004_CD ,_, based_VBN on_IN the_DT above_JJ quoted_VBN market_NN price_NN ,_, was_VBD $_$ 116,000_CD compared_VBN to_TO a_DT carrying_VBG value_NN of_IN $_$ 115,000_CD ._.
In_IN addition_NN at_IN December_NNP 31_CD ,_, 2004_CD the_DT fair_JJ value_NN of_IN listed_VBN financial_JJ assets_NNS ,_, based_VBN on_IN their_PRP$ quoted_VBN market_NN price_NN ,_, was_VBD $_$ 16_CD million_CD above_IN carrying_VBG value_NN ._.
There_EX were_VBD no_DT other_JJ material_NN differences_NNS between_IN the_DT carrying_VBG values_NNS and_CC fair_JJ values_NNS of_IN all_DT other_JJ Group_NNP financial_JJ assets_NNS and_CC liabilities_NNS at_IN December_NNP 31_CD ,_, 2004_CD ._.
Gains_NNS and_CC losses_NNS on_IN foreign_JJ exchange_NN contracts_NNS As_IN at_IN December_NNP 31_CD ,_, 2004_CD the_DT Group_NNP had_VBD two_CD outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN of_IN $_$ 39_CD million_CD used_VBN to_TO manage_VB the_DT risk_NN associated_VBN with_IN holding_VBG Canadian_JJ Dollar_NN financial_JJ assets_NNS ._.
There_EX were_VBD no_DT material_NN gains_NNS or_CC losses_NNS on_IN these_DT contracts_NNS ._.
27_CD Trade_NNP and_CC other_JJ payables_NNS 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Trade_NNP payables_NNS 70,958_CD 35,009_CD Other_JJ creditors_NNS 14,817_CD 27,383_CD Accruals_NNPS and_CC deferred_JJ income_NN 363,395_CD 289,443_CD SERP_NNP 29_CD 4,591_CD 5,495_CD Total_JJ 453,761_CD 357,330_CD Less_RBR :_: non-current_JJ portion_NN 18,036_CD 12,963_CD Current_JJ portion_NN 435,725_CD 344,367_CD Trade_NNP payables_NNS comprise_VBP amounts_NNS outstanding_JJ for_IN trade_NN purchases_NNS and_CC ongoing_JJ costs_NNS ._.
The_DT average_JJ credit_NN period_NN taken_VBN for_IN trade_NN payables_NNS is_VBZ 30_CD days_NNS 2004:18_CD days_NNS ._.
The_DT Directors_NNS consider_VBP that_IN the_DT carrying_VBG amount_NN of_IN trade_NN and_CC other_JJ payables_NNS approximates_VBZ to_TO their_PRP$ fair_JJ value_NN ._.
Accruals_NNS and_CC deferred_JJ income_NN includes_VBZ accrued_VBN rebates_NNS and_CC sales_NNS return_NN reserves_NNS ,_, accrued_VBN bonuses_NNS and_CC other_JJ accrued_VBN expenses_NNS ._.
84_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 85_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 28_CD Provisions_NNS for_IN other_JJ liabilities_NNS and_CC charges_NNS Reorganization_NN IDB_NNP Loan_NNP Other_JJ Total_JJ $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD January_NNP 1_CD ,_, 2005_CD 12,960_CD 43,161_CD 15,208_CD 71,329_CD Charge_NNP for_IN the_DT year_NN 2,299_CD 18,121_CD 20,420_CD Acquired_VBN 3,310_CD 3,310_CD Reversed_VBN unutilised_JJ 5,846_CD 5,846_CD Utilised_NNP 7,460_CD 43,161_CD 4,668_CD 55,289_CD December_NNP 31_CD ,_, 2005_CD 7,799_CD 26,125_CD 33,924_CD Less_RBR :_: Non-current_JJ portion_NN 25,401_CD Current_JJ portion_NN 8,523_CD Reorganization_NN IDB_NNP Loan_NNP Other_JJ Total_JJ $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD January_NNP 1_CD ,_, 2004_CD 8,887_CD 8,887_CD Charge_NNP for_IN the_DT year_NN 12,960_CD 43,161_CD 10,165_CD 66,286_CD Reversed_VBN unutilised_JJ 727_CD 727_CD Utilised_VBN 3,117_CD 3,117_CD December_NNP 31_CD ,_, 2004_CD 12,960_CD 43,161_CD 15,208_CD 71,329_CD Less_RBR :_: Non-current_JJ portion_NN 26,232_CD Current_JJ portion_NN 45,097_CD Reorganization_NNP The_NNP Group_NNP began_VBD a_DT consolidation_NN of_IN its_PRP$ North_JJ American_JJ sites_NNS in_IN 2004_CD see_VBP Note_VB 13_CD ._.
The_DT costs_NNS recognized_VBN as_IN a_DT provision_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD consist_VBP of_IN employee_NN severance_NN and_CC relocation_NN costs_NNS of_IN $_$ 0.6_CD million_CD that_WDT are_VBP expected_VBN to_TO be_VB paid_VBN in_IN 2006_CD and_CC costs_NNS of_IN duplicate_VBP facilities_NNS $_$ 7.2_CD million_CD that_WDT are_VBP expected_VBN to_TO be_VB paid_VBN over_IN the_DT remaining_VBG life_NN of_IN the_DT relevant_JJ leases_NNS ,_, which_WDT all_DT expire_VBP before_IN October_NNP 31_CD ,_, 2012_CD ._.
Other_JJ Other_JJ provisions_NNS relate_VBP to_TO long-term_JJ bonuses_NNS ,_, provisions_NNS for_IN guarantees_NNS and_CC insurance_NN ,_, and_CC onerous_JJ lease_NN provisions_NNS in_IN relation_NN to_TO vacated_VBN properties_NNS ._.
Provisions_NNS recognized_VBN in_IN relation_NN to_TO long-term_JJ bonuses_NNS total_VBP $_$ 9.9_CD million_CD ,_, of_IN which_WDT $_$ 5.1_CD million_CD is_VBZ expected_VBN to_TO be_VB paid_VBN in_IN 2006_CD and_CC the_DT remainder_NN on_IN the_DT maturity_NN of_IN the_DT underlying_VBG schemes_NNS over_IN the_DT next_JJ three_CD years_NNS ._.
Provisions_NNS for_IN insurance_NN and_CC guarantees_NNS totalling_VBG $_$ 12.9_CD million_CD are_VBP expected_VBN to_TO be_VB settled_VBN between_IN one_CD and_CC three_CD years_NNS ._.
Onerous_JJ lease_NN provisions_NNS of_IN $_$ 3.3_CD million_CD will_MD be_VB paid_VBN over_IN the_DT next_JJ three_CD years_NNS ,_, the_DT remaining_VBG life_NN of_IN the_DT relevant_JJ leases_NNS ._.
29_CD Retirement_NNP obligations_NNS The_DT Group_NNP has_VBZ a_DT number_NN of_IN defined_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
The_DT Groups_NNS contribution_NN is_VBZ fixed_VBN as_IN a_DT set_VBN percentage_NN of_IN employees_NNS base_JJ salary_NN ._.
The_DT pension_NN cost_NN charge_NN for_IN the_DT defined_VBN contribution_NN schemes_NNS for_IN the_DT year_NN was_VBD $_$ 14.1_CD million_CD 2004_CD :_: $_$ 9_CD million_CD ._.
The_DT closing_NN creditor_NN in_IN respect_NN of_IN pension_NN premiums_NNS at_IN December_NNP 31_CD ,_, 2005_CD is_VBZ $_$ 1.76_CD million_CD 2004_CD :_: $_$ 0.23_CD million_CD ._.
The_DT Group_NNP has_VBZ two_CD Supplemental_NNP Executive_NNP Retirement_NNP Plans_NNP SERPs_NNP ,_, which_WDT are_VBP defined_VBN benefit_NN plans_NNS ._.
The_DT Roberts_NNP SERP_NNP is_VBZ for_IN US_NNP employees_NNS of_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP Roberts_NNP who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
The_DT Group_NNP acquired_VBD Roberts_NNP in_IN 1999_CD ,_, and_CC the_DT plan_NN was_VBD discontinued_VBN in_IN 2000_CD :_: there_EX were_VBD no_DT contributions_NNS payable_JJ in_IN respect_NN of_IN 2005_CD ._.
The_DT Group_NNP paid_VBD a_DT lump_NN sum_NN of_IN $_$ 18_CD million_CD into_IN the_DT Roberts_NNP SERP_NNP ,_, which_WDT was_VBD accounted_VBN for_IN as_IN a_DT fair_JJ value_NN adjustment_NN on_IN the_DT acquisition_NN of_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP to_TO make_VB good_JJ the_DT deficit_NN on_IN this_DT scheme_NN at_IN the_DT time_NN of_IN acquisition_NN ._.
This_DT lump_NN sum_NN payment_NN has_VBZ led_VBN to_TO the_DT Group_NNP having_VBG no_DT future_JJ liability_NN under_IN the_DT SERP_NNP ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS with_IN contributions_NNS no_RB longer_RB payable_JJ by_IN existing_VBG members_NNS ._.
Assets_NNS are_VBP set_VBN aside_RB to_TO fund_VB these_DT benefits_NNS in_IN a_DT Rabbi_NNP Trust_NNP ._.
Accordingly_RB ,_, the_DT assets_NNS held_VBN by_IN the_DT trust_NN are_VBP not_RB plan_VB assets_NNS as_IN defined_VBN by_IN IAS_NNP 19_CD ,_, Employee_NNP Benefits_NNPS ,_, and_CC are_VBP recorded_VBN on_IN the_DT balance_NN sheet_NN see_VBP Note_NN 24_CD ._.
The_DT Shire_NNP SERP_NNP defined_VBD benefit_NN scheme_NN is_VBZ an_DT unfunded_JJ arrangement_NN :_: the_DT benefits_NNS are_VBP payable_JJ to_TO certain_JJ senior_JJ US_NNP employees_NNS as_IN lump_NN sums_NNS on_IN leaving_VBG the_DT Groups_NNS employment_NN or_CC earlier_JJR due_JJ to_TO death_NN ,_, disability_NN or_CC termination_NN ._.
The_DT amount_NN of_IN benefit_NN is_VBZ based_VBN on_IN the_DT value_NN of_IN notional_JJ contributions_NNS increased_VBN with_IN earned_VBN investment_NN returns_NNS as_IN if_IN they_PRP were_VBD invested_VBN in_IN investments_NNS of_IN the_DT employees_NNS choice_NN ._.
The_DT entire_JJ benefit_NN liability_NN has_VBZ been_VBN recognized_VBN on_IN the_DT balance_NN sheet_NN ._.
The_DT liabilities_NNS of_IN the_DT two_CD SERPs_NNS totalling_VBG $_$ 4.6_CD million_CD at_IN December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 5.5_CD million_CD are_VBP shown_VBN in_IN Note_NN 27_CD ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 85_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 86_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 30_CD Share_NN capital_NN 2005 2005 2004 2004_CD Number_NNP Number_NNP Ordinary_NNP shares_NNS 000_CD $_$ 000_CD 000_CD $_$ 000_CD Authorised_VBN At_IN January_NNP 1_CD ,_, ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 76,796_CD 800,000_CD 76,796_CD At_IN December_NNP 31_CD ,_, ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 18,333,006_CD 1,573,705_CD 800,000_CD 76,796_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN January_NNP 1_CD ,_, ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 484,916_CD 36,083_CD 477,895_CD 35,540_CD Effect_NN of_IN scheme_NN of_IN arrangement_NN and_CC capital_NN reduction_NN 5,713_CD Restated_VBN position_NN at_IN January_NNP 1_CD 484,916_CD 41,796_CD 477,895_CD 35,540_CD Issued_VBN on_IN exercise_NN of_IN options_NNS for_IN cash_NN consideration_NN 4,702_CD 405_CD 2,098_CD 191_CD Issued_VBN on_IN exchange_NN of_IN exchangeable_JJ shares_NNS 6,116_CD 527_CD 4,839_CD 344_CD Issue_NN of_IN ordinary_JJ share_NN capital_NN 84_CD 8_CD At_IN December_NNP 31_CD ,_, ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 495,734_CD 42,728_CD 484,916_CD 36,083_CD 2005 2005 2004 2004_CD Number_NNP Number_NNP Special_JJ ordinary_JJ voting_NN shares_NNS 000_CD $_$ 000_CD 000_CD $_$ 000_CD Authorised_VBN At_IN January_NNP 1_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD 17,500_CD At_IN December_NNP 31_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 10,000_CD 17,500_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN January_NNP 1_CD 4,226_CD 195,830_CD 5,840_CD 270,667_CD Cancelled_VBN following_VBG an_DT exchange_NN of_IN exchangeable_JJ shares_NNS for_IN ordinary_JJ shares_NNS 2,038_CD 94,582_CD 1,614_CD 74,837_CD At_IN December_NNP 31_CD ,_, 2,188_CD 101,248_CD 4,226_CD 195,830_CD Authorised_JJ share_NN capital_NN The_DT authorised_JJ stock_NN of_IN Shire_NNP plc_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD was_VBD 18,333,006,420_CD ordinary_JJ shares_NNS ,_, 10,000,000_CD special_JJ voting_NN shares_NNS ,_, 50,000_CD nonvoting_JJ preference_NN shares_NNS and_CC two_CD deferred_JJ ordinary_JJ shares_NNS ._.
The_DT special_JJ voting_NN shares_NNS are_VBP held_VBN by_IN a_DT Voting_NNP Trustee_NNP ,_, providing_VBG the_DT holders_NNS of_IN exchangeable_JJ shares_NNS in_IN Shire_NNP Acquisition_NNP ,_, Inc._NNP with_IN as_RB nearly_RB as_IN practicable_JJ voting_NN rights_NNS equivalent_NN to_TO those_DT attached_VBN to_TO Shires_NNP ordinary_JJ shares_NNS ._.
The_DT non-voting_JJ preference_NN shares_NNS and_CC deferred_VBN ordinary_JJ shares_NNS were_VBD authorised_VBN and_CC issued_VBN for_IN the_DT purpose_NN of_IN the_DT Scheme_NN of_IN Arrangement_NN only_RB and_CC will_MD be_VB redeemed_VBN in_IN 2006_CD ._.
As_IN at_IN December_NNP 31_CD ,_, 2004_CD the_DT authorised_JJ common_JJ stock_NN of_IN the_DT Company_NN was_VBD 40_CD million_CD $_$ 76.8_CD million_CD divided_VBN into_IN 799,999,965_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT and_CC 17,500,000_CD Special_JJ Ordinary_NNP Voting_NNP Shares_NNP of_IN 0.00001_CD p_NN each_DT ._.
Issue_NN of_IN ordinary_JJ shares_NNS During_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD the_DT Company_NN allotted_VBD 6,116,049_CD ordinary_JJ shares_NNS with_IN a_DT nominal_JJ value_NN of_IN 305,802_CD $_$ 527,000_CD on_IN the_DT exchange_NN of_IN exchangeable_JJ shares_NNS ,_, which_WDT were_VBD issued_VBN following_VBG the_DT acquisition_NN of_IN BioChem_NNP in_IN 2001_CD ._.
These_DT shares_NNS were_VBD issued_VBN at_IN a_DT premium_NN of_IN 66.2_CD million_CD $_$ 94.1_CD million_CD ._.
Exchange_NNP of_IN exchangeable_JJ shares_NNS and_CC cancellation_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS The_DT Company_NN exchanged_VBD 2,038,683_CD exchangeable_JJ shares_NNS and_CC canceled_VBD the_DT equivalent_JJ number_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS during_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD ._.
Each_DT exchangeable_JJ share_NN is_VBZ capable_JJ of_IN being_VBG exchanged_VBN for_IN ordinary_JJ shares_NNS or_CC ADSs_NNS ,_, at_IN a_DT rate_NN of_IN one_CD exchangeable_JJ share_NN for_IN three_CD ordinary_JJ shares_NNS or_CC one_CD exchangeable_JJ share_NN for_IN one_CD ADS_NNPS ,_, at_IN any_DT time_NN at_IN the_DT request_NN of_IN the_DT holder_NN ._.
Only_RB BioChem_NNP shareholders_NNS with_IN Canadian_JJ residency_NN had_VBD the_DT option_NN to_TO receive_VB exchangeable_JJ shares_NNS for_IN their_PRP$ shares_NNS of_IN BioChem_NNP at_IN the_DT time_NN of_IN acquisition_NN ._.
The_DT exchangeable_JJ shares_NNS were_VBD issued_VBN by_IN Shire_NNP Acquisition_NNP Inc._NNP a_DT company_NN incorporated_VBN under_IN the_DT Canada_NNP Business_NNP Corporations_NNS Act_NNP ,_, which_WDT is_VBZ a_DT wholly-owned_JJ subsidiary_NN of_IN the_DT Company_NN ,_, and_CC is_VBZ listed_VBN on_IN the_DT Toronto_NNP Stock_NNP Exchange_NNP ._.
Holders_NNS of_IN exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO vote_VB at_IN shareholder_NN meetings_NNS of_IN the_DT Company_NN and_CC are_VBP entitled_VBN to_TO a_DT dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN ordinary_JJ shares_NNS ,_, through_IN a_DT voting_NN trust_NN and_CC by_IN means_NNS of_IN the_DT special_JJ ordinary_JJ voting_NN shares_NNS in_IN Shire_NNP ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD 2,187,793_CD exchangeable_JJ shares_NNS remained_VBD unconverted_JJ ._.
The_DT Company_NN can_MD redeem_VB all_DT outstanding_JJ exchangeable_JJ shares_NNS for_IN ordinary_JJ shares_NNS after_IN May_NNP 11_CD ,_, 2011_CD or_CC earlier_JJR if_IN the_DT total_JJ number_NN of_IN exchangeable_JJ shares_NNS falls_VBZ below_IN one_CD million_CD ._.
The_DT exchangeable_JJ shares_NNS are_VBP included_VBN as_IN part_NN of_IN share_NN capital_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT consolidated_JJ Groups_NNS capital_NN structure_NN ,_, which_WDT differs_VBZ from_IN the_DT Companies_NNS Act_NNP 1985_CD requirements_NNS to_TO reflect_VB these_DT amounts_NNS as_IN minority_NN interests_NNS ,_, as_IN they_PRP will_MD become_VB ,_, and_CC are_VBP equivalent_JJ ,_, to_TO ordinary_JJ shares_NNS ._.
86_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 87_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 30_CD Share_NN capital_NN continued_VBD Share_NN warrants_NNS On_IN April_NNP 24_CD ,_, 2002_CD the_DT Company_NN issued_VBN 741,812_CD share_NN warrants_NNS ,_, at_IN 4.88_CD per_IN warrant_NN ,_, and_CC on_IN November_NNP 21_CD ,_, 2002_CD the_DT Company_NN issued_VBD a_DT further_JJ 604,595_CD share_NN warrants_NNS ,_, at_IN 4.895_CD per_IN warrant_NN ,_, both_DT issues_NNS being_VBG made_VBN to_TO Technology_NNP Partnership_NNP Canada_NNP TPC_NNP ,_, pursuant_JJ to_TO an_DT agreement_NN between_IN BioChem_NNP and_CC the_DT Government_NN of_IN Canada_NNP GOC_NNP ._.
Each_DT warrant_NN grants_NNS a_DT right_NN to_TO subscribe_VB for_IN a_DT corresponding_JJ number_NN of_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN within_IN five_CD years_NNS from_IN the_DT date_NN of_IN issue_NN of_IN the_DT warrant_NN ._.
31_CD Share_NN based_VBN payments_NNS Historically_NNP the_DT Group_NNP has_VBZ granted_VBN options_NNS to_TO directors_NNS and_CC employees_NNS over_IN ordinary_JJ shares_NNS under_IN six_CD stock_NN option_NN plans_NNS ._.
On_IN November_NNP 28_CD ,_, 2005_CD the_DT ordinary_JJ shareholders_NNS of_IN Shire_NNP approved_VBD the_DT adoption_NN of_IN the_DT Shire_NNP plc_NN Portfolio_NNP Share_NNP Plan_NNP Parts_NNP A_NNP and_CC B_NNP ,_, a_DT new_JJ share-based_JJ compensation_NN plan_NN ,_, which_WDT provides_VBZ for_IN stock-settled_JJ share_NN appreciation_NN rights_NNS and_CC performance_NN share_NN awards_NNS to_TO be_VB made_VBN to_TO directors_NNS and_CC employees_NNS over_IN ordinary_JJ shares_NNS and_CC American_JJ depositary_JJ shares_NNS ADS_NNPS ._.
No_DT further_JJ awards_NNS will_MD be_VB made_VBN under_IN the_DT previous_JJ stock_NN option_NN plans_NNS ._.
The_DT highest_JJS and_CC lowest_JJS market_NN prices_NNS during_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD were_VBD 7.53_CD and_CC 5.39_CD respectively_RB ._.
The_DT average_JJ share_NN price_NN during_IN the_DT year_NN was_VBD 6.37_CD ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 87_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 88_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 31_CD Share_NN based_VBN payments_NNS continued_VBD The_DT Group_NNP has_VBZ granted_VBN options_NNS to_TO Directors_NNS and_CC employees_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT following_VBG six_CD share_NN option_NN schemes_NNS :_: a_DT Stock_NN option_NN plans_VBZ i_FW Shire_FW Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three_CD years_NNS ,_, they_PRP are_VBP thereafter_RB tested_VBN quarterly_JJ by_IN reference_NN to_TO share_VB price_NN growth_NN over_IN the_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS will_MD become_VB exercisable_JJ ._.
On_IN February_NNP 28_CD ,_, 2000_CD ,_, the_DT Remuneration_NNP Committee_NNP of_IN the_DT Board_NNP exercised_VBD its_PRP$ powers_NNS to_TO amend_VB the_DT terms_NNS of_IN the_DT Executive_NNP Share_NNP Option_NN Scheme_NN so_RB as_IN to_TO include_VB a_DT cliff_NN vesting_VBG provision_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ._.
ii_FW Shire_FW plc_FW 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP 2000_CD Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN this_DT scheme_NN are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT option_NN granted_VBN prior_RB to_TO August_NNP 2002_CD ,_, if_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN becomes_VBZ exercisable_JJ in_IN full_JJ ._.
If_IN it_PRP increases_VBZ by_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN the_DT same_JJ three-year_JJ period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS granted_VBN become_VBN exercisable_JJ ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three-year_JJ measurement_NN period_NN ,_, they_PRP will_MD thereafter_RB be_VB tested_VBN quarterly_JJ by_IN reference_NN to_TO compound_VB annual_JJ share_NN price_NN growth_NN over_IN an_DT extended_JJ period_NN ._.
The_DT performance_NN criteria_NNS were_VBD reviewed_VBN in_IN 2002_CD to_TO ensure_VB the_DT criteria_NNS reflected_VBD the_DT market_NN in_IN which_WDT the_DT Group_NNP operates_VBZ ._.
Given_VBN the_DT Groups_NNS development_NN ,_, it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT earnings_NNS per_IN share-based_JJ measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
The_DT performance_NN criteria_NNS are_VBP based_VBN on_IN real_JJ growth_NN in_IN the_DT diluted_JJ earnings_NNS per_IN share_NN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN under_IN US_NNP GAAP_NNP ,_, adjusted_VBN to_TO ensure_VB a_DT consistent_JJ basis_NN of_IN measurement_NN ,_, as_IN approved_VBN by_IN the_DT Remuneration_NNP Committee_NNP ,_, including_VBG the_DT add_VB back_RB of_IN significant_JJ one_CD time_NN items_NNS option_NN EPS_NNP ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS were_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP option_NN EPS_NNP growth_NN over_IN a_DT three-year_JJ period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Prices_NNS Index_NNP RPI_NNP for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN Directors_NNS ,_, RPI_NNP plus_CC 15_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 15_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 21_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 27_CD %_NN The_DT new_JJ earnings_NNS per_IN share_NN performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
After_IN consultation_NN with_IN certain_JJ of_IN its_PRP$ institutional_JJ shareholders_NNS ,_, the_DT Group_NNP has_VBZ decided_VBN that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN from_IN 2004_CD onwards_NNS ,_, the_DT re-test_JJS of_IN the_DT performance_NN condition_NN if_IN Shires_NNP option_NN EPS_NNP growth_NN has_VBZ fallen_VBN short_JJ of_IN the_DT minimum_JJ annual_JJ average_JJ percentage_NN increase_NN over_IN the_DT three-year_JJ period_NN from_IN grant_NN ,_, has_VBZ been_VBN changed_VBN ._.
The_DT performance_NN condition_NN will_MD be_VB re-tested_VBN once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
Hence_RB the_DT level_NN of_IN option_NN EPS_NNP growth_NN in_IN the_DT next_JJ two_CD years_NNS needs_VBZ to_TO be_VB consequentially_RB higher_JJR to_TO meet_VB the_DT test_NN ._.
Six_CD weeks_NNS prior_RB to_TO the_DT expiration_NN date_NN ,_, any_DT options_NNS that_WDT have_VBP not_RB become_VB exercisable_JJ at_IN an_DT earlier_JJR date_NN ,_, automatically_RB vest_NN without_IN reference_NN to_TO the_DT performance_NN criteria_NNS ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
iii_FW Shire_FW Pharmaceuticals_NNPS Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
Employees_NNS may_MD enter_VB into_IN three_CD or_CC five-year_JJ savings_NNS contracts_NNS ._.
iv_FW Shire_FW plc_FW Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT offering_NN period_NN is_VBZ for_IN 27_CD months_NNS ._.
v_NN Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP Options_NNPS issued_VBN under_IN the_DT SLI_NNP Plan_NNP were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT company_NN acquired_VBN by_IN the_DT Group_NNP on_IN March_NNP 23_CD ,_, 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN Shire_NNP ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SLI_NNP Plan_NNP ._.
vi_FW BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP on_IN May_NNP 11_CD ,_, 2001_CD ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChem_NNP Pharma_NNP Inc._NNP s_VBZ common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN Shire_NNP ._.
All_DT BioChem_NNP Pharma_NNP Inc._NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN ._.
88_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 89_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 31_CD Share_NN based_VBN payments_NNS continued_VBD b_NN Stock-settled_JJ share_NN appreciation_NN rights_NNS vii_FW Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP Stock-settled_JJ share_NN appreciation_NN rights_NNS granted_VBN under_IN the_DT Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT award_NN made_VBD to_TO Executive_NNP Directors_NNS performance_NN conditions_NNS will_MD be_VB based_VBN on_IN relative_JJ total_JJ shareholder_NN return_NN ._.
Vesting_VBG will_MD depend_VB on_IN relative_JJ total_JJ shareholder_NN return_NN performance_NN against_IN two_CD comparator_NN groups_NNS ._.
For_IN one-third_NN of_IN the_DT award_NN ,_, the_DT comparator_NN group_NN will_MD be_VB the_DT Financial_NNP Times_NNP Stock_NNP Exchange_NNP 100_CD constituents_NNS excluding_VBG financial_JJ institutions_NNS and_CC for_IN two-thirds_NNS of_IN the_DT award_NN the_DT comparator_NN group_NN will_MD be_VB a_DT group_NN of_IN international_JJ companies_NNS from_IN the_DT pharmaceutical_JJ sector_NN ._.
In_IN addition_NN ,_, before_IN awards_NNS granted_VBN to_TO Executive_NNP Directors_NNS will_MD vest_NN ,_, the_DT Committee_NNP must_MD be_VB satisfied_VBN that_IN the_DT underlying_VBG performance_NN of_IN the_DT Group_NNP is_VBZ sufficient_JJ to_TO justify_VB this_DT ._.
Where_WRB median_JJ performance_NN is_VBZ achieved_VBN ,_, 1_CD 33_CD 3_CD %_NN of_IN stock-settled_JJ share_NN appreciation_NN rights_NNS will_MD vest_NN ,_, rising_VBG on_IN a_DT straight-line_JJ basis_NN to_TO full_JJ vesting_NN at_IN upper_JJ quartile_JJ performance_NN ._.
Awards_RB granted_VBN to_TO employees_NNS below_IN Executive_NNP Director_NNP level_NN will_MD not_RB be_VB subject_JJ to_TO performance_NN conditions_NNS ._.
Once_RB awards_NNS have_VBP vested_VBN ,_, participants_NNS will_MD have_VB until_IN the_DT fifth_JJ anniversary_NN of_IN the_DT date_NN of_IN grant_NN to_TO exercise_VB their_PRP$ awards_NNS ._.
c_NN Performance_NNP share_NN plan_NN viii_FW Portfolio_NNP Share_NNP Plan_NNP Part_NNP B_NNP Performance_NNP share_NN awards_NNS granted_VBN under_IN the_DT Portfolio_NNP Share_NNP Plan_NNP Part_NNP B_NNP are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
For_IN one-third_NN of_IN an_DT award_NN ,_, the_DT comparator_NN group_NN will_MD be_VB the_DT Financial_NNP Times_NNP Stock_NNP Exchange_NNP 100_CD constituents_NNS excluding_VBG financial_JJ institutions_NNS and_CC for_IN two-thirds_NNS of_IN the_DT award_NN the_DT comparator_NN group_NN will_MD be_VB a_DT group_NN of_IN international_JJ companies_NNS from_IN the_DT pharmaceutical_JJ sector_NN ._.
In_IN addition_NN ,_, before_IN awards_NNS granted_VBN to_TO Executive_NNP Directors_NNS will_MD vest_NN ,_, the_DT Committee_NNP must_MD be_VB satisfied_VBN 1_CD that_IN the_DT underlying_VBG performance_NN of_IN the_DT Group_NNP is_VBZ sufficient_JJ to_TO justify_VB this_DT ._.
Where_WRB median_JJ performance_NN is_VBZ achieved_VBN ,_, 33_CD 3_CD %_NN of_IN stock-settled_JJ share_NN appreciation_NN rights_NNS will_MD vest_NN ,_, rising_VBG on_IN a_DT straight-line_JJ basis_NN to_TO full_JJ vesting_NN at_IN upper_JJ quartile_JJ performance_NN ._.
At_IN December_NNP 31_CD ,_, 2005_CD no_DT awards_NNS had_VBD been_VBN made_VBN ._.
In_IN a_DT period_NN of_IN ten_CD years_NNS ,_, not_RB more_JJR than_IN 10_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Shire_NNP may_MD be_VB placed_VBN under_IN option_NN under_IN any_DT share_NN scheme_NN ._.
In_IN addition_NN ,_, the_DT following_VBG terms_NNS apply_VB to_TO options_NNS that_WDT may_MD be_VB granted_VBN under_IN the_DT various_JJ plans_NNS :_: 2000_CD Executive_NNP Scheme_NNP :_: the_DT maximum_JJ number_NN of_IN Shire_NNP ordinary_JJ shares_NNS over_IN which_WDT incentive_NN options_NNS may_MD be_VB granted_VBN under_IN Part_NN 3_CD of_IN the_DT scheme_NN is_VBZ 25,000,000_CD :_: and_CC Share_NN Purchase_NN Plan_NN :_: up_IN to_TO 2,000,000_CD Shire_NNP ordinary_JJ shares_NNS ._.
The_DT maximum_JJ term_NN and_CC vesting_JJ period_NN of_IN awards_NNS granted_VBN and_CC outstanding_JJ as_RB at_IN December_NNP 31_CD ,_, 2005_CD is_VBZ summarized_VBN below_IN :_: Expiration_NNP Compensation_NNP Number_NNP of_IN period_NN from_IN type_NN awards_NNS date_NN of_IN issue_NN Vesting_JJ period_NN Executive_NNP Scheme_NNP Stock_NNP options_NNS 1,176,784_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS 2000_CD Executive_NNP Scheme_NNP Stock_NNP options_NNS 22,787,658_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS Sharesave_NNP Scheme_NNP Stock_NNP options_NNS 337,371_CD 6_CD months_NNS after_IN vesting_VBG 3_CD or_CC 5_CD years_NNS Stock_NNP Purchase_NNP Plan_NNP Stock_NNP options_NNS 640,777_CD On_IN vesting_VBG date_NN 27_CD months_NNS SLI_NNP Plan_NNP Stock_NNP options_NNS 2,567_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN the_DT Group_NNP BioChem_NNP Plan_NNP Stock_NNP options_NNS 3,525,582_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN the_DT Group_NNP Total_NNP share_NN option_NN schemes_NNS 28,470,739_CD Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP Stock-settled_JJ share_NN 449,490_CD 5_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN appreciation_NN rights_NNS criteria_NNS for_IN Executive_NNP Directors_NNS only_RB ordinary_JJ shares_NNS Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP Stock-settled_JJ share_NN 2,812,176_CD 5_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN appreciation_NN rights_NNS criteria_NNS for_IN Executive_NNP Directors_NNS only_RB i_FW ADSs_NNPS Total_NNP Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP 3,261,666_CD Portfolio_NNP Share_NNP Plan_NNP Part_NNP B_NNP Performance_NNP shares_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS for_IN Executive_NNP Directors_NNS only_RB i_FW For_IN the_DT purposes_NNS of_IN this_DT table_NN the_DT 937,392_CD ADSs_NNS outstanding_JJ at_IN December_NNP 31_CD ,_, 2005_CD have_VBP been_VBN converted_VBN into_IN 2,812,176_CD ordinary_JJ shares_NNS ._.
One_CD ADS_NNPS is_VBZ equivalent_JJ to_TO three_CD ordinary_JJ shares_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 89_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 90_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 31_CD Share_NN based_VBN payments_NNS continued_VBD Options_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, 2005_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ exercise_NN price_NN average_NN of_IN options_NNS Number_NN of_IN options_NNS Number_NN of_IN Exercise_NN prices_NNS remaining_VBG outstanding_JJ of_IN options_NNS outstanding_JJ options_NNS outstanding_JJ life_NN exercisable_JJ 5,651,719_CD 0.014.00_CD 6.8_CD 3.46_CD 26,547_CD 3.19_CD 14,772,839_CD 4.016.00_CD 8.1_CD 5.36_CD 2,070,405_CD 5.19_CD 5,739,709_CD 6.0110.00_CD 4.3_CD 7.05_CD 3,669,918_CD 7.20_CD 2,306,472_CD 10.0113.00_CD 4.0_CD 11.84_CD 2,220,499_CD 11.89_CD 28,470,739_CD 7,987,369_CD Stock-settled_JJ share_NN appreciation_NN rights_NNS over_IN ordinary_JJ shares_NNS outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, 2005_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ exercise_NN price_NN average_NN of_IN options_NNS Number_NN of_IN options_NNS Number_NN of_IN Exercise_NN prices_NNS remaining_VBG outstanding_JJ of_IN options_NNS outstanding_JJ options_NNS outstanding_JJ life_NN exercisable_JJ 449,490_CD 6.0110.00_CD 4.9_CD 7.17_CD Stock-settled_JJ share_NN appreciation_NN rights_NNS over_IN American_JJ depositary_JJ shares_NNS outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, 2005_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ exercise_NN price_NN average_NN of_IN options_NNS Number_NN of_IN options_NNS Number_NN of_IN Exercise_NN prices_NNS remaining_VBG outstanding_JJ of_IN options_NNS outstanding_JJ options_NNS outstanding_JJ life_NN exercisable_JJ 937,392_CD 35.0140.00_CD 4.9_CD 37.80_CD Options_NNS and_CC stock-settled_JJ share_NN appreciation_NN rights_NNS granted_VBN in_IN the_DT period_NN were_VBD valued_VBN using_VBG the_DT Black-Scholes_NNP option-pricing_NN model_NN ._.
No_DT performance_NN conditions_NNS were_VBD included_VBN in_IN the_DT fair_JJ value_NN calculations_NNS as_IN there_EX were_VBD no_DT market_NN based_VBN conditions_NNS ._.
The_DT fair_JJ value_NN per_IN option_NN granted_VBN and_CC the_DT assumptions_NNS used_VBN in_IN the_DT calculations_NNS are_VBP as_IN follows_VBZ :_: 2005_CD 2004_CD Weighted-average_JJ share_NN price_NN at_IN grant_NN dates_NNS 6.29_CD 5.18_CD Weighted-average_JJ share_NN exercise_NN price_NN 6.23_CD 5.15_CD Shares_NNS under_IN option_NN 12,004,477_CD 7,148,616_CD Vesting_JJ period_NN years_NNS 2.255_CD 2.255_CD Expected_VBN volatility_NN 32-50_CD %_NN 32-50_CD %_NN Option_NN life_NN years_NNS 2.2510_CD 2.2510_CD Expected_VBN life_NN years_NNS 2.257_CD 2.257_CD Risk_NNP free_JJ interest_NN rate_NN 3.934.59_CD %_NN 2.464.19_CD %_NN Expected_VBN dividends_NNS expressed_VBD as_IN a_DT dividend_NN yield_NN 0.6_CD %_NN 0_CD %_NN 0.6_CD %_NN Estimated_VBN annual_JJ forfeiture_NN rate_NN 5_CD %_NN 5_CD %_NN Average_JJ fair_JJ value_NN per_IN option_NN 2.98_CD 2.74_CD The_DT weighted_JJ average_NN expected_VBN volatility_NN is_VBZ based_VBN on_IN historical_JJ volatility_NN of_IN a_DT term_NN consistent_JJ with_IN the_DT assumed_JJ option_NN life_NN ._.
The_DT risk_NN free_JJ rate_NN of_IN return_NN is_VBZ the_DT yield_NN on_IN zero-coupon_JJ US_NNP government_NN bonds_NNS of_IN a_DT term_NN consistent_JJ with_IN the_DT assumed_JJ option_NN life_NN ._.
In_IN addition_NN to_TO equity-settled_JJ share-based_JJ schemes_NNS discussed_VBN above_IN ,_, the_DT Group_NNP operates_VBZ a_DT cash-settled_JJ share-based_JJ scheme_NN for_IN senior_JJ executives_NNS ,_, the_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP LTIP_NNP ._.
The_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP the_DT Plan_NN was_VBD adopted_VBN at_IN the_DT Companys_NNP 1998_CD Annual_JJ General_NNP Meeting_VBG and_CC amended_VBN in_IN 2000_CD ._.
Under_IN the_DT Plan_NN ,_, the_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN to_TO make_VB awards_NNS of_IN shares_NNS subject_JJ to_TO a_DT maximum_NN of_IN 100_CD %_NN of_IN salary_NN a_DT year_NN ._.
The_DT performance_NN condition_NN attached_VBN to_TO the_DT vesting_NN of_IN the_DT share_NN awards_NNS made_VBN under_IN the_DT Plan_NN is_VBZ Shires_NNP Total_NNP Shareholder_NN Return_NN TSR_NNP relative_JJ to_TO the_DT FTSE_NNP 100_CD Index_NNP over_IN a_DT three-year_JJ period_NN ._.
The_DT Committee_NNP considers_VBZ that_IN this_DT measure_NN is_VBZ a_DT reliable_JJ and_CC appropriate_JJ measure_NN of_IN the_DT Groups_NNS performance_NN and_CC that_IN the_DT FTSE_NNP 100_CD is_VBZ an_DT appropriate_JJ benchmark_NN given_VBN that_IN the_DT Company_NN is_VBZ a_DT member_NN of_IN the_DT Index_NN ._.
90_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 91_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 31_CD Share_NN based_VBN payments_NNS continued_VBD Under_IN this_DT Plan_NN :_: all_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ in_IN the_DT top_JJ 10_CD %_NN of_IN the_DT FTSE_NNP 100_CD :_: 20_CD %_NN of_IN the_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ at_IN the_DT median_NN of_IN the_DT FTSE_NNP 100_CD ,_, with_IN vesting_VBG between_IN these_DT points_NNS on_IN a_DT linear_JJ basis_NN :_: and_CC no_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ below_IN the_DT median_NN of_IN the_DT FTSE_NNP 100_CD ._.
The_DT Remuneration_NNP Committee_NNP determines_VBZ whether_IN and_CC to_TO what_WP extent_NN the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN on_IN the_DT basis_NN of_IN data_NNS provided_VBN by_IN an_DT independent_JJ third-party_JJ ._.
To_TO date_NN ,_, all_DT awards_NNS made_VBN under_IN the_DT Plan_NN have_VBP been_VBN made_VBN as_IN a_DT conditional_JJ allocation_NN ,_, thereby_RB allowing_VBG ,_, at_IN the_DT Remuneration_NNP Committees_NNS discretion_NN ,_, for_IN a_DT cash_NN equivalent_NN to_TO be_VB paid_VBN on_IN maturity_NN of_IN the_DT award_NN ._.
Whilst_IN the_DT performance_NN period_NN is_VBZ measured_VBN over_IN three_CD years_NNS ,_, an_DT award_NN is_VBZ normally_RB transferred_VBN after_IN the_DT fourth_JJ anniversary_NN of_IN grant_NN ,_, to_TO the_DT extent_NN the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN ._.
For_IN awards_NNS made_VBN under_IN the_DT LTIP_NNP prior_RB to_TO June_NNP 2001_CD ,_, performance_NN is_VBZ measured_VBN over_IN a_DT three-year_JJ period_NN but_CC the_DT performance_NN conditions_NNS are_VBP based_VBN on_IN criteria_NNS of_IN i_FW 50_CD %_NN TSR_NNP benchmarked_VBD against_IN FTSE_NNP mid-250_CD index_NN and_CC ii_FW 50_CD %_NN subject_NN to_TO an_DT EPS_NNP condition_NN measured_VBN against_IN the_DT diluted_VBN EPS_NNP of_IN the_DT Group_NNP for_IN the_DT financial_JJ year_NN ended_VBD before_IN the_DT commencement_NN of_IN the_DT performance_NN period_NN and_CC the_DT diluted_VBN EPS_NNP of_IN the_DT Group_NNP for_IN the_DT financial_JJ year_NN ended_VBN on_IN or_CC before_IN the_DT end_NN of_IN the_DT performance_NN period_NN ._.
For_IN awards_NNS made_VBN on_IN March_NNP 1_CD ,_, 2000_CD the_DT Committee_NNP determined_VBD that_IN 44.84_CD %_NN of_IN the_DT part_NN of_IN the_DT award_NN subject_NN to_TO TSR_NNP performance_NN measures_NNS and_CC 100_CD %_NN of_IN the_DT part_NN of_IN the_DT award_NN subject_NN to_TO EPS_NNP performance_NN measures_NNS could_MD be_VB transferred_VBN ,_, resulting_VBG in_IN 72.42_CD %_NN of_IN the_DT total_JJ award_NN being_VBG transferred_VBN to_TO participants_NNS ._.
These_DT calculations_NNS were_VBD verified_VBN by_IN external_JJ advisers_NNS ._.
The_DT total_JJ liability_NN under_IN LTIP_NNP scheme_NN is_VBZ $_$ 2.5_CD million_CD 2004_CD :_: $_$ 2.7_CD million_CD and_CC is_VBZ included_VBN in_IN other_JJ provisions_NNS as_IN disclosed_VBN in_IN Note_NN 28_CD ._.
There_EX were_VBD no_DT liabilities_NNS outstanding_JJ for_IN which_WDT the_DT right_NN to_TO cash_NN had_VBD vested_VBN at_IN the_DT year-end_NN ._.
The_DT total_JJ charge_NN for_IN the_DT year_NN relating_VBG to_TO employee_NN share-based_JJ payment_NN plans_NNS was_VBD $_$ 27.4_CD million_CD 2004_CD :_: $_$ 15.8_CD million_CD ,_, of_IN which_WDT $_$ 27.4_CD million_CD 2004_CD :_: $_$ 15.5_CD million_CD related_VBN to_TO equity-settled_JJ share-based_JJ payment_NN transactions_NNS ._.
32_CD Treasury_NNP shares_NNS The_DT Employee_NNP Share_NNP Ownership_NNP Plan_NNP ESOP_NNP reserve_NN arises_VBZ in_IN connection_NN with_IN the_DT ESOP_NNP trust_NN ,_, a_DT discretionary_JJ trust_NN established_VBN to_TO facilitate_VB the_DT operation_NN of_IN the_DT Groups_NNS long-term_JJ incentive_NN scheme_NN for_IN senior_JJ management_NN ._.
The_DT amount_NN of_IN the_DT reserve_NN represents_VBZ the_DT deduction_NN in_IN arriving_VBG at_IN shareholders_NNS funds_NNS for_IN the_DT consideration_NN paid_VBN for_IN the_DT Companys_NNP shares_NNS purchased_VBN by_IN the_DT trust_NN which_WDT had_VBD not_RB vested_VBN unconditionally_RB to_TO employees_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT Deferred_NNP Bonus_NNP Plan_NNP the_DT Plan_NNP provides_VBZ for_IN participants_NNS to_TO use_VB up_RP to_TO 50_CD %_NN of_IN their_PRP$ annual_JJ bonus_NN to_TO buy_VB shares_NNS in_IN the_DT Company_NN ._.
The_DT Group_NNP will_MD match_VB any_DT shares_NNS bought_VBD ,_, but_CC the_DT matched_VBN shares_NNS will_MD vest_NN ,_, for_IN Executive_NNP Directors_NNS ,_, only_RB if_IN the_DT Groups_NNS EPS_VBP grows_VBZ by_IN more_JJR than_IN 15_CD %_NN in_IN excess_NN of_IN RPI_NNP over_IN a_DT three-year_JJ period_NN 9_CD %_NN in_IN excess_NN of_IN RPI_NNP for_IN other_JJ eligible_JJ employees_NNS ._.
Recent_JJ fiscal_JJ changes_NNS in_IN the_DT US_NNP have_VBP made_VBN the_DT Plan_NNP less_RBR attractive_JJ to_TO participants_NNS and_CC the_DT Remuneration_NNP Committee_NNP discontinued_VBD the_DT Plan_NN after_IN bonus_NN awards_NNS for_IN the_DT 2004_CD financial_JJ year_NN ._.
The_DT number_NN and_CC market_NN value_NN of_IN the_DT ordinary_JJ shares_NNS held_VBN by_IN the_DT ESOP_NNP trust_NN at_IN December_NNP 31_CD ,_, was_VBD 2005 2005 2004 2004_CD Number_NNP Market_NNP value_NN Number_NNP Market_NNP value_NN 000_CD $_$ 000_CD 000_CD $_$ 000_CD Shares_NNP allocated_VBN but_CC not_RB vested_JJ 51_CD 651_CD 50_CD 246_CD Unallocated_JJ shares_NNS 198_CD 2,532_CD 218_CD 249_CD 3,183_CD 52_CD 264_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 91_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 92_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 33_CD Shareholders_NNS funds_NNS and_CC statement_NN of_IN changes_NNS in_IN shareholders_NNS equity_NN Capital_NN Share_NN Share_NN Treasury_NNP Exchangeable_JJ reduction_NN Capital_NN Other_JJ Retained_VBN capital_NN premium_NN shares_NNS shares_NNS reserve_NN reserve_NN reserve_NN earnings_NNS Total_JJ $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Balance_NN at_IN January_NNP 1_CD ,_, 2005_CD 36,083_CD 4,883,219_CD 264_CD 195,830_CD 4,729_CD 36,121_CD 910,786_CD 4,244,932_CD Effect_NN of_IN Scheme_NN of_IN Arrangement_NNP 2,889,562_CD 4,883,219_CD 4,729_CD 1,998,386_CD Effect_NN of_IN capital_NN reduction_NN 2,883,849_CD 2,883,849_CD Balance_NN at_IN January_NNP 1_CD ,_, 2005_CD restated_VBN 41,796_CD 264_CD 195,830_CD 2,883,849_CD 2,034,507_CD 910,786_CD 4,244,932_CD Foreign_JJ currency_NN translation_NN differences_NNS 28,855_CD 28,855_CD Net_JJ income_NN recognized_VBN directly_RB in_IN equity_NN 28,855_CD 28,855_CD Employee_NN share_NN option_NN scheme_NN :_: value_NN of_IN employee_NN services_NNS 27,383_CD 27,383_CD proceeds_NNS from_IN shares_NNS issued_VBN 405_CD 2,977_CD 26,268_CD 7,463_CD 37,113_CD Issue_NN of_IN share_NN capital_NN Exchange_NN of_IN exchangeable_JJ shares_NNS 527_CD 94,582_CD 36,373_CD 57,682_CD Purchase_NN of_IN treasury_NN shares_NNS 2,549_CD 2,549_CD Dividends_NNPS 28,460_CD 28,460_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 1,721_CD 1,721_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ securities_NNS 9,226_CD 9,226_CD Loss_NN for_IN the_DT year_NN 177,378_CD 177,378_CD Balance_NN at_IN December_NNP 31_CD ,_, 2005_CD 42,728_CD 2,977_CD 2,813_CD 101,248_CD 2,946,490_CD 2,099,652_CD 1,107,149_CD 4,083,133_CD The_DT cumulative_JJ foreign_JJ exchange_NN differences_NNS on_IN translation_NN amount_NN to_TO a_DT $_$ 5.2_CD million_CD gain_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD ._.
Capital_NNP Share_NNP Share_NNP Treasury_NNP Exchangeable_JJ reduction_NN Capital_NN Other_JJ Retained_VBN capital_NN premium_NN shares_NNS shares_NNS reserve_NN reserve_NN reserve_NN earnings_NNS Total_JJ $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Balance_NN at_IN January_NNP 1_CD ,_, 2004_CD before_IN effect_NN of_IN Scheme_NN of_IN Arrangement_NNP 35,540_CD 4,794,738_CD 270,667_CD 4,729_CD 36,121_CD 1,047,920_CD 4,093,875_CD Foreign_JJ currency_NN translation_NN differences_NNS 34,066_CD 34,066_CD Net_JJ income_NN recognized_VBN directly_RB in_IN equity_NN 34,066_CD 34,066_CD Employee_NN share_NN option_NN scheme_NN :_: value_NN of_IN employee_NN services_NNS 15,464_CD 15,464_CD proceeds_NNS from_IN shares_NNS issued_VBN 191_CD 13,225_CD 13,416_CD Issue_NN of_IN share_NN capital_NN 8_CD 763_CD 771_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 344_CD 74,493_CD 74,837_CD Purchase_NN of_IN treasury_NN shares_NNS 264_CD 264_CD Dividends_NNPS 8,905_CD 8,905_CD Profit_NN for_IN the_DT year_NN 96,509_CD 96,509_CD Balance_NN at_IN December_NNP 31_CD ,_, 2004_CD 36,083_CD 4,883,219_CD 264_CD 195,830_CD 4,729_CD 36,121_CD 910,786_CD 4,244,932_CD The_DT capital_NN and_CC other_JJ reserves_NNS arose_VBD in_IN relation_NN to_TO various_JJ Group_NNP reconstructions_NNS and_CC certain_JJ financing_NN transactions_NNS ._.
92_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 93_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 34_CD Cash_NN generated_VBD from_IN operations_NNS For_IN the_DT For_IN the_DT year_NN ended_VBD year_NN ended_VBD December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Operating_NN loss_NN profit_NN 158,873_CD 290,786_CD Adjustments_NNS for_IN :_: Depreciation_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 23,003_CD 22,668_CD Amortization_NN of_IN intangible_JJ assets_NNS 49,516_CD 42,138_CD Impairment_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 6,458_CD 1,587_CD Impairment_NN of_IN intangible_JJ assets_NNS 4,410_CD 19,626_CD Impairment_NN of_IN goodwill_NN 526,956_CD 132,576_CD Movements_NNS in_IN financial_JJ assets_NNS 1,974_CD 16,253_CD Increase_VBP in_IN provision_NN for_IN sale_NN deductions_NNS 18,616_CD 50,746_CD Loss_NN profit_NN on_IN disposal_NN of_IN non-financial_JJ assets_NNS 185_CD 325_CD Profit_NN on_IN disposal_NN of_IN financial_JJ assets_NNS 4,100_CD 14,805_CD Gain_NN on_IN sale_NN of_IN drug_NN formulation_NN business_NN 3,561_CD Stock_NN option_NN compensation_NN 27,383_CD 15,464_CD Operating_NN cash_NN flows_VBZ before_IN movements_NNS in_IN working_VBG capital_NN 491,967_CD 576,714_CD Decrease_NN in_IN inventories_NNS 8,582_CD 2,185_CD Increase_VBP in_IN trade_NN and_CC other_JJ receivables_NN 146,741_CD 28,066_CD Increase_VBP decrease_NN in_IN other_JJ assets_NNS 731_CD 16,136_CD Increase_VBP in_IN trade_NN and_CC other_JJ payables_NNS 120,422_CD 61,448_CD Deferred_JJ income_NN 13,520_CD 6,151_CD Cash_NN flow_NN from_IN discontinued_VBN operations_NNS 362_CD 30,525_CD Cash_NN generated_VBD from_IN operations_NNS 459,617_CD 604,043_CD Interest_NN paid_VBN 4,334_CD 14,771_CD Income_NN tax_NN paid_VBN 54,096_CD 123,510_CD Net_JJ cash_NN flows_VBZ from_IN operating_VBG activities_NNS 401,187_CD 465,762_CD Additions_NNS to_TO fixtures_NNS and_CC equipment_NN during_IN the_DT year_NN amounting_VBG to_TO $_$ 71.9_CD million_CD included_VBD acquisitions_NNS of_IN $_$ 4.6_CD million_CD financed_VBN by_IN new_JJ finance_NN leases_NNS ._.
Cash_NN and_CC cash_NN equivalents_NNS which_WDT are_VBP presented_VBN as_IN a_DT single_JJ category_NN of_IN assets_NNS on_IN the_DT face_NN of_IN the_DT balance_NN sheet_NN comprise_VBP cash_NN at_IN bank_NN and_CC other_JJ short-term_JJ highly_RB liquid_JJ investments_NNS with_IN a_DT maturity_NN of_IN three_CD months_NNS or_CC less_JJR ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 93_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 94_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 35_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS a_DT Leases_NNP The_NNP Group_NNP leases_VBZ property_NN ,_, computer_NN and_CC office_NN equipment_NN and_CC motor_NN vehicles_NNS on_IN short-term_JJ operating_NN leases_NNS ._.
The_DT rents_NNS payable_JJ under_IN property_NN leases_NNS are_VBP subject_JJ to_TO renegotiation_NN at_IN various_JJ intervals_NNS specified_VBN in_IN the_DT leases_NNS ._.
The_DT Group_NNP pays_VBZ for_IN substantially_RB all_DT of_IN the_DT insurance_NN ,_, maintenance_NN and_CC repair_NN of_IN these_DT assets_NNS ._.
The_DT future_JJ aggregate_JJ minimum_NN lease_NN payments_NNS under_IN non-cancellable_JJ operating_NN leases_NNS are_VBP as_IN follows_VBZ :_: Land_NNP and_CC Motor_NNP buildings_NNS Equipment_NNP vehicles_NNS Total_JJ 2005_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Not_RB later_RB than_IN 1_CD year_NN 18,847_CD 1,502_CD 2,828_CD 23,177_CD Later_RB than_IN 1_CD year_NN and_CC not_RB later_RB than_IN 5_CD years_NNS 75,002_CD 1,808_CD 7,618_CD 84,428_CD Later_RB than_IN 5_CD years_NNS 50,013_CD 3_CD 50,016_CD 143,862_CD 3,313_CD 10,446_CD 157,621_CD Land_NNP and_CC Motor_NNP buildings_NNS Equipment_NNP vehicles_NNS Total_JJ 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Not_RB later_RB than_IN 1_CD year_NN 6,579_CD 4,561_CD 2,246_CD 13,386_CD Later_RB than_IN 1_CD year_NN and_CC not_RB later_RB than_IN 5_CD years_NNS 27,486_CD 4,996_CD 3,090_CD 35,572_CD Later_RB than_IN 5_CD years_NNS 37,707_CD 37,707_CD 71,772_CD 9,557_CD 5,336_CD 86,665_CD The_DT future_NN aggregate_JJ payments_NNS for_IN land_NN and_CC buildings_NNS include_VBP $_$ 57.6_CD million_CD in_IN respect_NN of_IN operating_VBG leases_NNS expiring_VBG in_IN 2016_CD on_IN the_DT Groups_NNS new_JJ headquarters_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
b_NN Guarantees_NNS and_CC collateral_NN At_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD $_$ 5.5_CD million_CD 2004_CD :_: $_$ 5.3_CD million_CD of_IN restricted_VBN cash_NN held_VBN as_IN collateral_NN for_IN certain_JJ equipment_NN leases_NNS ._.
c_NN Letters_NNS of_IN credit_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Group_NNP had_VBD the_DT following_VBG letters_NNS of_IN credit_NN :_: i_FW An_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Barclays_NNP Bank_NNP plc_NN in_IN the_DT amount_NN of_IN $_$ 15_CD million_CD 2004_CD :_: $_$ 15_CD million_CD providing_VBG security_NN on_IN the_DT recoverability_NN of_IN insurance_NN claims_NNS ._.
The_DT Group_NNP had_VBD restricted_VBN cash_NN of_IN $_$ 15_CD million_CD 2004_CD :_: $_$ 16_CD million_CD as_IN required_VBN by_IN this_DT letter_NN of_IN credit_NN ._.
ii_FW An_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Bank_NNP of_IN America_NNP in_IN the_DT amount_NN of_IN $_$ 7.9_CD million_CD ,_, providing_VBG security_NN on_IN the_DT payment_NN of_IN lease_NN obligations_NNS ._.
The_DT Group_NNP has_VBZ restricted_VBN cash_NN of_IN $_$ 7.9_CD million_CD ,_, as_IN required_VBN by_IN this_DT letter_NN of_IN credit_NN ._.
d_LS Capital_NNP commitments_NNS i_FW DAYTRANA_NNP In_IN connection_NN with_IN the_DT Groups_NNS acquisition_NN in_IN 2003_CD from_IN Noven_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Noven_NNP of_IN the_DT worldwide_JJ sales_NNS and_CC marketing_NN rights_NNS to_TO DAYTRANA_NNP ,_, the_DT Group_NNP has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN the_DT following_VBG milestones_NNS :_: $_$ 50_CD million_CD upon_IN FDA_NNP approval_NN of_IN the_DT product_NN ,_, which_WDT will_MD be_VB capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN :_: and_CC up_RB to_TO $_$ 75_CD million_CD ,_, linked_VBN to_TO future_JJ sales_NNS performance_NN ._.
An_DT approvable_JJ letter_NN was_VBD received_VBN from_IN the_DT FDA_NNP on_IN December_NNP 23_CD ,_, 2005_CD ._.
Final_JJ regulatory_JJ approval_NN is_VBZ currently_RB expected_VBN to_TO be_VB in_IN 2006_CD ._.
ii_FW NRP104_CD In_IN connection_NN with_IN the_DT Groups_NNS collaboration_NN with_IN New_NNP River_NNP to_TO commercialise_VB NRP104_NNP ,_, the_DT Group_NNP has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN the_DT following_VBG milestones_NNS :_: $_$ 50_CD million_CD upon_IN the_DT FDAs_NNS acceptance_NN of_IN filing_NN of_IN the_DT NDA_NNP :_: up_RP to_TO $_$ 300_CD million_CD following_VBG the_DT first_JJ commercial_JJ sale_NN of_IN the_DT product_NN ,_, depending_VBG on_IN the_DT characteristics_NNS of_IN the_DT approved_VBN product_NN labeling_VBG :_: $_$ 100_CD million_CD on_IN achieving_VBG a_DT significant_JJ sales_NNS target_NN :_: and_CC $_$ 5_CD million_CD following_VBG the_DT first_JJ commercial_JJ sale_NN in_IN certain_JJ specified_VBN EU_NN markets_NNS ._.
An_DT upfront_JJ payment_NN of_IN $_$ 50_CD million_CD was_VBD capitalized_VBN during_IN the_DT first_JJ quarter_NN of_IN 2005_CD ._.
The_DT NDA_NNP for_IN NRP104_NNP was_VBD filed_VBN on_IN December_NNP 6_CD ,_, 2005_CD and_CC accepted_VBD for_IN review_NN by_IN the_DT FDA_NNP on_IN January_NNP 26_CD ,_, 2006_CD ,_, triggering_VBG the_DT $_$ 50_CD million_CD milestone_NN payment_NN ,_, which_WDT has_VBZ now_RB been_VBN paid_VBN ._.
iii_FW FOSRENOL_NNP patent_NN rights_NNS In_IN connection_NN with_IN the_DT Groups_NNS purchase_NN of_IN the_DT global_JJ patents_NNS for_IN FOSRENOL_NNP from_IN AnorMED_NNP Inc._NNP in_IN 2004_CD ,_, the_DT Group_NNP has_VBZ outstanding_JJ commitments_NNS to_TO pay_VB AnorMED_NNP Inc._NNP $_$ 6_CD million_CD when_WRB FOSRENOL_NNP is_VBZ approved_VBN in_IN certain_JJ European_JJ countries_NNS and_CC $_$ 6_CD million_CD upon_IN receipt_NN of_IN regulatory_JJ approval_NN in_IN Japan_NNP ._.
iv_NN Other_JJ research_NN and_CC development_NN commitments_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Group_NNP had_VBD commitments_NNS of_IN $_$ 18_CD million_CD payable_JJ on_IN achievement_NN of_IN specified_VBN milestones_NNS for_IN products_NNS under_IN development_NN in-licensed_JJ from_IN third_JJ parties_NNS ,_, of_IN which_WDT $_$ 6.6_CD million_CD is_VBZ committed_VBN to_TO be_VB paid_VBN in_IN 2006_CD ._.
94_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 95_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 35_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD v_JJ TKT_NNP shareholders_NNS seeking_VBG appraisal_NN rights_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, appraisal_NN rights_NNS had_VBD been_VBN asserted_VBN in_IN respect_NN of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN ._.
For_IN further_JJ information_NN see_VBP section_NN g_NN below_IN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP recorded_VBD a_DT liability_NN of_IN $_$ 419.9_CD million_CD based_VBN on_IN the_DT merger_NN consideration_NN of_IN $_$ 37_CD per_IN share_NN for_IN the_DT 11.3_CD million_CD shares_NNS subject_JJ to_TO appraisal_NN rights_NNS at_IN that_DT time_NN plus_IN a_DT provision_NN for_IN interest_NN of_IN $_$ 7.7_CD million_CD that_WDT may_MD be_VB awarded_VBN by_IN the_DT Court_NNP see_VB Note_VB 11_CD ._.
Until_IN such_JJ time_NN as_IN the_DT appraisal_NN process_NN is_VBZ complete_JJ the_DT Group_NNP is_VBZ unable_JJ to_TO determine_VB the_DT extent_NN of_IN its_PRP$ liability_NN ._.
For_IN every_DT $_$ 1_CD increase_NN decrease_NN in_IN the_DT merger_NN consideration_NN applicable_JJ to_TO those_DT former_JJ TKT_NNP shareholders_NNS who_WP have_VBP asserted_VBN appraisal_NN rights_NNS ,_, the_DT total_JJ estimated_JJ purchase_NN price_NN would_MD increase_VB decrease_NN by_IN approximately_RB $_$ 11.3_CD million_CD ._.
vi_FW Clinical_JJ testing_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Group_NNP had_VBD committed_VBN to_TO pay_VB approximately_RB $_$ 16.3_CD million_CD to_TO contract_VB vendors_NNS for_IN administering_VBG and_CC executing_VBG clinical_JJ trials_NNS ._.
The_DT timing_NN of_IN payments_NNS is_VBZ not_RB reasonably_RB certain_JJ as_IN payments_NNS are_VBP dependent_JJ upon_IN actual_JJ services_NNS performed_VBN by_IN the_DT organizations_NNS as_IN determined_VBN by_IN patient_JJ enrolment_NN levels_NNS and_CC related_JJ activities_NNS ._.
However_RB ,_, the_DT Group_NNP expects_VBZ to_TO pay_VB $_$ 13.2_CD million_CD for_IN these_DT commitments_NNS throughout_IN 2006_CD as_IN ongoing_JJ trials_NNS are_VBP completed_VBN and_CC the_DT remainder_NN in_IN 2007_CD ._.
vii_FW Contract_NNP manufacturing_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD committed_VBN to_TO pay_VB approximately_RB $_$ 23.1_CD million_CD in_IN respect_NN of_IN contract_NN manufacturing_NN over_IN the_DT next_JJ 12_CD months_NNS ._.
viii_FW Investment_NN commitments_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD outstanding_JJ commitments_NNS to_TO subscribe_VB for_IN interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG $_$ 25.2_CD million_CD 2004_CD :_: $_$ 22_CD million_CD of_IN which_WDT $_$ 9.9_CD million_CD is_VBZ committed_VBN in_IN 2006_CD and_CC a_DT further_JJ $_$ 2.9_CD million_CD could_MD be_VB payable_JJ in_IN 2006_CD ,_, depending_VBG on_IN the_DT timing_NN of_IN capital_NN calls_NNS ._.
ix_NN Manufacturing_NNP facilities_NNS At_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD committed_VBN a_DT total_NN of_IN $_$ 6.1_CD million_CD to_TO the_DT expansion_NN and_CC modification_NN of_IN its_PRP$ manufacturing_NN facilities_NNS at_IN Owings_NNP Mills_NNP ,_, Maryland_NNP and_CC Cambridge_NNP ,_, Massachusetts_NNP ._.
Of_IN this_DT total_NN ,_, $_$ 3.2_CD million_CD is_VBZ to_TO facilitate_VB the_DT production_NN and_CC packaging_NN of_IN additional_JJ strategic_JJ products_NNS and_CC $_$ 2.9_CD million_CD is_VBZ for_IN the_DT design_NN and_CC construction_NN of_IN a_DT technology_NN center_NN at_IN Owings_NNP Mills_NNP ._.
All_DT costs_NNS are_VBP expected_VBN to_TO be_VB incurred_VBN in_IN 2006_CD ._.
x_LS Basingstoke_NNP ,_, UK_NNP expansion_NN The_NNP Group_NNP is_VBZ in_IN the_DT process_NN of_IN expanding_VBG its_PRP$ UK_NNP headquarters_NN at_IN Basingstoke_NNP ,_, UK_NNP ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Group_NNP had_VBD an_DT outstanding_JJ commitment_NN of_IN $_$ 4.5_CD million_CD ,_, which_WDT is_VBZ expected_VBN to_TO be_VB incurred_VBN in_IN 2006_CD ._.
e_LS Contingent_JJ liabilities_NNS The_DT Group_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS ,_, including_VBG those_DT set_VBN out_RP below_IN ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS referred_VBD to_TO below_IN ,_, Shire_NNP believes_VBZ that_IN they_PRP will_MD not_RB have_VB a_DT materially_RB adverse_JJ effect_NN on_IN the_DT Groups_NNS reported_VBD financial_JJ position_NN ._.
PHENTERMINE_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, is_VBZ a_DT defendant_NN in_IN ten_NN lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
SUS_NNP ,_, formerly_RB known_VBN as_IN Shire_NNP Richwood_NNP Inc._NNP has_VBZ been_VBN sued_VBN as_IN a_DT manufacturer_NN and_CC distributor_NN of_IN phentermine_NN ,_, an_DT anorectic_NN used_VBN in_IN the_DT short-term_JJ treatment_NN of_IN obesity_NN and_CC one_CD of_IN the_DT products_NNS addressed_VBN by_IN the_DT lawsuits_NNS ._.
The_DT suits_NNS relate_VBP to_TO phentermine_VB either_CC alone_RB or_CC together_RB with_IN fenfluramine_NN or_CC dexenfluramine_NN ._.
The_DT lawsuits_NNS generally_RB allege_VBP the_DT following_VBG claims_NNS :_: the_DT defendants_NNS marketed_VBN phentermine_NN and_CC other_JJ products_NNS for_IN the_DT treatment_NN of_IN obesity_NN and_CC misled_VBD users_NNS about_IN the_DT products_NNS and_CC dangers_NNS associated_VBN with_IN them_PRP :_: the_DT defendants_NNS failed_VBD adequately_RB to_TO test_NN phentermine_NN individually_RB and_CC when_WRB taken_VBN in_IN combination_NN with_IN the_DT other_JJ drugs_NNS :_: and_CC the_DT defendants_NNS knew_VBD or_CC should_MD have_VB known_VBN about_IN the_DT negative_JJ effects_NNS of_IN the_DT drugs_NNS and_CC should_MD have_VB informed_VBN the_DT public_JJ about_IN such_JJ risks_NNS and_CC or_CC failed_VBD to_TO provide_VB appropriate_JJ warning_NN labels_NNS ._.
SUS_NNP has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT total_NN of_IN 4,199_CD such_JJ phentermine_NN lawsuits_NNS ,_, in_IN respect_NN of_IN which_WDT SUS_NNP has_VBZ been_VBN dismissed_VBN as_IN a_DT defendant_NN in_IN 4,189_CD cases_NNS ._.
Five_CD of_IN the_DT ten_NN remaining_VBG cases_NNS name_NN SUS_NNP as_IN a_DT defendant_NN ,_, but_CC have_VBP not_RB been_VBN served_VBN as_IN required_VBN by_IN state_NN and_CC federal_JJ rules_NNS of_IN civil_JJ procedure_NN ._.
It_PRP is_VBZ expected_VBN that_IN SUS_NNP will_MD be_VB dismissed_VBN from_IN the_DT remaining_VBG cases_NNS based_VBN upon_IN lack_NN of_IN product_NN identification_NN or_CC agreement_NN of_IN the_DT parties_NNS ._.
SUS_NNP became_VBD involved_VBN with_IN phentermine_NN through_IN its_PRP$ acquisition_NN of_IN certain_JJ assets_NNS of_IN Rexar_NNP Pharmacal_NNP Corporation_NNP Rexar_NNP in_IN January_NNP 1994_CD ._.
In_IN addition_NN to_TO SUS_NNP potentially_RB incurring_VBG liability_NN as_IN a_DT result_NN of_IN its_PRP$ own_JJ production_NN of_IN Oby-Cap_NNP ,_, a_DT phentermine_JJ product_NN ,_, the_DT plaintiffs_NNS may_MD additionally_RB seek_VB to_TO impose_VB liability_NN on_IN SUS_NNP as_IN successor_NN to_TO Rexar_NNP ._.
SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB all_PDT the_DT lawsuits_NNS ._.
SUS_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB prescribed_VBN ,_, causes_VBZ the_DT alleged_JJ side_NN effects_NNS and_CC that_IN SUS_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Accordingly_RB ,_, SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Group_NNP in_IN respect_NN of_IN phentermine_NN ._.
Legal_JJ expenses_NNS to_TO date_NN have_VBP been_VBN paid_VBN by_IN Eon_NNP Labs_NNPS ,_, Inc._NNP ._.
Eon_NNP ,_, the_DT supplier_NN to_TO SUS_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN November_NNP 30_CD ,_, 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 95_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 96_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 35_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD ADDERALL_NNP XR_NNP i_FW Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
The_DT Groups_NNS extended_VBD release_NN once_RB daily_JJ version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ._.
6,322,819_CD the_DT 819_CD Patent_NN and_CC US_NNP patent_NN No._NN ._.
In_IN January_NNP 2003_CD Shire_NNP was_VBD notified_VBN that_IN Barr_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP Barrs_NNP ANDA_NNP products_NNS prior_RB to_TO the_DT expiration_NN date_NN of_IN Shires_NNP 819_CD Patent_NN ,_, and_CC alleging_VBG that_IN the_DT 819_CD Patent_NN is_VBZ not_RB infringed_VBN by_IN Barrs_NNP ANDA_NNP products_NNS ._.
In_IN August_NNP 2003_CD Shire_NNP was_VBD notified_VBN that_IN Barr_NNP also_RB was_VBD seeking_VBG permission_NN to_TO market_VB its_PRP$ ANDA_NNP products_NNS prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN and_CC alleging_VBG that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ ._.
Shire_NNP Laboratories_NNPS ,_, Inc_NNP ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Barr_NNP for_IN infringement_NN of_IN the_DT 819_CD Patent_NN in_IN February_NNP 2003_CD and_CC for_IN infringement_NN of_IN the_DT 300_CD Patent_NN in_IN September_NNP 2003_CD ._.
The_DT schedules_NNS for_IN the_DT lawsuits_NNS against_IN Barr_NNP with_IN respect_NN to_TO the_DT 819_CD and_CC 300_CD Patents_NNP were_VBD consolidated_VBN in_IN December_NNP 2003_CD ._.
Shire_NNP Laboratories_NNPS is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP and_CC ANDA_NNP products_NNS infringe_VBP the_DT 819_CD and_CC 300_CD Patents_NNP and_CC that_IN its_PRP$ ANDA_NNP should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT patents_NNS ._.
Shire_NNP Laboratories_NNPS is_VBZ also_RB seeking_VBG injunctions_NNS to_TO prevent_VB Barr_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP products_NNS before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialization_NN and_CC its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN September_NNP 27_CD ,_, 2004_CD Barr_NNP filed_VBD an_DT amended_VBN Answer_NNP ,_, Affirmative_NNP Defense_NNP and_CC Counterclaim_NNP in_IN which_WDT Barr_NNP added_VBD the_DT following_VBG counterclaims_NNS :_: invalidity_NN of_IN the_DT 819_CD patent_NN ,_, non-infringement_NN of_IN the_DT 300_CD Patent_NN and_CC unenforceability_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP due_JJ to_TO inequitable_JJ conduct_NN ._.
Shire_NNP Laboratories_NNP has_VBZ asserted_VBN affirmative_JJ defences_NNS ,_, alleging_VBG ,_, among_IN other_JJ things_NNS ,_, that_IN Barr_NNP has_VBZ waived_VBN its_PRP$ right_NN to_TO assert_VB the_DT counterclaims_NNS set_VBN forth_RB in_IN its_PRP$ September_NNP 27_CD ,_, 2004_CD amended_VBN Answer_NNP ._.
Under_IN the_DT Courts_NNPS schedule_NN summary_NN judgement_NN motions_NNS were_VBD to_TO be_VB filed_VBN and_CC fully_RB briefed_VBN by_IN October_NNP 14_CD ,_, 2005_CD ._.
Neither_DT Shire_NNP Laboratories_NNPS nor_CC Barr_NNP filed_VBD summary_NN judgement_NN motions_NNS ._.
At_IN a_DT March_NNP 10_CD ,_, 2006_CD pre-trial_JJ conference_NN the_DT Court_NNP set_VBD a_DT bench_NN trial_NN date_NN of_IN October_NNP 30_CD ,_, 2006_CD ._.
Shires_NNP lawsuits_NNS triggered_VBD stays_NNS of_IN final_JJ FDA_NNP approval_NN of_IN Barrs_NNP ANDA_NNP of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT date_NN of_IN the_DT Companys_NNP receipt_NN of_IN Barrs_NNP notice_NN letters_NNS ._.
The_DT 30_CD month_NN stay_VB related_VBN to_TO the_DT lawsuit_NN regarding_VBG the_DT 300_CD Patent_NN expired_VBD on_IN February_NNP 18_CD ,_, 2006_CD ._.
As_IN the_DT stay_NN has_VBZ expired_VBN ,_, the_DT FDA_NNP may_MD approve_VB Barrs_NNP ANDA_NNP ,_, subject_JJ to_TO satisfaction_NN by_IN Barr_NNP of_IN the_DT FDAs_NNS requirements_NNS ._.
Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ ANDA_NNP products_NNS upon_IN receipt_NN of_IN final_JJ FDA_NNP approval_NN ._.
On_IN October_NNP 19_CD ,_, 2005_CD the_DT Company_NN brought_VBD another_DT lawsuit_NN against_IN Barr_NNP in_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP alleging_VBG infringement_NN of_IN US_NNP Patent_NNP No._NN ._.
The_DT Company_NN is_VBZ seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN infringing_VBG the_DT 768_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD commercialise_VB its_PRP$ ANDA_NNP Products_NNPS ,_, attorneys_NNS fees_NNS and_CC costs_NNS ._.
Barr_NNP has_VBZ moved_VBN to_TO dismiss_VB this_DT action_NN asserting_VBG that_IN there_EX is_VBZ no_DT subject_JJ matter_NN jurisdiction_NN ._.
A_DT hearing_NN on_IN this_DT motion_NN was_VBD held_VBN on_IN February_NNP 17_CD ,_, 2006_CD ._.
No_DT decision_NN on_IN this_DT motion_NN has_VBZ yet_RB been_VBN made_VBN ._.
In_IN November_NNP 2003_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Impax_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Impax_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 30mg_JJ strength_NN of_IN ADDERALL_NNP XR_NNP Impaxs_NNP ANDA_NNP product_NN prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
In_IN December_NNP 2003_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP received_VBD an_DT additional_JJ notification_NN from_IN Impax_NNP advising_VBG of_IN the_DT filing_NN of_IN an_DT amendment_NN to_TO its_PRP$ ANDA_NNP for_IN a_DT generic_JJ version_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ and_CC 25mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP in_IN addition_NN to_TO the_DT 30mg_JJ strength_NN ,_, the_DT subject_NN of_IN Impaxs_NNP initial_JJ ANDA_NNP submission_NN ._.
In_IN January_NNP 2005_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
As_IN part_NN of_IN the_DT October_NNP 19_CD ,_, 2005_CD lawsuit_NN against_IN Barr_NNP ,_, Shire_NNP also_RB brought_VBD suit_NN in_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN Impax_NNP for_IN infringing_VBG the_DT 768_CD Patent_NN ._.
Impax_NNP filed_VBD a_DT declaratory_JJ judgement_NN action_NN in_IN Delaware_NNP alleging_VBG that_IN the_DT 768_CD Patent_NN was_VBD invalid_JJ and_CC that_IN its_PRP$ ANDA_NNP did_VBD not_RB infringe_VB the_DT 768_CD Patent_NN ._.
On_IN January_NNP 19_CD ,_, 2006_CD ,_, Shire_NNP and_CC Impax_NNP announced_VBD that_IN all_DT pending_VBG litigation_NN in_IN connection_NN with_IN Impaxs_NNP ANDA_NNP had_VBD been_VBN settled_VBN ._.
As_IN part_NN of_IN the_DT settlement_NN ,_, Impax_NNP confirmed_VBD that_IN its_PRP$ proposed_VBN generic_JJ products_NNS infringe_VBP Shires_NNP 819_CD ,_, 300_CD and_CC 768_CD Patents_NNP and_CC that_IN the_DT three_CD patents_NNS are_VBP valid_JJ and_CC enforceable_JJ ._.
Under_IN the_DT terms_NNS of_IN the_DT settlement_NN agreement_NN ,_, Impax_NNP will_MD be_VB permitted_VBN to_TO market_NN generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP in_IN the_DT United_NNP States_NNPS no_RB later_RB than_IN January_NNP 1_CD ,_, 2010_CD and_CC will_MD pay_VB Shire_NNP a_DT royalty_NN from_IN those_DT sales_NNS ._.
In_IN certain_JJ situations_NNS ,_, such_JJ as_IN the_DT launch_NN of_IN another_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP ,_, Impax_NNP may_MD be_VB permitted_VBN to_TO enter_VB the_DT market_NN as_IN Shires_NNP authorised_VBD generic_JJ ._.
No_DT payments_NNS to_TO Impax_NNP are_VBP involved_VBN in_IN the_DT settlement_NN agreement_NN ._.
The_DT settlement_NN agreement_NN ,_, which_WDT was_VBD effective_JJ immediately_RB ,_, has_VBZ been_VBN submitted_VBN to_TO the_DT United_NNP States_NNPS Federal_NNP Trade_NNP Commission_NNP FTC_NNP for_IN its_PRP$ review_NN ,_, as_IN required_VBN by_IN law_NN ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Colony_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Colony_NN had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
Shire_NNP has_VBZ chosen_VBN not_RB to_TO sue_VB Colony_NNP ._.
96_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 97_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 35_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD iv_NN Teva_NNP Pharmaceuticals_NNP USA_NNP ,_, Inc._NNP ._.
In_IN February_NNP 2005_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Teva_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Teva_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 10mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
In_IN June_NNP 2005_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Teva_NNP had_VBD amended_VBN its_PRP$ ANDA_NNP to_TO seek_VB permission_NN to_TO market_NN additional_JJ strengths_NNS of_IN 5mg_CD ,_, 15mg_CD and_CC 20mg_CD of_IN its_PRP$ generic_JJ ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
In_IN January_NNP 2006_CD ,_, Shire_NNP received_VBD a_DT third_JJ notice_NN letter_NN that_WDT Teva_NNP had_VBD further_JJ amended_VBN its_PRP$ ANDA_NNP to_TO seek_VB permission_NN to_TO market_VB the_DT 25mg_JJ strength_NN generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
On_IN March_NNP 2_CD ,_, 2006_CD ,_, Shire_NNP filed_VBD a_DT lawsuit_NN in_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP alleging_VBG that_IN Tevas_NNP ANDA_NNP products_NNS infringe_VBP both_DT the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT lawsuit_NN will_MD trigger_VB a_DT stay_NN of_IN FDA_NNP approval_NN of_IN Tevas_NNP 25mg_JJ strength_NN product_NN for_IN up_RB to_TO 30_CD months_NNS from_IN the_DT date_NN of_IN the_DT Companys_NNP receipt_NN of_IN Tevas_NNP notice_NN ._.
There_EX is_VBZ no_DT such_JJ stay_NN with_IN respect_NN to_TO Tevas_NNP 5mg_CD ,_, 10mg_CD ,_, 15mg_CD ,_, 20mg_JJ and_CC 30mg_JJ strength_NN versions_NNS of_IN ADDERALL_NNP XR_NNP ._.
None_NN of_IN Barr_NNP ,_, Colony_NNP or_CC Teva_NNP may_MD launch_VB their_PRP$ generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP before_IN they_PRP receive_VBP final_JJ FDA_NNP approval_NN of_IN their_PRP$ respective_JJ ANDAs_NNS ._.
The_DT FDA_NNP may_MD grant_VB 180_CD days_NNS of_IN generic_JJ market_NN exclusivity_NN to_TO Barr_NNP as_IN the_DT first_JJ to_TO file_VB an_DT ANDA_NNP for_IN a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP ._.
Neither_DT Colony_NNP nor_CC Teva_NNP may_MD market_VB their_PRP$ ANDA_NNP products_NNS until_IN the_DT FDA_NNP grants_NNS a_DT final_JJ approval_NN of_IN their_PRP$ ANDAs_NNS and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
CARBATROL_NNP In_IN August_NNP 2003_CD ,_, the_DT Company_NN was_VBD notified_VBN that_IN Nostrum_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Nostrum_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 300mg_JJ strength_NN of_IN CARBATROL_NNP Nostrums_NNPS ANDA_NNP product_NN prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS US_NNP patents_NNS for_IN CARBATROL_NNP ,_, US_NNP patent_NN No._NN ._.
5,912,013_CD the_DT 013_CD Patent_NN and_CC US_NNP patent_NN No._NN ._.
The_DT notification_NN alleges_VBZ that_IN the_DT 013_CD and_CC 570_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP ANDA_NNP product_NN ._.
On_IN September_NNP 18_CD ,_, 2003_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Nostrum_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP alleging_VBG infringement_NN of_IN these_DT two_CD patents_NNS by_IN Nostrums_NNP ANDA_NNP and_CC ANDA_NNP product_NN ._.
Shire_NNP Laboratories_NNP was_VBD seeking_VBG a_DT ruling_NN that_WDT Nostrums_VBZ ANDA_NNP infringes_VBZ the_DT 013_CD and_CC 570_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ._.
Shire_NNP Laboratories_NNP was_VBD also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Nostrum_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Nostrum_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN January_NNP 23_CD ,_, 2004_CD ,_, Shire_NNP Laboratories_NNPS amended_VBD the_DT complaint_NN to_TO drop_VB the_DT allegations_NNS with_IN respect_NN to_TO the_DT 013_CD Patent_NN while_IN maintaining_VBG the_DT suit_NN with_IN respect_NN to_TO the_DT 570_CD Patent_NN ._.
By_IN way_NN of_IN counterclaims_NNS Nostrum_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 570_CD and_CC 013_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP ANDA_NNP product_NN ._.
Nostrum_NNP also_RB was_VBD seeking_VBG actual_JJ and_CC punitive_JJ damages_NNS for_IN alleged_JJ abuse_NN of_IN process_NN by_IN Shire_NNP Laboratories_NNPS ._.
On_IN July_NNP 12_CD ,_, 2004_CD ,_, the_DT Court_NNP dismissed_VBD Nostrums_NNP abuse_NN of_IN process_NN counterclaim_NN for_IN failure_NN to_TO state_VB a_DT claim_NN upon_IN which_WDT relief_NN can_MD be_VB granted_VBN ._.
On_IN December_NNP 10_CD ,_, 2004_CD ,_, Nostrum_NNP filed_VBD a_DT summary_NN judgement_NN motion_NN seeking_VBG a_DT declaration_NN of_IN non-infringement_NN of_IN the_DT 570_CD Patent_NN ._.
Shire_NNP Laboratories_NNPS opposition_NN to_TO this_DT motion_NN was_VBD filed_VBN on_IN January_NNP 14_CD ,_, 2005_CD ._.
The_DT Court_NNP heard_VBD arguments_NNS with_IN respect_NN to_TO Nostrums_NNP motion_NN on_IN July_NNP 15_CD ,_, 2005_CD ._.
At_IN the_DT conclusion_NN of_IN the_DT hearing_VBG the_DT Court_NNP denied_VBD Nostrums_NNP motion_NN for_IN summary_NN judgement_NN of_IN noninfringement_NN ._.
During_IN the_DT March_NNP 10_CD ,_, 2006_CD status_NN conference_NN call_NN with_IN the_DT Court_NNP ,_, previously_RB scheduled_VBN expert_NN dispositions_NNS and_CC Markman_NNP briefing_NN were_VBD adjourned_VBN ._.
No_DT trial_NN date_NN has_VBZ been_VBN set_VBN ._.
Nostrum_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN CARBATROL_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuit_NN triggered_VBD a_DT stay_NN of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Companys_NNP receipt_NN of_IN Nostrums_NNP notice_NN letter_NN ._.
The_DT 30_CD month_NN stay_VB expired_VBN on_IN February_NNP 6_CD ,_, 2006_CD ._.
Following_VBG expiry_NN of_IN the_DT stay_NN ,_, Nostrum_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ 300mg_JJ extended-release_NN carbamazepine_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ._.
GA-GCB_NNP In_IN January_NNP 2005_CD ,_, Genzyme_NNP Corporation_NNP Genzyme_NNP filed_VBD suit_NN against_IN TKT_NNP in_IN the_DT District_NNP Court_NNP of_IN Tel_NNP Aviv-Jaffa_NNP ,_, Israel_NNP ,_, claiming_VBG that_IN TKTs_NNP Phase_NN 1_CD 2_CD clinical_JJ trial_NN in_IN Israel_NNP evaluating_VBG GA-GCB_NNP for_IN the_DT treatment_NN of_IN Gaucher_NNP disease_NN infringes_VBZ one_CD or_CC more_JJR claims_NNS of_IN Genzymes_NNP Israeli_NNP Patent_NNP No._NN ._.
In_IN addition_NN ,_, Genzyme_NNP filed_VBD a_DT motion_NN for_IN preliminary_JJ injunction_NN ,_, including_VBG a_DT request_NN for_IN an_DT ex_FW parte_FW hearing_NN and_CC relief_NN on_IN the_DT merits_NNS ,_, to_TO immediately_RB seize_VB and_CC destroy_VB all_DT GA-GCB_NNP being_VBG used_VBN to_TO treat_VB patients_NNS and_CC to_TO prevent_VB TKT_NNP from_IN submitting_VBG data_NNS generated_VBD from_IN the_DT clinical_JJ trial_NN to_TO regulatory_JJ agencies_NNS ._.
In_IN March_NNP 2005_CD the_DT District_NNP Court_NNP refused_VBD to_TO grant_VB Genzymes_NNP motion_NN for_IN a_DT preliminary_JJ injunction_NN ._.
The_DT lawsuit_NN was_VBD dismissed_VBN in_IN January_NNP 2006_CD ._.
DYNEPO_NNP In_IN April_NNP 1997_CD ,_, Amgen_NNP Inc._NNP ._.
Amgen_NNP commenced_VBD a_DT patent_NN infringement_NN action_NN against_IN TKT_NNP and_CC Sanofi-Aventis_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP ._.
In_IN January_NNP 2001_CD ,_, the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP concluded_VBD that_IN DYNEPO_NNP infringed_VBD eight_CD of_IN the_DT 18_CD claims_NNS of_IN five_CD patents_NNS that_WDT Amgen_NNP had_VBD asserted_VBN ._.
Amgen_NNP did_VBD not_RB seek_VB and_CC was_VBD not_RB awarded_VBN monetary_JJ damages_NNS ._.
This_DT decision_NN was_VBD subsequently_RB appealed_VBN to_TO the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
In_IN January_NNP 2003_CD ,_, the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP issued_VBD a_DT decision_NN affirming_VBG in_IN part_NN and_CC reversing_VBG in_IN part_NN the_DT decision_NN of_IN the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP ,_, remanded_VBD the_DT action_NN to_TO the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP for_IN further_JJ proceedings_NNS and_CC instructed_VBD the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP to_TO reconsider_VB the_DT validity_NN of_IN Amgens_NNP patents_NNS in_IN the_DT light_NN of_IN potentially_RB invalidating_VBG prior_RB art_NN ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 97_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 98_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 35_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD In_IN October_NNP 2004_CD ,_, the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP issued_VBD a_DT decision_NN on_IN the_DT remanded_VBN issues_NNS ,_, finding_VBG that_IN certain_JJ claims_NNS related_VBN to_TO four_CD patents_NNS held_VBN by_IN Amgen_NNP are_VBP infringed_VBN by_IN TKT_NNP and_CC Sanofi-Aventis_NNP ._.
In_IN December_NNP 2004_CD ,_, TKT_NNP and_CC Sanofi-Aventis_NNP filed_VBD a_DT notice_NN of_IN appeal_NN of_IN the_DT decision_NN of_IN the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP to_TO the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
An_DT oral_JJ hearing_NN was_VBD held_VBN at_IN the_DT Federal_NNP Circuit_NNP in_IN December_NNP 2005_CD ._.
No_DT decision_NN has_VBZ been_VBN rendered_VBN at_IN this_DT time_NN ._.
If_IN TKT_NNP and_CC Sanofi-Aventis_NNP are_VBP not_RB successful_JJ in_IN the_DT DYNEPO_NNP litigation_NN at_IN the_DT appellate_JJ level_NN ,_, TKT_NNP and_CC Sanofi-Aventis_NNP would_MD be_VB precluded_VBN from_IN making_VBG ,_, using_VBG and_CC selling_VBG DYNEPO_NNP in_IN the_DT United_NNP States_NNPS until_IN the_DT expiration_NN of_IN the_DT relevant_JJ patents_NNS ._.
TKT_NNP is_VBZ required_VBN to_TO reimburse_VB Sanofi-Aventis_NNP ,_, which_WDT controls_VBZ the_DT litigation_NN and_CC is_VBZ paying_VBG the_DT litigation_NN expenses_NNS ,_, for_IN 50_CD %_NN of_IN the_DT expenses_NNS incurred_VBN in_IN connection_NN with_IN the_DT litigation_NN from_IN and_CC after_IN March_NNP 26_CD ,_, 2004_CD ._.
In_IN the_DT event_NN that_WDT Sanofi-Aventis_NNP launches_VBZ DYNEPO_NNP in_IN the_DT US_NNP ,_, Sanofi-Aventis_NNP is_VBZ entitled_VBN to_TO deduct_VB up_RP to_TO 50_CD %_NN of_IN any_DT royalties_NNS that_WDT Sanofi-Aventis_NNP may_MD otherwise_RB owe_VB to_TO TKT_NNP with_IN respect_NN to_TO the_DT sale_NN of_IN DYNEPO_NNP until_IN Sanofi-Aventis_NNP has_VBZ recouped_VBN the_DT full_JJ amount_NN of_IN TKTs_NNS share_NN of_IN the_DT litigation_NN expenses_NNS ._.
TKT_NNP has_VBZ the_DT right_NN to_TO control_VB any_DT other_JJ litigation_NN that_WDT might_MD arise_VB outside_IN of_IN the_DT United_NNP States_NNPS and_CC is_VBZ responsible_JJ for_IN all_DT litigation_NN expenses_NNS incurred_VBN in_IN connection_NN with_IN such_JJ litigation_NN from_IN and_CC after_IN March_NNP 26_CD ,_, 2004_CD ._.
Gene_NNP activation_NN In_IN 1996_CD ,_, Applied_NNP Research_NNP Systems_NNP Holding_NNP N._NNP V._NNP a_DT wholly-owned_JJ subsidiary_NN of_IN Serono_NNP S._NNP A._NNP Serono_NNP and_CC Cell_NNP Genesys_NNP ,_, became_VBD involved_VBN in_IN a_DT patent_NN interference_NN involving_VBG Seronos_NNP US_NNP Patent_NNP No._NN ._.
5,272,071_CD the_DT 071_CD Patent_NN ,_, which_WDT purportedly_RB covers_VBZ certain_JJ methods_NNS of_IN gene_NN activation_NN ._.
In_IN June_NNP 2004_CD ,_, the_DT Board_NNP of_IN Patent_NNP Appeals_NNPS and_CC Interferences_NNPS of_IN the_DT US_NNP Patent_NNP and_CC Trademark_NNP Office_NNP PTO_NNP held_VBD that_IN both_DT Serono_NNP and_CC Cell_NNP Genesys_NNPS were_VBD entitled_VBN to_TO certain_JJ claims_NNS in_IN their_PRP$ respective_JJ patent_NN and_CC patent_NN application_NN ,_, and_CC Serono_NNP and_CC Cell_NNP Genesys_NNP each_DT appealed_VBD the_DT decision_NN of_IN the_DT interference_NN to_TO the_DT US_NNP District_NNP Court_NNP of_IN Massachusetts_NNP and_CC the_DT US_NNP District_NNP Court_NNP of_IN the_DT District_NNP of_IN Columbia_NNP ,_, respectively_RB ._.
TKT_NNP was_VBD not_RB a_DT party_NN to_TO this_DT interference_NN ._.
In_IN August_NNP 2004_CD ,_, Serono_NNP served_VBD TKT_NNP with_IN an_DT amended_VBN complaint_NN in_IN the_DT appeal_NN of_IN the_DT PTO_NNP decision_NN that_WDT was_VBD filed_VBN in_IN the_DT US_NNP District_NNP Court_NNP of_IN Massachusetts_NNP ._.
The_DT amended_VBN complaint_NN alleges_VBZ that_IN TKT_NNP infringes_VBZ Seronos_NNP 071_CD Patent_NN ._.
In_IN August_NNP 2005_CD ,_, the_DT US_NNP District_NNP Court_NNP of_IN Massachusetts_NNP severed_VBD and_CC stayed_VBD the_DT infringement_NN action_NN pending_VBG resolution_NN of_IN the_DT interference_NN claim_NN at_IN the_DT District_NNP Court_NNP level_NN ._.
Appraisal_NN rights_NNS In_IN connection_NN with_IN the_DT Groups_NNS merger_NN with_IN TKT_NNP ,_, former_JJ holders_NNS of_IN approximately_RB 11.7_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN submitted_VBN written_VBN demands_NNS to_TO the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP for_IN appraisal_NN of_IN these_DT shares_NNS and_CC ,_, as_IN a_DT result_NN ,_, elected_VBN not_RB to_TO accept_VB the_DT $_$ 37_CD per_IN share_NN merger_NN consideration_NN ._.
To_TO the_DT extent_NN that_IN the_DT remaining_VBG demands_NNS were_VBD validly_RB asserted_VBN in_IN accordance_NN with_IN the_DT applicable_JJ requirements_NNS of_IN Delaware_NNP law_NN and_CC the_DT former_JJ holders_NNS perfect_JJ their_PRP$ rights_NNS thereunder_NN ,_, such_JJ former_JJ holders_NNS will_MD be_VB entitled_VBN to_TO receive_VB the_DT fair_JJ value_NN of_IN these_DT shares_NNS as_IN determined_VBN by_IN the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP ._.
This_DT could_MD change_VB if_IN the_DT Group_NNP is_VBZ required_VBN to_TO pay_VB a_DT different_JJ amount_NN of_IN consideration_NN in_IN respect_NN of_IN the_DT approximately_RB 11.3_CD million_CD shares_NNS for_IN which_WDT holders_NNS have_VBP asserted_VBN appraisal_NN rights_NNS ._.
Until_IN such_JJ time_NN as_IN the_DT appraisal_NN process_NN is_VBZ complete_JJ ,_, the_DT Group_NNP is_VBZ unable_JJ to_TO determine_VB the_DT final_JJ extent_NN of_IN its_PRP$ liability_NN ._.
Class_NN action_NN shareholder_NN suit_NN In_IN January_NNP and_CC February_NNP 2003_CD ,_, various_JJ parties_NNS filed_VBD purported_JJ class_NN action_NN lawsuits_NNS against_IN TKT_NNP and_CC Richard_NNP Selden_NNP ,_, TKTs_NNP former_JJ Chief_NNP Executive_NNP Officer_NNP ,_, in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP ._.
The_DT complaints_NNS generally_RB allege_VBP securities_NNS fraud_NN during_IN the_DT period_NN from_IN January_NNP 2001_CD through_IN January_NNP 2003_CD ._.
Each_DT of_IN the_DT complaints_NNS asserts_VBZ claims_NNS under_IN Section_NN 10_CD b_NN of_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD ,_, Rule_NNP 10b-5_JJ promulgated_VBN thereunder_NN ,_, and_CC Section_NNP 20_CD a_DT of_IN the_DT Exchange_NNP Act_NNP ,_, and_CC alleges_VBZ that_IN TKT_NNP and_CC its_PRP$ officers_NNS made_VBD false_JJ and_CC misleading_JJ statements_NNS and_CC failed_VBD to_TO disclose_VB material_NN information_NN concerning_VBG the_DT status_NN and_CC progress_NN for_IN obtaining_VBG United_NNP States_NNPS marketing_NN approval_NN of_IN TKTs_NNS REPLAGAL_NNP product_NN to_TO treat_VB Fabry_NNP Disease_NNP during_IN that_DT period_NN ._.
In_IN March_NNP 2003_CD ,_, various_JJ plaintiffs_NNS filed_VBD motions_NNS to_TO consolidate_VB ,_, to_TO appoint_VB lead_JJ plaintiff_NN ,_, and_CC to_TO approve_VB plaintiffs_NNS selections_NNS of_IN lead_NN plaintiffs_NNS counsel_NN ._.
In_IN April_NNP 2003_CD ,_, various_JJ plaintiffs_NNS filed_VBD a_DT Joint_NNP Stipulation_NNP and_CC Proposed_NNP Order_NNP of_IN Lead_JJ Plaintiff_NNP Applicants_NNPS to_TO Consolidate_VB Actions_NNS ,_, to_TO Appoint_VB Lead_JJ Plaintiffs_NNS and_CC to_TO Approve_VB Lead_JJ Plaintiffs_NNS Selection_NN of_IN Lead_JJ Counsel_NNP ,_, Executive_NNP Committee_NNP and_CC Liaison_NNP Counsel_NNP ._.
In_IN April_NNP 2003_CD ,_, the_DT Court_NNP endorsed_VBD the_DT Proposed_NNP Order_NNP ,_, thereby_RB consolidating_VBG the_DT various_JJ matters_NNS under_IN one_CD matter_NN :_: In_IN re_NN Transkaryotic_NNP Therapies_NNPS ,_, Inc._NNP ._.
Securities_NNP Litigation_NNP ,_, C._NNP A._NNP In_NNP July_NNP 2003_CD ,_, the_DT plaintiffs_NNS filed_VBD a_DT Consolidated_NNP and_CC Amended_NNP Class_NNP Action_NNP Complaint_NNP the_DT Amended_NNP Complaint_NNP against_IN TKT_NNP :_: Dr_NNP Selden_NNP :_: Daniel_NNP Geffken_NNP ,_, TKTs_NNP former_JJ Chief_NNP Financial_NNP Officer_NNP :_: Walter_NNP Gilbert_NNP ,_, Jonathan_NNP S._NNP Leff_NNP ,_, Rodman_NNP W._NNP Moorhead_NNP ,_, III_NNP ,_, and_CC Wayne_NNP P._NNP Yetter_NNP ,_, then_RB members_NNS of_IN TKTs_NNP Board_NNP of_IN Directors_NNS :_: William_NNP R._NNP Miller_NNP and_CC James_NNP E._NNP Thomas_NNP ,_, former_JJ members_NNS of_IN TKTs_NNP Board_NNP of_IN Directors_NNS :_: and_CC SG_NNP Cowen_NNP Securities_NNP Corporation_NNP ,_, Deutsche_NNP Bank_NNP Securities_NNP Inc._NNP ._.
Pacific_NNP Growth_NNP Equities_NNPS ,_, Inc._NNP and_CC Leerink_NNP Swann_NNP &_CC Company_NNP ,_, underwriters_NNS of_IN TKTs_NNS common_JJ stock_NN in_IN prior_JJ public_JJ offerings_NNS ._.
98_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 99_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 35_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD The_DT Amended_NNP Complaint_NNP alleges_VBZ securities_NNS fraud_NN during_IN the_DT period_NN from_IN January_NNP 4_CD ,_, 2001_CD ,_, through_IN January_NNP 10_CD ,_, 2003_CD ._.
The_DT Amended_NNP Complaint_NNP alleges_VBZ that_IN the_DT defendants_NNS made_VBD false_JJ and_CC misleading_JJ statements_NNS and_CC failed_VBD to_TO disclose_VB material_NN information_NN concerning_VBG the_DT status_NN and_CC progress_NN for_IN obtaining_VBG United_NNP States_NNPS marketing_NN approval_NN of_IN REPLAGAL_NNP during_IN that_DT period_NN ._.
The_DT Amended_NNP Complaint_NNP asserts_VBZ claims_NNS against_IN Dr_NNP Selden_NNP and_CC TKT_NNP under_IN Section_NNP 10_CD b_NN of_IN the_DT Exchange_NNP Act_NNP and_CC Rule_NNP 10b-5_JJ promulgated_VBN thereunder_NN :_: and_CC against_IN Dr_NNP Selden_NNP under_IN Section_NNP 20_CD a_DT of_IN the_DT Exchange_NNP Act_NNP ._.
The_DT Amended_NNP Complaint_NNP also_RB asserts_VBZ claims_NNS based_VBN on_IN TKTs_NNS public_JJ offerings_NNS of_IN June_NNP 29_CD ,_, 2001_CD ,_, December_NNP 18_CD ,_, 2001_CD and_CC December_NNP 26_CD ,_, 2001_CD ,_, against_IN each_DT of_IN the_DT defendants_NNS under_IN Section_NN 11_CD of_IN the_DT Securities_NNP Act_NNP of_IN 1933_CD and_CC against_IN Dr_NNP Selden_NNP under_IN Section_NNP 15_CD of_IN the_DT Securities_NNP Act_NNP :_: and_CC against_IN SG_NNP Cowen_NNP Securities_NNP Corporation_NNP ,_, Deutsche_NNP Bank_NNP Securities_NNP Inc._NNP ._.
Pacific_NNP Growth_NNP Equities_NNPS ,_, Inc._NNP and_CC Leerink_NNP Swann_NNP &_CC Company_NNP under_IN Section_NNP 12_CD a_DT 2_CD of_IN the_DT Securities_NNP Act_NNP ._.
The_DT plaintiffs_NNS seek_VBP equitable_JJ and_CC monetary_JJ relief_NN ,_, an_DT unspecified_JJ amount_NN of_IN damages_NNS ,_, with_IN interest_NN ,_, and_CC attorneys_NNS fees_NNS and_CC costs_NNS ._.
In_IN September_NNP 2003_CD ,_, TKT_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT Amended_NNP Complaint_NNP ._.
A_DT hearing_NN of_IN the_DT motion_NN occurred_VBD in_IN December_NNP 2003_CD ._.
In_IN May_NNP 2004_CD ,_, the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP issued_VBD a_DT Memorandum_NNP of_IN Decision_NNP and_CC Order_NNP denying_VBG in_IN part_NN and_CC granting_VBG in_IN part_NN TKTs_NNS motion_NN to_TO dismiss_VB the_DT purported_JJ class_NN action_NN lawsuit_NN ._.
In_IN the_DT Memorandum_NNP ,_, the_DT Court_NNP found_VBD several_JJ allegations_NNS against_IN TKT_NNP arose_VBD out_IN of_IN forward-looking_JJ statements_NNS protected_VBN by_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT Private_JJ Securities_NNPS Litigation_NNP Reform_NNP Act_NNP of_IN 1995_CD PSLRA_NNP ._.
The_DT Court_NNP dismissed_VBD those_DT statements_NNS as_IN falling_VBG within_IN the_DT PSLRAs_NNP safe_JJ harbor_NN provisions_NNS ._.
The_DT Court_NNP also_RB dismissed_VBD claims_NNS based_VBN on_IN the_DT public_JJ offerings_NNS of_IN June_NNP 29_CD ,_, 2001_CD ,_, and_CC December_NNP 18_CD ,_, 2001_CD ,_, because_IN no_DT plaintiff_NN had_VBD standing_VBG to_TO bring_VB such_JJ claims_NNS ._.
The_DT Court_NNP allowed_VBD all_DT other_JJ allegations_NNS to_TO remain_VB ._.
In_IN June_NNP 2004_CD ,_, TKT_NNP submitted_VBD an_DT unopposed_JJ motion_NN seeking_VBG clarification_NN from_IN the_DT Court_NNP that_IN the_DT Memorandum_NNP dismissed_VBD claims_NNS based_VBN on_IN the_DT first_JJ two_CD offerings_NNS as_IN to_TO all_DT defendants_NNS ._.
The_DT Court_NNP granted_VBD the_DT motion_NN ._.
In_IN July_NNP 2004_CD ,_, the_DT plaintiffs_NNS voluntarily_RB dismissed_VBD all_DT claims_NNS based_VBN on_IN the_DT third_JJ offering_NN because_IN no_DT plaintiff_NN had_VBD standing_VBG to_TO bring_VB such_JJ claims_NNS ._.
The_DT plaintiffs_NNS subsequently_RB filed_VBD a_DT motion_NN seeking_VBG permission_NN to_TO notify_VB certain_JJ TKT_NNP investors_NNS of_IN the_DT dismissal_NN of_IN the_DT claims_NNS based_VBN on_IN the_DT offerings_NNS ,_, and_CC to_TO inform_VB those_DT investors_NNS of_IN their_PRP$ opportunity_NN to_TO intervene_VB in_IN the_DT lawsuit_NN ._.
TKT_NNP filed_VBD an_DT opposition_NN to_TO this_DT motion_NN in_IN July_NNP 2004_CD ._.
A_DT hearing_NN on_IN this_DT motion_NN was_VBD held_VBN in_IN September_NNP 2004_CD ._.
The_DT Court_NNP denied_VBD this_DT motion_NN ._.
TKT_NNP filed_VBD an_DT answer_NN to_TO the_DT Amended_NNP Complaint_NNP in_IN July_NNP 2004_CD ._.
The_DT plaintiffs_NNS then_RB filed_VBD a_DT motion_NN for_IN class_NN certification_NN in_IN July_NNP 2004_CD ._.
TKT_NNP filed_VBD an_DT opposition_NN to_TO this_DT motion_NN in_IN March_NNP 2005_CD ,_, and_CC the_DT plaintiffs_NNS filed_VBD a_DT reply_NN in_IN April_NNP 2005_CD ._.
A_DT hearing_NN on_IN class_NN certification_NN was_VBD held_VBN in_IN April_NNP 2005_CD ._.
Following_VBG that_DT hearing_NN ,_, TKT_NNP filed_VBD a_DT supplemental_JJ brief_NN in_IN opposition_NN to_TO the_DT motion_NN for_IN class_NN certification_NN and_CC the_DT plaintiffs_NNS filed_VBD a_DT supplemental_JJ brief_NN in_IN support_NN of_IN the_DT motion_NN ._.
In_IN November_NNP 2005_CD ,_, the_DT Court_NNP granted_VBD the_DT plaintiffs_NNS motion_NN for_IN class_NN certification_NN ._.
On_IN September_NNP 14_CD ,_, 2005_CD ,_, the_DT plaintiffs_NNS filed_VBD a_DT Notice_NNP of_IN Related_NNP Case_NNP Pursuant_NNP to_TO Local_JJ Rule_NNP 40.1_CD G_NNP ,_, in_IN which_WDT they_PRP appeared_VBD to_TO seek_VB reassignment_NN of_IN a_DT matter_NN filed_VBN on_IN September_NNP 1_CD ,_, 2005_CD ,_, entitled_VBN Securities_NNP and_CC Exchange_NNP Commission_NNP v._CC Richard_NNP B._NNP Selden_NNP ,_, Civil_NNP Action_NNP No._NN ._.
the_DT SEC_NNP Action_NNP ,_, to_TO the_DT Court_NNP considering_VBG this_DT matter_NN ._.
On_IN September_NNP 15_CD ,_, 2005_CD ,_, the_DT defendants_NNS filed_VBD a_DT response_NN to_TO the_DT notice_NN ,_, opposing_VBG reassignment_NN of_IN the_DT SEC_NNP Action_NNP ._.
On_IN October_NNP 7_CD ,_, 2005_CD ,_, the_DT plaintiffs_NNS filed_VBD a_DT memorandum_NN in_IN response_NN to_TO the_DT defendants_NNS response_NN ._.
On_IN October_NNP 21_CD ,_, 2005_CD ,_, the_DT Court_NNP entered_VBD an_DT Order_NN ,_, which_WDT stated_VBD that_IN it_PRP did_VBD not_RB deem_VB the_DT cases_NNS related_VBN under_IN Local_JJ Rule_NNP 40.1_CD ._.
The_DT Group_NNP is_VBZ obligated_VBN to_TO indemnify_VB Dr_NNP Selden_NNP for_IN his_PRP$ costs_NNS incurred_VBN in_IN connection_NN with_IN the_DT SEC_NNP Action_NNP ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 99_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 100_CD Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS 36_CD Principal_NN subsidiaries_NNS The_DT Company_NN and_CC the_DT Group_NNP have_VBP investments_NNS in_IN the_DT following_JJ subsidiary_NN undertakings_NNS which_WDT principally_RB affected_VBD the_DT results_NNS or_CC net_JJ assets_NNS of_IN the_DT Group_NNP ._.
To_TO avoid_VB a_DT statement_NN of_IN excessive_JJ length_NN ,_, details_NNS of_IN investments_NNS which_WDT are_VBP not_RB significant_JJ have_VBP been_VBN omitted_VBN ._.
Country_NN Principal_NN activity_NN Holding_VBG %_NN Shire_NNP LLC_NNP US_NNP Licensing_NNP ,_, development_NN ,_, production_NN and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP US_NNP ,_, Inc._NNP ._.
US_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP France_NNP SA_NNP France_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co._NNP ._.
KG_NNP Germany_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Italia_NNP SpA_NNP Italy_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Iberia_NNP SL_NNP Spain_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Group_NNP Limited_NNP UK_NNP Holding_NNP Company_NNP 100_CD %_NN Shire_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
US_NNP Management_NNP services_NNS company_NN 100_CD %_NN Shire_NNP Development_NNP ,_, Inc._NNP ._.
US_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Regulatory_NNP ,_, Inc._NNP ._.
US_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Ireland_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP BioChem_NNP ,_, Inc._NNP ._.
Canada_NNP Marketing_NNP ,_, research_NN and_CC development_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP International_NNP Licensing_NNP BV_NNP Netherlands_NNP Licensing_NNP and_CC development_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceutical_NNP Development_NNP Limited_NNP UK_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP US_NNP Development_NNP ,_, Inc._NNP ._.
US_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN Shire_NNP Finance_NNP Limited_NNP Cayman_NNP Islands_NNP Issuer_NNP of_IN convertible_JJ notes_NNS 100_CD %_NN Shire_NNP US_NNP Manufacturing_NNP ,_, Inc._NNP ._.
US_NNP Manufacturer_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Human_NNP Genetic_NNP Therapies_NNPS ,_, Inc._NNP formerly_RB known_VBN as_IN Transkaryotic_NNP Therapies_NNPS ,_, Inc._NNP ._.
US_NNP Marketing_NNP ,_, research_NN and_CC development_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS 100_CD %_NN TKT_NNP Europe_NNP AB_NNP Sweden_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Held_VBN directly_RB by_IN Shire_NNP plc._NN ._.
All_DT subsidiary_NN undertakings_NNS have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
Country_NN of_IN incorporation_NN or_CC principal_NN business_NN address_NN ._.
37_CD Employees_NNS ,_, directors_NNS and_CC key_JJ management_NN Staff_NN The_DT average_JJ monthly_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD Number_NNP Number_NNP Manufacturing_NNP and_CC distribution_NN 384_CD 358_CD Sales_NNS and_CC marketing_NN 994_CD 837_CD General_NNP and_CC administrative_JJ 300_CD 265_CD Research_NNP and_CC development_NN 412_CD 432_CD 2,090_CD 1,892_CD Aggregate_NNP remuneration_NN of_IN Directors_NNS The_DT total_JJ amounts_NNS for_IN remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Emoluments_NNP 4,289_CD 4,751_CD Post-employment_NN benefits_NNS 488_CD 450_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 159_CD Termination_NN benefits_NNS 1,172_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 194_CD 216_CD 4,971_CD 6,748_CD No_DT fees_NNS were_VBD payable_JJ to_TO third_JJ parties_NNS in_IN respect_NN of_IN Directors_NNS services_NNS for_IN either_DT year_NN ._.
100_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 101_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 37_CD Employees_NNS ,_, directors_NNS and_CC key_JJ management_NN continued_VBD The_DT numbers_NNS of_IN Directors_NNS who_WP were_VBD members_NNS of_IN Group_NNP retirement_NN schemes_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD Number_NNP Number_NNP Defined_NNP contribution_NN schemes_NNS 2_CD 3_CD Defined_VBN benefit_NN scheme_NN SERP_NNP 1_CD 1_CD The_DT above_JJ amounts_NNS for_IN remuneration_NN include_VBP the_DT following_VBG in_IN respect_NN of_IN the_DT highest_JJS paid_VBN Director_NNP :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Aggregate_JJ emoluments_NNS 2,286_CD 2,601_CD Pension_NN contributions_NNS 323_CD 227_CD 2,609_CD 2,828_CD Aggregate_NNP remuneration_NN of_IN key_JJ management_NN The_DT total_JJ amounts_NNS for_IN remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Salaries_NNS and_CC other_JJ short-term_JJ employee_NN benefits_NNS 12,133_CD 13,242_CD Post-employment_NN benefits_NNS 1,189_CD 1,147_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 538_CD Termination_NN benefits_NNS 5,225_CD Share-based_JJ payments_NNS 5,159_CD 3,027_CD 18,481_CD 23,179_CD The_DT key_JJ management_NN figures_NNS given_VBN above_IN include_VBP Directors_NNS ._.
38_CD Related-party_JJ transactions_NNS Professional_JJ fees_NNS The_DT Group_NNP incurred_VBD professional_JJ fees_NNS with_IN Stikeman_NNP Elliott_NNP ,_, a_DT law_NN firm_NN in_IN which_WDT the_DT Hon_NNP James_NNP Grant_NNP ,_, a_DT Non-Executive_JJ Director_NNP of_IN Shire_NNP ,_, is_VBZ a_DT partner_NN ,_, totalling_VBG $_$ 0.5_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 2.1_CD million_CD :_: 2003_CD :_: $_$ 0.8_CD million_CD ._.
In_IN April_NNP 2004_CD ,_, the_DT Group_NNP contributed_VBD cash_NN of_IN $_$ 3.7_CD million_CD CAN$_NNP 5.0_CD million_CD and_CC equipment_NN and_CC intellectual_JJ property_NN to_TO the_DT start-up_NN of_IN a_DT new_JJ Canadian-based_JJ pharmaceutical_JJ research_NN and_CC development_NN organization_NN ,_, ViroChem_NNP Pharma_NNP Inc._NNP ._.
ViroChem_NNP ,_, in_IN return_NN for_IN an_DT equity_NN interest_NN and_CC royalties_NNS on_IN the_DT sale_NN of_IN certain_JJ products_NNS subsequently_RB launched_VBN by_IN ViroChem_NNP ._.
In_IN April_NNP 2005_CD ,_, the_DT Group_NNP contributed_VBD cash_NN of_IN $_$ 4.1_CD million_CD CAN$_NNP 5.0_CD million_CD to_TO ViroChem_NNP in_IN return_NN for_IN an_DT additional_JJ equity_NN interest_NN ._.
Dr_NNP Bellini_NNP ,_, a_DT Non-Executive_JJ Director_NNP of_IN BioChem_NNP and_CC ,_, until_IN May_NNP 10_CD ,_, 2003_CD ,_, a_DT Non-Executive_JJ Director_NNP of_IN Shire_NNP ,_, had_VBD ,_, at_IN the_DT time_NN of_IN the_DT transaction_NN ,_, an_DT indirect_JJ substantial_JJ interest_NN in_IN a_DT company_NN ,_, which_WDT is_VBZ a_DT co-investor_NN of_IN ViroChem_NNP ._.
The_DT Group_NNP has_VBZ undertaken_VBN to_TO invest_VB an_DT additional_JJ $_$ 4.3_CD million_CD CAN$_NNP 5.0_CD million_CD in_IN ViroChem_NNP ._.
In_IN October_NNP 2005_CD ,_, the_DT Group_NNP sub-leased_VBD its_PRP$ office_NN premises_NNS in_IN Newport_NNP to_TO Xanodyne_NNP Pharmaceuticals_NNP Inc._NNP ._.
Dr_NNP James_NNP Cavanaugh_NNP ,_, the_DT Non-Executive_NNP Chairman_NNP of_IN Shire_NNP ,_, is_VBZ the_DT Chairman_NNP of_IN Xanodyne_NNP Pharmaceuticals_NNP Inc._NNP ._.
As_IN a_DT result_NN of_IN the_DT transaction_NN the_DT Group_NNP will_MD receive_VB $_$ 7.8_CD million_CD net_NN of_IN inducements_NNS in_IN lease_NN income_NN over_IN the_DT sub-lease_JJ period_NN from_IN Xanodyne_NNP ._.
In_IN April_NNP 2004_CD Shire_NNP BioChem_NNP Inc._NNP ._.
BioChem_NNP ,_, a_DT subsidiary_NN of_IN Shire_NNP ,_, sold_VBD a_DT Canadian_JJ property_NN to_TO NeuroChem_NNP Inc._NNP for_IN $_$ 7.8_CD million_CD CAN$_NNP 10.5_CD million_CD ._.
Dr_NNP Bellini_NNP ,_, a_DT Non-Executive_JJ Director_NNP of_IN Biochem_NNP and_CC ,_, until_IN May_NNP 10_CD ,_, 2003_CD ,_, a_DT Non-Executive_JJ Director_NNP of_IN Shire_NNP and_CC Mr_NNP Nordmann_NNP ,_, a_DT Non-Executive_JJ Director_NNP of_IN Shire_NNP are_VBP both_DT directors_NNS of_IN NeuroChem_NNP Inc._NNP ._.
Dr_NNP Bellini_NNP had_VBD an_DT indirect_JJ substantial_JJ interest_NN in_IN the_DT issued_VBN share_NN capital_NN of_IN Neurochem_NNP Inc._NNP at_IN the_DT time_NN of_IN the_DT transaction_NN ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 101_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 102_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 39_CD Post_NNP balance_NN sheet_NN events_NNS ADDERALL_NNP XR_NNP patent_NN litigation_NN Third_NNP notice_NN letter_NN from_IN Teva_NNP On_IN January_NNP 18_CD ,_, 2006_CD ,_, the_DT Group_NNP received_VBD a_DT third_JJ notice_NN letter_NN from_IN Teva_NNP Pharmaceuticals_NNP USA_NNP ,_, Inc._NNP advising_VBG it_PRP of_IN an_DT amendment_NN to_TO Tevas_NNP existing_VBG ANDA_NNP for_IN generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP ._.
The_DT amendment_NN is_VBZ directed_VBN to_TO an_DT additional_JJ strength_NN of_IN 25mg_JJ ._.
As_IN previously_RB announced_VBN ,_, Tevas_NNP February_NNP 2005_CD notice_NN letter_NN was_VBD directed_VBN only_RB to_TO 10mg_CD and_CC 30mg_CD dosages_NNS and_CC Tevas_NNP June_NNP 2005_CD notice_NN letter_NN was_VBD directed_VBN only_RB to_TO 5mg_CD ,_, 15mg_CD and_CC 20mg_CD dosages_NNS ._.
The_DT Group_NNP is_VBZ currently_RB reviewing_VBG the_DT details_NNS of_IN Tevas_NNP latest_JJS notice_NN letter_NN ._.
Settlement_NNP of_IN Impax_NNP litigations_NNS On_IN January_NNP 19_CD ,_, 2006_CD ,_, the_DT Group_NNP settled_VBD its_PRP$ ADDERALL_NNP XR_NNP patent_NN infringement_NN lawsuits_NNS with_IN Impax_NNP ._.
The_DT litigations_NNS involved_VBN Shire_NNP US_NNP patents_NNS ,_, Nos._NNP ._.
As_IN part_NN of_IN the_DT settlement_NN ,_, Impax_NNP has_VBZ confirmed_VBN that_IN its_PRP$ proposed_VBN generic_JJ ADDERALL_NNP XR_NNP product_NN infringes_VBZ the_DT Groups_NNS 819_CD ,_, 300_CD and_CC 768_CD Patents_NNP and_CC that_IN the_DT three_CD patents_NNS are_VBP valid_JJ and_CC enforceable_JJ ._.
Under_IN the_DT terms_NNS of_IN the_DT settlement_NN ,_, Impax_NNP will_MD be_VB permitted_VBN to_TO market_NN generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP in_IN the_DT US_NNP no_RB later_RB than_IN January_NNP 1_CD ,_, 2010_CD and_CC will_MD pay_VB the_DT Group_NNP a_DT royalty_NN from_IN those_DT sales_NNS ._.
In_IN certain_JJ situations_NNS ,_, such_JJ as_IN the_DT launch_NN of_IN another_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP ,_, Impax_NNP may_MD be_VB permitted_VBN to_TO enter_VB the_DT market_NN as_IN the_DT Groups_NNS authorised_VBD generic_JJ ._.
NRP104_CD On_IN January_NNP 26_CD ,_, 2006_CD ,_, the_DT FDA_NNP accepted_VBD New_NNP Rivers_NNP NDA_NNP for_IN NRP104_NNP for_IN review_NN ._.
This_DT has_VBZ triggered_VBN a_DT $_$ 50_CD million_CD milestone_NN payment_NN by_IN the_DT Group_NNP to_TO New_NNP River_NNP ._.
MESAVANCE_NNP SPD476_NNP The_NNP Group_NNP has_VBZ submitted_VBN applications_NNS for_IN marketing_NN approval_NN to_TO a_DT number_NN of_IN European_JJ regulatory_JJ agencies_NNS and_CC also_RB filed_VBD a_DT New_NNP Drug_NNP Submission_NNP for_IN SPD476_NNP with_IN Health_NNP Canada_NNP ._.
IDB_NNP loan_NN repayment_NN On_IN February_NNP 10_CD ,_, 2006_CD ,_, the_DT Group_NNP received_VBD notice_NN from_IN IDB_NNP that_IN it_PRP intended_VBD to_TO repay_VB in_IN full_JJ all_DT of_IN its_PRP$ loan_NN drawings_NNS for_IN injectable_JJ flu_NN development_NN of_IN $_$ 70.6_CD million_CD ,_, together_RB with_IN accrued_VBN and_CC capitalized_VBN interest_NN of_IN $_$ 8.1_CD million_CD ._.
The_DT Group_NNP received_VBD the_DT $_$ 78.7_CD million_CD outstanding_JJ on_IN February_NNP 14_CD ,_, 2006_CD ._.
The_DT amounts_NNS outstanding_JJ in_IN respect_NN of_IN IDB_NNP drawings_NNS for_IN pipeline_NN development_NN principal_JJ drawings_NNS $_$ 29.4_CD million_CD ,_, are_VBP unaffected_JJ by_IN this_DT repayment_NN ._.
40_CD Explanation_NN of_IN transition_NN to_TO IFRS_NNP This_DT is_VBZ the_DT first_JJ year_NN that_IN the_DT Company_NN has_VBZ presented_VBN its_PRP$ financial_JJ statement_NN under_IN IFRS_NNP ._.
The_DT following_VBG disclosures_NNS are_VBP required_VBN in_IN the_DT year_NN of_IN transition_NN ._.
The_DT last_JJ financial_JJ statements_NNS under_IN UK_NNP GAAP_NNP were_VBD for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2004_CD and_CC the_DT date_NN of_IN transition_NN to_TO IFRS_NNP was_VBD therefore_RB January_NNP 1_CD ,_, 2004_CD ._.
Exemptions_NNS from_IN full_JJ retrospective_JJ application_NN elected_VBN by_IN the_DT Group_NNP The_NNP Group_NNP has_VBZ elected_VBN to_TO apply_VB the_DT following_VBG optional_JJ exemptions_NNS from_IN full_JJ retrospective_JJ application_NN ._.
Business_NNP combinations_NNS exemption_NN The_DT Group_NNP has_VBZ applied_VBN the_DT business_NN combination_NN exemption_NN in_IN IFRS_NNP 1_CD ._.
It_PRP has_VBZ not_RB restated_VBN business_NN combinations_NNS that_WDT took_VBD place_NN prior_RB to_TO the_DT January_NNP 1_CD ,_, 2004_CD transition_NN date_NN in_IN accordance_NN with_IN IFRS_NNP 3_CD ,_, Business_NNP Combinations_NNPS ._.
Cumulative_JJ translation_NN differences_NNS exemption_NN The_DT Group_NNP has_VBZ elected_VBN to_TO set_VB the_DT previously_RB accumulated_VBN cumulative_JJ translation_NN differences_NNS arising_VBG on_IN the_DT translation_NN and_CC consolidation_NN of_IN results_NNS of_IN foreign_JJ operations_NNS and_CC balance_NN sheets_NNS denominated_VBN in_IN foreign_JJ currencies_NNS to_TO zero_CD at_IN January_NNP 1_CD ,_, 2004_CD ._.
This_DT exemption_NN has_VBZ been_VBN applied_VBN to_TO all_DT subsidiaries_NNS in_IN accordance_NN with_IN IFRS_NNP 1_CD ._.
Exemption_NN from_IN restatement_NN of_IN comparatives_NNS for_IN IAS_NNP 32_CD and_CC IAS_NNP 39_CD The_NNP Group_NNP has_VBZ elected_VBN to_TO apply_VB this_DT exemption_NN ._.
It_PRP applies_VBZ UK_NNP GAAP_NNP rules_NNS to_TO derivatives_NNS ,_, financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS and_CC to_TO hedging_VBG relationships_NNS for_IN the_DT 2004_CD comparative_JJ information_NN ._.
The_DT adjustments_NNS required_VBN for_IN differences_NNS between_IN UK_NNP GAAP_NNP and_CC IAS_NNP 32_CD and_CC IAS_NNP 39_CD are_VBP determined_VBN and_CC recognized_VBN at_IN January_NNP 1_CD ,_, 2005_CD ._.
Designation_NN of_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS exemption_NN The_DT Group_NNP reclassified_VBD various_JJ equity_NN investments_NNS as_IN available-for-sale_JJ investments_NNS ._.
The_DT adjustments_NNS relating_VBG to_TO IAS_NNP 32_CD and_CC IAS_NNP 39_CD are_VBP required_VBN and_CC determined_VBN at_IN the_DT opening_NN balance_NN sheet_NN date_NN of_IN January_NNP 1_CD ,_, 2005_CD the_DT IAS_NNP 32_CD and_CC IAS_NNP 39_CD transition_NN date_NN ._.
Share-based_JJ payment_NN transaction_NN exemption_NN The_DT Group_NNP has_VBZ elected_VBN to_TO apply_VB the_DT share-based_JJ payment_NN exemption_NN ._.
It_PRP applied_VBD IFRS_NNP 2_CD from_IN January_NNP 1_CD ,_, 2004_CD to_TO those_DT options_NNS that_WDT were_VBD issued_VBN after_IN November_NNP 7_CD ,_, 2002_CD but_CC that_WDT have_VBP not_RB vested_VBN by_IN January_NNP 1_CD ,_, 2005_CD ._.
Fair_NNP value_NN measurement_NN of_IN financial_JJ assets_NNS or_CC liabilities_NNS at_IN initial_JJ recognition_NN The_DT Group_NNP has_VBZ applied_VBN the_DT exemption_NN offered_VBN by_IN the_DT revision_NN of_IN IAS_NNP 39_CD on_IN the_DT initial_JJ recognition_NN of_IN the_DT financial_JJ instruments_NNS measured_VBN at_IN fair_JJ value_NN through_IN the_DT income_NN statement_NN where_WRB there_EX is_VBZ no_DT active_JJ market_NN ._.
102_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 103_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 40_CD Explanation_NN of_IN transition_NN to_TO IFRS_NNP continued_VBD Exceptions_NNS from_IN full_JJ retrospective_JJ application_NN followed_VBN by_IN the_DT Group_NNP The_NNP Group_NNP has_VBZ applied_VBN the_DT following_VBG mandatory_JJ exceptions_NNS from_IN retrospective_JJ application_NN :_: fide-recognition_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS exception_NN Financial_JJ assets_NNS and_CC liabilities_NNS fide-recognised_VBN before_IN January_NNP 1_CD ,_, 2004_CD are_VBP not_RB re-recognised_VBN under_IN IFRS_NNP ._.
The_DT application_NN of_IN the_DT exemption_NN from_IN restating_VBG comparatives_NNS for_IN IAS_NNP 32_CD and_CC IAS_NNP 39_CD means_VBZ that_IN the_DT Group_NNP should_MD recognize_VB from_IN January_NNP 1_CD ,_, 2005_CD any_DT financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS derecognised_VBD since_IN January_NNP 1_CD ,_, 2004_CD that_WDT do_VBP not_RB meet_VB the_DT IAS_NNP 39_CD fide-recognition_NN criteria_NNS ._.
Management_NNP chose_VBD not_RB to_TO apply_VB the_DT IAS_NNP 39_CD fide-recognition_NN criteria_NNS to_TO an_DT earlier_JJR date_NN ._.
Hedge_VB accounting_NN exception_NN The_DT Group_NNP is_VBZ able_JJ to_TO claim_VB hedge_JJ accounting_NN from_IN January_NNP 1_CD ,_, 2005_CD ,_, only_RB if_IN the_DT hedge_NN relationship_NN meets_VBZ all_PDT the_DT hedge_NN accounting_NN criteria_NNS under_IN IAS_NNP 39_CD ._.
Estimates_NNS exception_NN Estimates_NNS under_IN IFRS_NNP at_IN January_NNP 1_CD ,_, 2004_CD should_MD be_VB consistent_JJ with_IN estimates_NNS made_VBN for_IN the_DT same_JJ date_NN under_IN previous_JJ GAAP_NNP ,_, unless_IN there_EX is_VBZ evidence_NN that_IN those_DT estimates_NNS were_VBD in_IN error_NN ._.
Assets_NNS held_VBD for_IN sale_NN and_CC discontinued_VBN operations_NNS exception_NN The_DT Group_NNP elected_VBD to_TO apply_VB IFRS_NNP 5_CD ,_, Non-Current_NNP Assets_NNPS Held_NNP for_IN Sale_NNP and_CC Discontinued_NNP Operations_NNP retrospectively_RB as_IN all_DT required_VBN information_NN was_VBD available_JJ at_IN the_DT time_NN of_IN disposal_NN of_IN the_DT vaccines_NNS business_NN ._.
Only_RB a_DT reclassification_NN adjustment_NN was_VBD required_VBN as_RB at_IN January_NNP 1_CD ,_, 2004_CD ._.
Reconciliations_NNS between_IN IFRS_NNP and_CC UK_NNP GAAP_NNP Reconciliation_NNP of_IN equity_NN at_IN December_NNP 31_CD ,_, 2004_CD and_CC January_NNP 1_CD ,_, 2004_CD At_IN December_NNP 31_CD At_IN January_NNP 1_CD ,_, Notes_NNP 2004_CD 2004_CD Equity_NN under_IN UK_NNP GAAP_NNP in_IN 000_CD 2,232,211_CD 2,308,500_CD $_$ 000_CD $_$ 000_CD Equity_NN under_IN UK_NNP GAAP_NNP restated_VBN in_IN US_NNP $_$ 000_CD 4,285,625_CD 4,132,445_CD Goodwill_NNP restated_VBN to_TO acquirees_NNS functional_JJ currency_NN a_DT 231,308_CD 63,244_CD Reverse_VB goodwill_NN amortization_NN and_CC impairment_NN in_IN 2004_CD b_NN 298,058_CD Goodwill_NNP impairment_NN charge_NN on_IN restated_VBN basis_NN c_NN 132,198_CD Dividends_NNPS not_RB recognized_VBN as_IN a_DT liability_NN d_SYM 19,107_CD Intangible_JJ assets_NNS recognized_VBN under_IN IAS_NNP 38_CD e_SYM 11,465_CD 11,465_CD Impairment_NN of_IN intangibles_NNS above_IN in_IN the_DT year_NN f_SYM 6,149_CD Adjustment_NNP to_TO deferred_VBN tax_NN g_NN 332_CD 13,209_CD Equity_NN restated_VBN under_IN IFRS_NNP 4,244,932_CD 4,093,875_CD Reconciliation_NNP of_IN net_JJ income_NN for_IN the_DT year_NN 12_CD months_NNS to_TO December_NNP 31_CD ,_, Notes_NNP 2004_CD Loss_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP 000_CD 13,431_CD $_$ 000_CD Loss_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP restated_VBN in_IN US_NNP $_$ 000_CD 34,861_CD Reverse_VB goodwill_NN amortization_NN and_CC impairment_NN in_IN 2004_CD b_NN 298,058_CD Goodwill_NNP impairment_NN charge_NN on_IN restated_VBN basis_NN c_NN 132,198_CD Impairment_NN of_IN intangibles_NNS recognized_VBN under_IN IFRS_NNP f_SYM 6,149_CD Fair_NNP value_NN of_IN share-based_JJ payments_NNS h_VBP 15,464_CD Adjustment_NNP to_TO deferred_VBN tax_NN g_NN 12,877_CD Profit_NN for_IN the_DT period_NN restated_VBN under_IN IFRS_NNP 96,509_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 103_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 104_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 40_CD Explanation_NN of_IN transition_NN to_TO IFRS_NNP continued_VBD Explanation_NN of_IN material_NN adjustments_NNS to_TO equity_NN at_IN December_NNP 31_CD ,_, 2004_CD and_CC January_NNP 1_CD ,_, 2004_CD and_CC to_TO profit_VB for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2004_CD ._.
Note_VB a_DT :_: IAS_NNP 21_CD ,_, The_DT Effects_NNPS of_IN Changes_NNS in_IN Foreign_NNP Exchange_NNP Rates_NNP Under_IN UK_NNP GAAP_NNP the_DT Group_NNP capitalized_VBD and_CC amortised_VBD goodwill_NN and_CC certain_JJ intangible_JJ assets_NNS over_IN the_DT period_NN of_IN their_PRP$ expected_VBN useful_JJ lives_NNS ._.
Goodwill_NN and_CC intangible_JJ assets_NNS purchased_VBD prior_RB to_TO January_NNP 1,1998_CD ,_, were_VBD written-off_JJ in_IN the_DT year_NN of_IN acquisition_NN as_IN a_DT movement_NN in_IN profits_NNS recognized_VBN directly_RB in_IN equity_NN ._.
As_IN permitted_VBN under_IN IFRS_NNP 1_CD ,_, the_DT Group_NNP has_VBZ elected_VBN to_TO apply_VB IAS_NNP 21_CD retrospectively_RB to_TO goodwill_NN arising_VBG in_IN all_DT business_NN combinations_NNS that_WDT occurred_VBD before_IN the_DT date_NN of_IN transition_NN to_TO IFRS_NNP ._.
Under_IN UK_NNP GAAP_NNP ,_, goodwill_NN was_VBD held_VBN in_IN the_DT functional_JJ currency_NN of_IN the_DT acquirer_NN ._.
Applying_VBG IAS_NNP 21_CD retrospectively_RB expresses_VBZ that_IN goodwill_NN in_IN the_DT acquirees_NNS functional_JJ currency_NN ._.
The_DT adjustment_NN reflects_VBZ the_DT translation_NN of_IN goodwill_NN from_IN the_DT acquirers_NNS functional_JJ currency_NN into_IN the_DT acquirees_NNS functional_JJ currency_NN ._.
Note_VB b_NN :_: IFRS_NNS 3_CD ,_, Business_NNP Combinations_NNPS Under_IN IFRS_NNP 3_CD ,_, from_IN January_NNP 1_CD ,_, 2004_CD the_DT Group_NNP has_VBZ no_RB longer_RBR systematically_RB amortised_VBN goodwill_NN ,_, but_CC has_VBZ instead_RB tested_VBN these_DT assets_NNS for_IN impairment_NN on_IN at_IN least_JJS an_DT annual_JJ basis_NN ._.
The_DT amortization_NN charge_NN under_IN UK_NNP GAAP_NNP for_IN goodwill_NN in_IN 2004_CD was_VBD $_$ 298.1_CD million_CD and_CC consequently_RB this_DT amount_NN has_VBZ been_VBN reversed_VBN for_IN IFRS_NNP ._.
On_IN disposal_NN ,_, goodwill_NN acquired_VBN and_CC written_VBN off_RP on_IN acquisition_NN prior_RB to_TO January_NNP 1_CD ,_, 1998_CD will_MD no_RB longer_RB be_VB reinstated_VBN as_IN part_NN of_IN the_DT profit_NN or_CC loss_NN on_IN disposal_NN ._.
Note_VB c_NN :_: IAS_NNP 36_CD ,_, Impairment_NN of_IN Assets_NNPS Following_VBG the_DT reversal_NN of_IN goodwill_NN amortization_NN as_IN described_VBN in_IN note_NN b_NN above_IN ,_, an_DT adjustment_NN was_VBD required_VBN to_TO reduce_VB the_DT value_NN of_IN goodwill_NN created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP which_WDT was_VBD impaired_VBN ,_, to_TO its_PRP$ recoverable_JJ amount_NN ._.
Note_NN d_SYM :_: IAS_NNP 10_CD ,_, Events_NNS After_IN the_DT Balance_NNP Sheet_NNP Date_NNP Under_IN IFRS_NNP interim_JJ dividends_NNS declared_VBD but_CC unpaid_JJ do_VBP not_RB meet_VB the_DT definition_NN of_IN a_DT liability_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP accounted_VBD for_IN such_JJ dividends_NNS as_IN a_DT transaction_NN in_IN the_DT accounting_NN period_NN in_IN which_WDT the_DT dividend_NN was_VBD declared_VBN ,_, and_CC a_DT liability_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT declared_VBN but_CC unpaid_JJ interim_JJ dividends_NNS for_IN 2004_CD amounted_VBD to_TO 3.85_CD c_NN per_IN 5p_JJ ordinary_JJ share_NN ,_, totalling_VBG $_$ 19.1_CD million_CD ._.
At_IN January_NNP 1_CD ,_, 2004_CD there_EX were_VBD no_DT declared_VBN but_CC unpaid_JJ dividends_NNS ._.
The_DT amount_NN at_IN December_NNP 31_CD ,_, 2004_CD has_VBZ been_VBN reclassified_VBN from_IN current_JJ liabilities_NNS to_TO retained_VBN profit_NN ._.
Note_NN e_SYM :_: IAS_NNP 38_CD ,_, Intangible_NNP Assets_NNPS Under_IN IAS_NNP 38_CD ,_, when_WRB the_DT recognition_NN criteria_NNS are_VBP met_VBN intangible_JJ assets_NNS are_VBP capitalized_VBN and_CC amortised_VBN over_IN their_PRP$ useful_JJ economic_JJ life_NN from_IN product_NN launch_NN ._.
Payments_NNS to_TO in-license_JJ products_NNS and_CC compounds_NNS from_IN external_JJ third_JJ parties_NNS ,_, generally_RB taking_VBG the_DT form_NN of_IN up-front_JJ payments_NNS and_CC milestones_NNS ,_, are_VBP capitalized_VBN ._.
Under_IN UK_NNP GAAP_NNP ,_, Group_NNP policy_NN was_VBD to_TO capitalize_VB only_RB those_DT intangible_JJ assets_NNS with_IN an_DT immediate_JJ defined_VBN revenue_NN stream_NN acquired_VBN for_IN valuable_JJ consideration_NN ._.
Following_VBG a_DT review_NN of_IN the_DT Groups_NNS intangible_JJ purchases_NNS from_IN external_JJ third_JJ parties_NNS ,_, $_$ 11.5_CD million_CD of_IN payments_NNS to_TO in-license_JJ products_NNS and_CC compounds_NNS previously_RB expensed_VBN under_IN UK_NNP GAAP_NNP ,_, have_VBP been_VBN added_VBN to_TO the_DT balance_NN sheet_NN under_IN IFRS_NNP ._.
Note_NN f_SYM :_: IAS_NNP 36_CD ,_, Impairment_NN of_IN Assets_NNPS Following_VBG the_DT addition_NN to_TO the_DT balance_NN sheet_NN of_IN the_DT intangibles_NNS described_VBN in_IN note_NN e_SYM above_IN ,_, a_DT review_NN identified_VBD that_IN following_VBG management_NN decisions_NNS to_TO terminate_VB certain_JJ research_NN and_CC development_NN projects_NNS in_IN 2004_CD ,_, some_DT of_IN these_DT assets_NNS were_VBD being_VBG carried_VBN above_IN their_PRP$ recoverable_JJ amount_NN ,_, requiring_VBG an_DT impairment_NN charge_NN of_IN $_$ 6.1_CD million_CD ._.
Note_VB g_NN :_: IAS_NNP 12_CD ,_, Income_NNP Taxes_NNS Under_IN UK_NNP GAAP_NNP the_DT Group_NNP recognized_VBD deferred_VBN tax_NN only_RB on_IN timing_NN differences_NNS that_WDT arose_VBD from_IN the_DT inclusion_NN of_IN gains_NNS and_CC losses_NNS in_IN tax_NN assessments_NNS in_IN periods_NNS different_JJ from_IN those_DT in_IN which_WDT they_PRP were_VBD recognized_VBN in_IN the_DT financial_JJ statements_NNS ._.
Under_IN IFRS_NNP deferred_VBD tax_NN is_VBZ recognized_VBN in_IN respect_NN of_IN all_DT taxable_JJ temporary_JJ differences_NNS arising_VBG between_IN the_DT tax_NN base_NN and_CC the_DT accounting_NN base_NN of_IN balance_NN sheet_NN items_NNS ._.
This_DT means_VBZ that_IN deferred_VBN tax_NN is_VBZ recognized_VBN on_IN certain_JJ temporary_JJ differences_NNS that_WDT would_MD not_RB have_VB given_VBN rise_NN to_TO deferred_VBN tax_NN under_IN UK_NNP GAAP_NNP ._.
The_DT additional_JJ deferred_JJ tax_NN included_VBN in_IN the_DT balance_NN sheet_NN under_IN IFRS_NNP amounted_VBD to_TO a_DT net_JJ movement_NN of_IN $_$ 13.2_CD million_CD as_IN at_IN January_NNP 1_CD ,_, 2004_CD and_CC $_$ 0.3_CD million_CD as_IN at_IN December_NNP 31_CD ,_, 2004_CD ._.
Included_VBN in_IN these_DT amounts_NNS is_VBZ $_$ 13.2_CD million_CD at_IN January_NNP 1_CD ,_, 2004_CD in_IN respect_NN of_IN internal_JJ transfer_NN of_IN assets_NNS and_CC purchases_NNS to_TO in-license_JJ products_NNS and_CC compounds_NNS previously_RB expensed_VBN under_IN UK_NNP GAAP_NNP ,_, but_CC added_VBD to_TO the_DT balance_NN sheet_NN under_IN IFRS_NNP ,_, creating_VBG differences_NNS between_IN the_DT tax_NN and_CC accounting_NN base_NN under_IN IFRS_NNP ._.
Note_VB h_NN :_: IFRS_NNS 2_CD ,_, Share_NN Based_VBD Payments_NNS In_IN accordance_NN with_IN IFRS_NNP 2_CD ,_, the_DT Group_NNP has_VBZ recognized_VBN a_DT charge_NN to_TO income_NN representing_VBG the_DT fair_JJ value_NN of_IN outstanding_JJ employee_NN share_NN options_NNS granted_VBN to_TO employees_NNS ._.
The_DT fair_JJ value_NN has_VBZ been_VBN calculated_VBN using_VBG the_DT Black-Scholes_NNP options_NNS valuation_NN model_NN and_CC is_VBZ charged_VBN to_TO income_NN over_IN the_DT relevant_JJ option_NN vesting_NN periods_NNS ,_, adjusted_VBN to_TO reflect_VB actual_JJ and_CC expected_JJ levels_NNS of_IN vesting_NN ._.
The_DT Group_NNP has_VBZ adopted_VBN the_DT IFRS_NNP 1_CD optional_JJ transitional_JJ arrangements_NNS ,_, which_WDT allow_VBP companies_NNS that_WDT have_VBP previously_RB disclosed_VBN the_DT fair_JJ value_NN charge_NN ,_, to_TO apply_VB IFRS_NNP 2_CD fully_RB retrospectively_RB to_TO all_DT options_NNS granted_VBN after_IN November_NNP 7_CD ,_, 2002_CD but_CC not_RB fully_RB vested_VBN at_IN the_DT relevant_JJ reporting_NN date_NN ._.
As_IN a_DT result_NN ,_, the_DT share-based_JJ payment_NN charge_NN for_IN 2004_CD includes_VBZ all_DT options_NNS granted_VBN after_IN November_NNP 7_CD ,_, 2002_CD and_CC not_RB fully_RB vested_VBN at_IN December_NNP 31_CD ,_, 2003_CD ._.
The_DT operating_NN profit_NN and_CC profit_NN for_IN the_DT year_NN impact_NN in_IN 2004_CD is_VBZ a_DT charge_NN of_IN $_$ 15.5_CD million_CD ._.
The_DT basis_NN of_IN calculation_NN for_IN deferred_VBN taxation_NN is_VBZ the_DT difference_NN between_IN the_DT market_NN price_NN at_IN the_DT date_NN of_IN the_DT financial_JJ statements_NNS and_CC the_DT option_NN exercise_NN price_NN :_: as_IN a_DT result_NN the_DT tax_NN effect_NN will_MD not_RB correlate_VB to_TO the_DT charge_NN ._.
The_DT deferred_JJ tax_NN impact_NN of_IN share-based_JJ payment_NN has_VBZ been_VBN included_VBN in_IN the_DT amounts_NNS described_VBN in_IN Note_NN g_NN above_IN ._.
104_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 105_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 40_CD Explanation_NN of_IN transition_NN to_TO IFRS_NNP continued_VBD Other_JJ material_NN adjustments_NNS affecting_VBG the_DT balance_NN sheet_NN and_CC income_NN statement_NN Software_NNP Under_IN UK_NNP GAAP_NNP the_DT Group_NNP classified_VBD capitalized_JJ costs_NNS incurred_VBN in_IN purchasing_VBG and_CC developing_VBG software_NN as_IN tangible_JJ fixed_JJ assets_NNS ._.
Under_IN IFRS_NNP the_DT Group_NNP has_VBZ reclassified_VBN these_DT costs_NNS as_IN intangible_JJ assets_NNS ,_, in_IN line_NN with_IN IAS_NNP 38_CD ._.
The_DT net_JJ book_NN value_NN of_IN purchased_VBN and_CC internally_RB developed_VBD software_NN as_IN at_IN January_NNP 1_CD ,_, 2004_CD and_CC at_IN December_NNP 31_CD ,_, 2004_CD amounted_VBD to_TO $_$ nil_JJ and_CC $_$ 9.7_CD million_CD respectively_RB ._.
Joint_NNP ventures_NNS and_CC associates_NNS Under_IN UK_NNP GAAP_NNP associates_NNS were_VBD accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ,_, but_CC with_IN the_DT Groups_NNS share_NN of_IN associate_JJ operating_NN profit_NN presented_VBD separately_RB in_IN the_DT income_NN statement_NN ._.
Interest_NN and_CC tax_NN of_IN associates_NNS were_VBD included_VBN within_IN the_DT headings_NNS of_IN interest_NN and_CC tax_NN in_IN the_DT income_NN statement_NN ._.
Under_IN IFRS_NNP the_DT Group_NNP has_VBZ continued_VBN to_TO account_VB for_IN associates_NNS under_IN the_DT equity_NN method_NN ._.
The_DT presentation_NN of_IN the_DT results_NNS of_IN associates_NNS has_VBZ changed_VBN however_RB as_IN IAS_NNP 1_CD ,_, Presentation_NN of_IN Financial_NNP Statements_NNP requires_VBZ that_IN the_DT share_NN of_IN profit_NN or_CC loss_NN after_IN tax_NN from_IN associates_NNS is_VBZ presented_VBN as_IN a_DT separate_JJ item_NN on_IN the_DT face_NN of_IN the_DT income_NN statement_NN as_IN part_NN of_IN profit_NN before_IN tax_NN but_CC below_IN operating_NN profit_NN ._.
There_EX is_VBZ no_DT impact_NN on_IN net_JJ profit_NN as_IN a_DT result_NN of_IN this_DT change_NN ._.
Under_IN UK_NNP GAAP_NNP the_DT Group_NNP accounted_VBD for_IN its_PRP$ own_JJ share_NN of_IN the_DT assets_NNS ,_, liabilities_NNS and_CC cash_NN flows_NNS of_IN the_DT Canadian_JJ commercialization_NN partnership_NN with_IN GSK_NNP ._.
Under_IN IFRS_NNP Shire_NNP has_VBZ accounted_VBN for_IN this_DT partnership_NN as_IN allowed_VBN by_IN IAS_NNP 31_CD ,_, Interests_NNPS in_IN Joint_NNP Ventures_NNP using_VBG the_DT equity_NN method_NN ._.
IAS_NNP 17_CD ,_, Leases_NNP Shire_NNP is_VBZ party_NN to_TO certain_JJ motor_NN vehicle_NN leases_NNS in_IN the_DT US_NNP that_WDT are_VBP classified_VBN as_IN finance_NN leases_NNS under_IN IFRS_NNP ,_, as_IN the_DT leases_NNS contain_VBP clauses_NNS that_WDT effectively_RB pass_VBP risks_NNS and_CC rewards_NNS of_IN ownership_NN as_IN defined_VBN by_IN IAS_NNP 17_CD to_TO the_DT lessee_NN the_DT Group_NNP ._.
At_IN December_NNP 31_CD ,_, 2004_CD the_DT net_NN book_NN value_NN of_IN these_DT vehicles_NNS now_RB recorded_VBN on_IN the_DT balance_NN sheet_NN was_VBD $_$ 6.5_CD million_CD ,_, and_CC a_DT corresponding_JJ finance_NN lease_NN creditor_NN of_IN $_$ 6.5_CD million_CD was_VBD also_RB recorded_VBN ._.
IAS_NNP 21_CD ,_, The_DT Effects_NNPS of_IN Changes_NNS in_IN Foreign_NNP Exchange_NNP Rates_NNP Under_IN IFRS_NNP cumulative_JJ foreign_JJ currency_NN translation_NN differences_NNS arising_VBG on_IN the_DT translation_NN and_CC consolidation_NN of_IN foreign_JJ operations_NNS income_NN statements_NNS and_CC balance_NN sheets_NNS denominated_VBN in_IN foreign_JJ currencies_NNS must_MD be_VB recorded_VBN as_IN a_DT separate_JJ component_NN of_IN equity_NN ._.
Applying_VBG the_DT exemption_NN under_IN IFRS_NNP 1_CD ,_, the_DT Group_NNP has_VBZ measured_VBN and_CC recorded_VBN all_DT cumulative_JJ foreign_JJ currency_NN translation_NN differences_NNS arising_VBG after_IN the_DT transition_NN date_NN of_IN January_NNP 1_CD ,_, 2004_CD ._.
On_IN disposal_NN of_IN a_DT foreign_JJ operation_NN the_DT cumulative_JJ translation_NN differences_NNS will_MD be_VB transferred_VBN to_TO the_DT income_NN statement_NN as_IN part_NN of_IN the_DT gain_NN or_CC loss_NN on_IN disposal_NN ._.
All_DT of_IN the_DT above_JJ changes_NNS have_VBP been_VBN implemented_VBN from_IN January_NNP 1_CD ,_, 2004_CD ._.
From_IN January_NNP 1_CD ,_, 2005_CD the_DT Group_NNP has_VBZ implemented_VBN the_DT following_VBG additional_JJ changes_NNS in_IN accounting_NN policies_NNS ._.
These_DT changes_NNS will_MD be_VB applied_VBN prospectively_RB from_IN January_NNP 1_CD ,_, 2005_CD and_CC will_MD therefore_RB not_RB affect_VB the_DT 2004_CD comparative_JJ information_NN in_IN the_DT Annual_JJ Report_NNP and_CC Accounts_NNPS 2005_CD ._.
IAS_NNP 32_CD ,_, Financial_NNP Instruments_NNPS :_: Disclosure_NN and_CC Presentation_NN and_CC IAS_NNP 39_CD ,_, Financial_NNP Instruments_NNPS :_: Recognition_NN and_CC Measurement_NNP From_IN January_NNP 1_CD ,_, 2005_CD the_DT Group_NNP has_VBZ applied_VBN IAS_NNP 32_CD and_CC IAS_NNP 39_CD ._.
These_DT standards_NNS are_VBP applied_VBN prospectively_RB ,_, and_CC therefore_RB no_DT restatements_NNS are_VBP made_VBN to_TO the_DT income_NN statement_NN for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2004_CD and_CC the_DT balance_NN sheets_NNS as_IN at_IN January_NNP 1_CD ,_, 2004_CD and_CC December_NNP 31_CD ,_, 2004_CD ._.
These_DT standards_NNS have_VBP many_JJ detailed_JJ consequences_NNS :_: however_RB the_DT key_JJ areas_NNS of_IN impact_NN for_IN the_DT Group_NNP are_VBP described_VBN below_IN :_: Non-derivative_JJ financial_JJ assets_NNS and_CC liabilities_NNS Under_IN UK_NNP GAAP_NNP the_DT Group_NNP held_VBD most_RBS non-derivative_JJ financial_JJ assets_NNS on_IN the_DT balance_NN sheet_NN at_IN fair_JJ value_NN ,_, with_IN movements_NNS recognized_VBN in_IN the_DT income_NN statement_NN ._.
Most_JJS non-derivative_JJ financial_JJ liabilities_NNS were_VBD held_VBN at_IN cost_NN ._.
IAS_NNP 39_CD requires_VBZ certain_JJ non-derivative_JJ financial_JJ assets_NNS those_DT classified_VBN as_IN available-for-sale_JJ to_TO be_VB held_VBN at_IN fair_JJ value_NN with_IN unrealized_JJ movements_NNS in_IN fair_JJ value_NN recognized_VBN directly_RB within_IN equity_NN ._.
Non-derivative_JJ financial_JJ liabilities_NNS will_MD continue_VB to_TO be_VB measured_VBN at_IN amortised_JJ cost_NN ,_, unless_IN they_PRP form_VBP part_NN of_IN a_DT fair_JJ value_NN hedge_NN accounting_NN relationship_NN when_WRB they_PRP are_VBP measured_VBN at_IN amortised_JJ cost_NN plus_CC the_DT fair_JJ value_NN of_IN the_DT hedged_VBN risk_NN ._.
Derivative_JJ financial_JJ instruments_NNS The_DT Group_NNP uses_VBZ certain_JJ derivative_JJ financial_JJ instruments_NNS for_IN the_DT purposes_NNS of_IN hedging_VBG foreign_JJ exchange_NN and_CC interest_NN rate_NN risk_NN ._.
Under_IN UK_NNP GAAP_NNP a_DT form_NN of_IN hedge_JJ accounting_NN was_VBD applied_VBN to_TO these_DT derivative_JJ financial_JJ instruments_NNS meaning_VBG that_IN some_DT derivatives_NNS were_VBD held_VBN off_RP balance_NN sheet_NN for_IN at_IN least_JJS part_NN of_IN their_PRP$ lives_NNS ._.
IAS_NNP 39_CD requires_VBZ recognition_NN of_IN all_DT derivative_JJ financial_JJ instruments_NNS on_IN the_DT balance_NN sheet_NN and_CC that_IN they_PRP are_VBP measured_VBN at_IN fair_JJ value_NN ._.
The_DT standard_NN also_RB places_VBZ significant_JJ restrictions_NNS on_IN the_DT use_NN of_IN hedge_JJ accounting_NN and_CC changes_VBZ the_DT hedge_NN accounting_NN methodology_NN ._.
As_IN a_DT result_NN ,_, from_IN January_NNP 1_CD ,_, 2005_CD ,_, the_DT Group_NNP has_VBZ recognized_VBN all_DT derivative_JJ financial_JJ instruments_NNS on_IN balance_NN sheet_NN at_IN fair_JJ value_NN and_CC has_VBZ applied_VBN the_DT new_JJ hedge_NN accounting_NN methodology_NN to_TO all_DT qualifying_VBG hedging_NN relationships_NNS ._.
Cash_NN flow_NN The_DT transition_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP has_VBZ no_DT effect_NN upon_IN the_DT cash_NN flows_VBZ generated_VBN by_IN the_DT Group_NNP ._.
The_DT IFRS_NNP cash_NN flow_NN statement_NN is_VBZ presented_VBN in_IN a_DT different_JJ format_NN from_IN that_DT required_VBN by_IN UK_NNP GAAP_NNP with_IN cash_NN flows_NNS split_VBD into_IN three_CD categories_NNS of_IN activities_NNS operating_VBG activities_NNS ,_, investing_VBG activities_NNS and_CC financing_NN activities_NNS ._.
The_DT reconciling_VBG items_NNS between_IN the_DT UK_NNP GAAP_NNP presentation_NN and_CC the_DT IFRS_NNP presentation_NN have_VBP no_DT net_JJ impact_NN on_IN the_DT cash_NN flows_VBZ generated_VBN ._.
In_IN preparing_VBG the_DT cash_NN flow_NN statement_NN under_IN IFRS_NNP ,_, cash_NN and_CC cash_NN equivalents_NNS include_VBP cash_NN at_IN bank_NN and_CC in_IN hand_NN and_CC highly_RB liquid_JJ interest_NN bearing_VBG securities_NNS with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ,_, but_CC excludes_VBZ restricted_VBN cash_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT cash_NN flow_NN also_RB recognized_VBD restricted_VBN cash_NN within_IN cash_NN and_CC cash_NN equivalents_NNS ._.
Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT 105_CD year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN
